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Abstract
Glioblastoma multiforme (GBM) is the most aggressive form of glioma, 
classified by the World Health Organisation (WHO) as a grade III or IV 
tumour [1]. Despite receiving a combination of radiotherapy, chemotherapy 
and surgical treatment, average survival is poor of 14 6 months and only a two 
year survival of 27 2% [2].
Present studies on cell surface markers, such as G D I5, suggest that 
GBM is composed of a heterogeneous population of cells, derived from a brain 
tumour stem cell (BTSC). BTSC cells play an essential role in the growth of 
tumours and thus treatment therapies may be more beneficial if adapted to 
inhibit the development of these cells.
RIO cells are a patient derived GBM cell line provided by the 
Addenbrooke’s Hospital in Cambridge. Isolating the RIO cell line for the G D I5 
marker can allow for the sensitivity of the subpopulations within the tumour to 
be determined. A better understanding of these sensitivities could allow for a 
more optimal treatment to be developed, which exploits the different 
sensitivities of each subpopulation. Experimental results showed that each 
subpopulation of the RIO cell line has significantly different doubling times and 
sensitivities to drug and irradiation.
A population balance equation is used to model the growth of a BTSG 
cell. The aim was to model a new fractionation schedule, which improves the 
treatment of GBM. This was achieved by means of predicting the number of 
cells killed in each cell line using the data from the RIO cell line. The model
IV
implements an asymmetric radiotherapy (ART) treatment that gives two initial 
low doses followed by a third dose that delivers a total daily dose of 2 Gy. All 
doses and the inter-fraction intervals could be varied to find the optimum 
treatment schedule.
The optimum schedule from ART delivers two initial doses of 0 7 Gy, 
followed by a dose of 0 6 Gy with intervals of 1 hour, for 5 days a week for 
6 weeks. A daily dose of 2 Gy and a total dose of 60 Gy were given to ensure 
that if a patient were to show no signs of hyper-radiosensitivty (HRS) they 
would still be treated efficiently. However, it was found that the standard 
radiotherapy treatment was more beneficial with this scenario.
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caused by a defect in the ATM gene. The ATM gene is responsible for the 
cells response to double strand breaks (DSB) in the DNA.
B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein. It belongs to the Bel-2 
family, of which it is the principal member. Members of the Bcl-2 family 
regulate apoptosis and are therefore either anti-apoptotic or pro-apoptotic.
Blebs are the protrusion of the cell membrane during apoptosis.
Cell adhesion molecules (CAM) are proteins found on the surface of the cell, 
which allow cells to bind with the extracellular matrix (ECM) or with other cells. 
There are four families of CAM; Immunoglobulins (Ig), integrins, selectins 
and cadherins.
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Gate a region drawn around the cells of interest after analysis by flow 
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Glial Cells are cells found in the central nervous system. They are not neuron 
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glial cells: astrocytes, oligodendrocytes, and microglia. The different types of 
brain tumours depend on the type of glial cell that has mutated.
Homeostasis is a vital property needed to maintain and regulate normal cell 
processes to ensure a regular and stable environment.
Homologous recombination is a repair pathway that uses a homologous 
template to accurately repair breaks in the DNA.
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Immunoglobulins, also known as antibodies, are large proteins produced by 
B lymphocyte cells due to a response from an antigen. Immunoglobulins are 
made up of four polypeptide chains; two identical heavy and two identical light 
chains. These four chains are held together by di-sulphide bonds to form a Y 
shaped molecule. Each of the heavy and light chains has a variable region at 
the top end of the chain, which is the antigen binding site, therefore making 
each antibody specific for each antigen. This specific binding, allows the 
precise detection of antigens during immunohistochemistry (IHC) and 
immunocytochemistry (ICC) staining.
Ionisation is the emissions of high energy particles or short wavelength 
electromagnetic waves that collide with atoms along its path. Such collisions 
remove or add electrons from the outer shell, thus giving it a positive or 
negative charge.
Isotype control reagents An antibody of the same Ig class/subclass with the 
same fluorescent conjugate, that recognises an irrelevant antigen
Keratlnocytes are the most common type of skin cell.
Kinases are a type of enzyme that transfers phosphate from a high energy 
donor to specific substrates.
Lamln are intermediate filament proteins of the nucleus. They provide 
structure and regulate the transient interactions of the nucleus.
Linear Energy Transfer (LET) The rate at which energy is released from the 
radiation source is described by linear energy transfer (LET).
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Metastasis, when regarding cancer, occurs when cells break away from the 
main tumour mass and spread to adjacent organs via the blood or lymphatic 
system and form secondary growths.
Mucositis inflammation and ulceration of the mucous membranes. 
Neurospheres spherical clusters of cells generated by NSC.
Non-homoiogous end-joining is a repair pathway that repairs double strand 
breaks in DNA without a homologous template.
NSG mice are laboratory mice that are immunodeficient.
Oncogenes and proto-oncogenes code for proteins that control cell 
apoptosis, proliferation, or both.
Oncosis cytoplasm vacuolisation, swelling of the mitochondria and, nucleus 
and cytoplasm.
Passage It is necessary to sub-culture the cells (known as passaging) 
Passaging makes it possible to produce large quantities of the cells and to 
continue the growth of the cell cultures because it avoids the prolonged high 
cell density that causes senescence.
Progenitor Cells can be defined as slightly more specialised cells than stem 
cells yet undifferentiated and are oligopotent.
Pseudopods are projections of the cytoplasm.
Sarcoma are malignant cancers developed from mesenchymal cells 
(connective tissue cells).
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Telomeres are nucleotides that extend the DNA. For normal cells, telomeres 
shorten with every cell division.
Upregulation the process of increasing the response to a stimulus; specifically 
: increase in a cellular response to a molecular stimulus due to increase in the 
number of receptors on the cell surface.
VEGF stimulates the proliferation of the endothelial cells from nearby 
capillaries to grow new capillaries to support the tumour mass.
Xenografts are tissues or organ in which cells from the tissue or organ of 
another species are transplanted.
X XX
Structure of this Dissertation
This dissertation consists of 11 chapters. A glossary of terms can be
found at the beginning of this dissertation, and the terms given in this glossary 
are shown in bold font throughout the report. A general overview of the project 
is introduced in Chapter 1. A summary of the motivation behind this project is 
given with the hypotheses stated. Seven main objectives needed to attempt to 
prove the hypothesis are identified.
A review of the literature that covers the biology aspect of this thesis is 
provided in Chapter 2. This chapter presents a wide survey of the topics 
involved in this project, which are critically addressed. In summary. Chapter 2 
focuses on the research of cancer stem (CSC) cells including the different 
techniques used to isolate the CSC cells in a heterogeneous tumour 
population. This chapter also discusses the different modalities of cell death for 
the purpose of choosing an appropriate endpoint assay for the experimental 
work. Chapter 2 also gives an overview of the studies involved in the treatment 
of cancer such as chemotherapy and radiotherapy.
Chapter 3 reviews the literature with regard to the mathematical aspects 
of this project. To begin the chapter discusses the pharmacokinetic and 
pharmacodynamic models with particular focus on the Hill model and its 
applications. Modelling cell cycles and the proliferation of stem cells are 
important topics for this project, therefore Chapter 3 also contains a section on 
the mathematical modelling of cell transition around the cell cycle phases and 
on modelling heterogeneous tumours. Finally, Chapter 3 reviews current 
models that simulate the effects of radiotherapy on cells.
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This dissertation then forms two main parts; an experimental aspect from 
Chapters 4-7, which is used to validate the mathematical model investigated in 
Chapters 8-11. Chapter 4 gives a summary of the flow cytometry equipment 
used in this work. Brief descriptions of the main mechanisms involved in flow 
cytometry are explained as well as the processes involved in the analysis of 
the data. This chapter is then followed by Chapter 5 which gives a detailed 
account of the experimental protocols involved in this project, to investigate the 
growth and proliferation of BTSC cells and the sensitivities of the sub 
populations of the RIO cell lines to radiation and drugs. The results and 
statistical analysis of these experiments are reported in Chapter 6 and 
discussed in Chapter 7.
Chapter 8 considers in detail the fundamentals of a population balance 
model with respect to age and time inciuding a descriptive explanation on the 
mechanisms of the algorithms and methods used to achieve the outcome of 
the model. The model uses the experimental data shown in Chapter 6 to 
attempt to grow a heterogeneous tumour and optimise radiotherapy treatment 
patterns. The results from the model are then reported and analysed in 
Chapter 9 and discussed in Chapter 10.
Finally, Chapter 11 concludes and reiterates the main findings, both 
experimentally and in terms of the modelling aspect of this project. This 
chapter discusses the implications these results may have on the treatment of 
glioblastoma and suggests future research that could be investigated.
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1. Introduction
The purpose of this chapter is to introduce the hypothesis of this project
and a summary of the motivation behind the work. There were seven main 
objectives that were achieved to accomplish this report, which are described at 
the end of this chapter.
This work is part of a longstanding project in conjunction with the 
Addenbrooke’s Hospital, Cambridge. The aim of the overall project is to 
improve the outcome of treatment for glioblastoma multiforme (GBM) by 
prolonging patient survival time. The work discussed in this report is involved in 
both the simulation and experimental aspects of the project, and predominantly 
focuses on the use of a population balance model with respect to age and 
time.
The most common form of malignant brain tumours are gliomas, of which 
the most fatal and aggressive form is GBM. In the UK, 268,758 new cases of 
malignant cancers, excluding non-melanoma skin cancer (NMSC), were 
registered in 2010 [4] for which prostate cancer accounted for 25 6% of 
cases [4j. In 2010, 156,729 mortalities, caused by cancer (excluding NMSC), 
were recorded with 22 2% resulting from lung cancer [5j. Although brain 
tumours make up less than 3% of all incident cancers, in 2009 only 41 -5% of 
patients with brain tumours have a median survival exceeding 1 year [5]. For 
this reason, the focus of this work will be on the cellular content of GBM and 
the nature of the growth of the cells within the tumour. GBM is composed of a 
heterogeneous population of cells, derived from a tumorigenic stem cell which 
will be referred to as a brain tumour stem cell (BTSC) for the remainder of this
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report. The concept of cancer stem cells (CSC) has been widely explored 
within the past decade due to the development and use of stem cell markers 
such as CD15, nestin and CD133; or progenitor markers such as NG2 or 
CD34. From this research it has been postulated that CSC cells may be the 
driving force in the growth of a tumour, and, it is possible that given a 
heterogeneous population of cells, there will be a variation in the sensitivity to 
radiation and chemotherapy drugs of the tumour population.
This work has five main phases; three modelling phases and two 
experimental phases. The first modelling phase develops previous work by 
Guest et al 2008 [6]. Guest et al introduced a basic four level, uni-directional 
differentiation cascade to simulate the growth of BTSC cells and their progeny, 
down the differentiation cascade and around individual cell cycles for each cell 
line. Although this model was an adequate representation of growth for BTSC 
cells that were capable only of differentiation and self-renewal, many 
improvements could be made to make the model more flexible for additional 
methods of proliferation. Therefore, the first modelling phase of this project 
describes a more accurate representation of the growth of a generic CSC cell 
into a heterogeneous tumour population, down a bi-directional, multi-level 
differentiation (BiDMuLD) cascade (see Figure 1) (see Chapter 5). The 
additional proliferation modes that the BiDMuLD cascade includes are 
differentiation of CSC cells and transit amplifying cells (TAC) down the 
cascade as well as de-differentiation up the cascade. Generically, the CSC 
cells will be modelled as CSC^/ progenitor', the TAC cells will be modelled as 
either of the following levels; CSC7progenitor’^ , CSC'/progenitor' and 
CSC'/progenitor'" cells. The model allows for up to two types of terminally
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differentiated cells (TDC), where the TDC cells are assumed not to proliferate 
or self-renew. For more details on the specific cascade for BTSC cells and the 
methods of proliferation see Chapter 5 and Section 8.3.
CSC
Progenitor'
TDC1
080 ^
Progenitor'
TDC2
CSC-
Progenitor'
CSC
Progenitor
Figure 1 : Bi-directional, multi-level (BiDMuLD) cascade.
The CSC cells can self-renew, differentiate both symmetrically and asymmetrically. The transit 
amplifying cells can self-renew, differentiate and de-differentiate both symmetrically and 
asymmetrically.
The second phase of the model determines the radiosensitivity of a cell 
for each cell cycle phase and for each cell line of the BiDMuLD cascade. It is 
highly unlikely that every subpopulation of cells, within a heterogeneous 
tumour population, has the same sensitivity to radiation and drug. It is more 
likely that the sensitivities will differ with a possibility of two main scenarios; a) 
due to the quiescent nature of BTSC cells, longer time is allowed for repair 
such that these cells will be more resistant to treatment than other 
subpopulations. Or the converse argument is true, b) BTSC cells are most 
sensitive because stem cells must not transmit effects of damage to the 
downstream lineages so they die easily. The radiosensitivity is quantified using 
the following three models that describe the relationship between radiation 
dose and cell survival; the linear quadratic (LQ) model, the induced repair
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response (IRR) model and the repairable-conditionally repairable (RCR) 
model. Furthermore, the population balance model determines the 
pharmacodynamics (PD) of each cell line and their cell cycle phase when 
treated with chemotherapy drugs such as temozolomide (TMZ). This is 
modelled using the Hill model (Equation 4) which is optimised with the random 
search and Nelder Mead algorithms to determine the model parameter values. 
Since the model is validated with data from in vitro experimentation, the 
pharmacokinetics of the drug is not incorporated into the model.
It is more appropriate to discuss the third and final phase of the model 
after introducing the two experimental phases. The first experimental phase 
will use the patient-derived GBM cell line R10 to attempt to validate the first 
phase of the model. With experimental data, some of the parameters needed 
to calculate the proportions of the subpopulations within a proliferating tumour 
can be estimated. Therefore, a more accurate account of the growth of cells 
within a tumour population and a better understanding of the structure of the 
differentiation cascade can be obtained. The focus of the first experimental 
phase will be predominantly on the growth and proliferation of the BTSC cells 
and progenitor cells that can be isolated with the antibody marker CD15, 
and thus not all the transient subpopulations of cells will be explored. Although 
the model simulates transition around the cell cycle, the experimental aspect of 
this work will not attempt to validate phase durations of each cell line.
The second phase of the experimental work will also use the R10 cell line 
and is designed to validate the second phase of the model. This phase will 
investigate the effects of radiotherapy, as well as chemotherapy drugs such as
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TMZ on the survival of the R10 cell line in four different forms; R10 cells in 
serum free media (SFR10), R10 cells in differentiating media (DMR10) and 
R10 cells isolated with CD15 (isolated GDIS'" and isolated GDIS’ cell lines). 
More detail on these different forms of the R10 cell line will be explained in 
Chapter S. Fitting experimental data to the model will identify unknown 
parameters and will be discussed in more detail in Section 3.4 and Section 8.4.
Finally, some background information will be briefly discussed to give 
some reasoning behind the third and final phase of the model. A notable 
feature of any Grade IV tumour is the exceptionally rapid proliferation rate, 
which, for GBM, is one of many contributing factors in the difficulty of killing all 
cells in the tumour mass. The antibody, MIB-1, can be used as an 
immunostaining label, which can detect and measure the activity of the cell 
proliferation marker the Ki-67 protein [7]. The activity of this marker can often 
run as high as 76 4% for GBM [8]. To achieve control of a rapidly proliferating 
GBM, it is necessary to provide a treatment that will negate the fast 
propagation of cells. It is important to kill the tumour sufficiently without 
exceeding the critical tolerance of the normal brain, hence increasing the 
therapeutic ratio.
Furthermore, as mentioned previously, considering that BTSG cells are 
thought to drive the growth of the tumour, and it is possible that they are more 
resistant to treatments such as drugs and radiotherapy, these factors may 
contribute to the difficulty of treating the disease to obtain a more satisfactory 
survival time. Therefore, it can be postulated that an alternative treatment, 
such as accelerated radiotherapy, with hyperfractionation (the use of fractions
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of dose smaller than 2 gray (Gy) in a larger number of higher periodic 
fractions) could improve patient survival. Such an approach has been tested 
clinically. The Continuous Hyperfractionated Accelerated Radiotherapy 
(CHART) trial for patients with locally advanced lung cancer demonstrated an 
increase in 2 year survival from 20 0% to 29-0%, a relative increase of 
45 0% [9] (see Section 2.6.2). The CHART approach was conceived as a 
radiobiologically optimised treatment ab initio. However, trials of a similar 
approach in patients with high grade astrocytoma or GBM have not improved 
survival [10,11]. Since the outcome of patients with GBM remains poor, even 
with advances in the multi-modality management, an imperative remains to 
develop more effective radiotherapy, as one of the key components of 
treatment.
An effective way to predict the success of a postulated treatment is to 
model the processes behind the proposed therapy, using experimental data to 
determine the parameters used to validate the model. The third and final 
phase of the model exploits the proportions of each cell line within the tumour 
population and hence their proliferation factors and the sensitivity of the cells 
to radiotherapy, and chemotherapy, to predict an optimal radiotherapy 
schedule. Therefore this project takes into account both an experimental 
approach (with a clinical mind-set) and a theoretical approach.
1.1. Hypothesis
It is necessary to biologically determine the growth of a BTSC cell and its 
progeny, down a differentiation cascade. In addition, it is possible that given a 
heterogeneous population of cells, there will be a variation in the sensitivity of
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each of the cell lines within the tumour population to radiotherapy and 
chemotherapy. Furthermore, there is the question of whether these biological 
concepts can be included into a mathematical model such that any variation in 
sensitivity can be exploited to improve patient survival by way of prediction and 
optimisation.
1.2. Aims and Objectives
The work presented in this dissertation aims to isolate and characterise 
BTSC cells with the antibody marker CD15, for the purpose of modelling the 
growth and proliferation into a heterogeneous tumour population. With the 
isolated cells and the other forms of the R10 cell line, the effects of 
radiotherapy and chemotherapy can be explored to therefore predict and 
optimise better treatments schedules for patients. In summary, it is necessary 
to achieve the following objectives to prove the stated hypothesis and achieve 
the aims:
1) Establish, experimentally, a differentiation cascade for the R10 cell line 
using the antibody marker CD15 and immunofluorescence with flow 
cytometry to identify and sort each subpopulation of cells.
2) Modify the model of Guest et al. 2008 [6] of a heterogeneous population of 
CSC cells and their progeny to accommodate a newly determined 
differentiation cascade.
a. Incorporate into the model, the effects of chemotherapy drugs 
through the use the Flill model; Chapter 3 provides more explanation 
of this model.
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b. Incorporate into the model the effects of radiotherapy through the 
use of an appropriate model of cell survival. A detailed description of 
these models can be found in Section 3.5.
3) Using fluorescent activated cell sorting (FACS) techniques, to sort and 
separate the subpopulations the R10 cell line.
4) With each subpopulation of cells the sensitivity of each cell line to 
radiotherapy and chemotherapy will be determined.
5) Compare the model to experimental results.
6) Relate the experimental data to the model and optimise the fit.
7) Experiment in siiico to establish an optimised fractionation pattern for these 
cells, including the possibility of asymmetric fractionation schedules.
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2. Literature Review: Biological Aspect
2.1. Introduction
Due to the multidisciplinary nature of this work, this chapter explores, in 
more detail, the main background theories involved in the project and 
establishes some principal definitions. This chapter will discuss a range of 
novel ideas that form the basis of this project; first and foremost the 
development of cancer and carcinogenesis, discussing the characteristics of 
cancer and the structure of tumours. Secondly, this chapter will consider the 
concept of CSC cells, in particular BTSC cells, to identify the objectives of the 
present investigations.
The following section will offer an account of the biological pathways 
involved in the cell cycle, to elucidate the reasoning behind the design of the 
first modelling phase described in Chapter 1 and Chapter 8. Continuing on a 
cellular level, the different classifications of death will be considered, careful 
definitions will be made clear according to the Nomenclature Committee on 
Cell Death (NCCD) [12]. This chapter will then give an overview of the current 
treatment modalities available for GBM and present the biological effects that 
chemotherapy drugs and radiotherapy routines have on cancer cells, to help 
predict and optimise radiotherapy treatments.
2.2. Cancer and Carcinogenesis
Introduction
Malignant (i.e. cancerous) neoplasms, known as tumours, develop from 
abnormally proliferating cells. Cancer is considered to be a group of diseases 
distinguished by unregulated growth and malignant spread around the body by
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metastasis. There are three classifications of cancer; carcinomas, sarcomas 
and adenocarcinomas. Furthermore, eight features of cancer have been 
defined by Flanahan and Weinberg [13,14], known as the “hallmarks of 
cancer,” which will be discussed in more detail in this section of this Chapter.
This section of the literature review will also introduce the development of 
cancer, which is a multistep process that engenders the accumulation of 
mutations brought about by carcinogenic processes. In summary, the 
processes involved are tumour initiation, promotion and progression. 
Furthermore, recent research has investigated the involvement of CSC cells on 
tumour initiation and growth. From these mutations, subpopulations of cells 
have a selective advantage and therefore prevail within the population, these 
traits are defined as an “enabling characteristics” [14].
The Hallmarks o f Cancer
Hanahan and Weinberg [14] define eight hallmarks of cancer, by which a 
hallmark of cancer is considered to be the biological functions that are 
essential for the survival, proliferation and spread of the disease, and hence 
tumourigenesis. Flanahan and Weinberg define the first hallmark of cancer to 
be the “sustained proliferative signalling” of the tumour [14]. One aspect of this 
hallmark is that cancer cells are autonomous in growth signals [13,14], such 
that growth factor signals required for transition of normal cells to the cell cycle 
from a quiescent (Go) state are not necessary in tumour cells [13]. Tumour 
cells are less constrained to external growth factors due to their ability to 
synthesise their own growth factors [13], such as platelet-derived growth factor 
(PDGF) in GBM [15]. Normal expression of the PDGF family instigates two
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known pathways; phosphoinositide 3-kinase (PI3K) and mitogen-activated 
protein kinase (MAPK) pathways that are involved in growth, proliferation, 
differentiation, angiogenesis and cell survival [16]. Expression of PDGF 
increases with tumour progression therefore there is a relationship between 
growth, differentiation and progression of the tumour. Some evidence has 
shown that cancer cells, particularly in GBM [17], may send signals to normal 
cells to encourage secretion of growth factors to support the tumour [14]. 
Furthermore, increased expressions of surface receptors on the cancer cells in 
turn increases sensitivity to limiting levels of growth factor [14].
Another contribution to this hallmark is the disruption of the negative 
feedback loops that are vital for the precise control of homeostasis particularly 
in cell proliferation and cell death. Disruption of cell proliferation feedback 
mechanisms results from mutations of the tumour suppressor gene, 
phosphatase and tensin homologue (PTEN). PTEN function is often lost in 
many tumours, therefore allowing for uncontrolled cell proliferation [14,18].
Hanahan and Weinberg define as the second hallmark of cancer as the 
ability to “evade growth suppressors.” For cellular growth, homeostasis is 
achieved through growth inhibitory signals that are directed to the 
retinoblastoma (Rb) protein which determines whether or not the cell 
progresses to the S phase [13] (see Section 2.4). Depending on the type of 
tumour, different mutations of the transforming growth factor beta (TGF P) 
protein interfere with the Rb signalling pathway and therefore allow the cell to 
continue on an irreversible post-mitotic state [13,14]. As a result, mutated cells 
can continue on through the cell cycle and proliferate.
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An additional hallmark of cancer is that tumours “resist cell death 
pathways” such as apoptosis or autophagy [13,14]. The relationship between 
cell death and cancer will be discussed in more detail in Section 2.5.2.
Hanahan and Weinberg define the fourth hallmark as the ability of cancer 
cells to “enable replicative immortality.” This hallmark concerns the 
autonomous process, replicative senescence. Senescence, present in normal 
cells, is independent of cell to cell signalling [13], and determines the finite 
number of times that a cell is capable of replication [19]. This finite number of 
replications in normal cells is controlled by the reduction of between 50 and 
100 base pairs (bp) in telomeres with each replication [19,20]. It was predicted 
and proven that germline cells and unicellular organisms overcome this 
mechanism through the activity of telomerase, an enzyme that lengthens the 
telomere strands [14]. Telomerase activity is switched on during oncogenesis; 
however this occurs during the late stages as telomeres are shorter than 
those in germline cells [19]. The telomeres therefore avoid senescence or 
apoptosis, hence the cancer cells become immortalised [14].
The fifth hall mark of cancer is the ability of tumour cells to “induce 
angiogenesis” for growth and development [13,14]. The role angiogenesis 
will be addressed in more detail later on in this chapter. Continuing on, we 
consider the sixth defined hallmark, “invasion and metastasis.” Metastasis is 
a multistep process, often referred to as the invasion-metastasis cascade (see 
Figure 2) [14,21], and is regarded as the main cause of death for cancer 
patients [13]. The multistep process begins with cellular changes causing local 
invasion of the tissue [14]. Integrins known as cell adhesion molecules
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(CAM) are altered to allow cells to break away from the tumour mass and 
spread [13,14], Tumour cells then enter the blood vessels and thus further 
transit throughout the lymphatic system [14], The final step of the cascade is 
the escape of the tumour cells from the lymph to distant organs and hence the 
growth of the new legion [14],
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Figure 2: The invasion-metastasis cascade.
Cellular changes causes local invasion of the tissue. Integrins and CAM are altered to allow 
cells to break away from the tumour mass and spread. Tumour cells then enter the blood 
vessels and thus further transit throughout the lymphatic system. The final step of the cascade 
is the escape of the tumour cells from the lymph to distant organs and hence the growth of the 
new legion. Image from [22]
Since Hanahan and Weinberg’s first review, considerable progress in the 
understanding of cancer development has been made. As a result “The 
Hallmarks of Cancer” has been revisited and two further hallmarks have 
developed from subsequent research, however they are referred to as 
emerging hallmarks as both functions have not yet been fully validated [14]. 
Hanahan and Weinberg describe these hallmarks as “reprogramming energy 
metabolism” and “evading immune destruction.”
“Reprogramming energy metabolism,” has been observed when cancer 
cells process glucose by glycolysis via the anaerobic pathway despite aerobic
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conditions [14]. Compensation for less efficient production of adenosine 
triphosphate (ATP) is achieved through the upregulation of glucose 
transporters to increase glucose uptake in the cell [14]. This method of glucose 
metabolism is thought to be related to activated oncogenes and mutated 
tumour suppressor genes [14]. “Aerobic glycolysis,” the programming of 
glucose metabolism, aids tumour development not only in areas that are 
hypoxic, but also by redirecting the products of glycolysis to biosynthetic 
pathways to generate the necessary organelles needed for cell division, thus 
enabling rapid proliferation [14].
Finally, the eighth hallmark of cancer, “evading immune destruction,” 
describes the role of the immune system in the development and progression 
of cancer [14]. Virus induced cancers often arise from immune-deficient or 
immune-compromised patients [14]. However, studies of tumour development 
in immuno-deficient and immuno-competent mice show that the immune 
system plays a substantial role in protecting the host from carcinogenesis [14]. 
Tumours that developed in immuno-deficient mice were unable to form 
secondary tumours in immuno-competent mice. On the contrary, transplanted 
tumour cells developed in immuno-competent hosts, were able to form tumour 
in both hosts.
Concluding Comments
The last section has described a detailed definition of cancer and its key 
features that allow for the growth and progression of the tumour. The next 
section will look at the etiology of cancer, known as carcinogenesis.
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Carcinogenesis
Many factors contribute to carcinogenesis such as; ionising and 
ultraviolet radiation, viral agents and chemicals known as carcinogens. Both 
particle and photon radiation are highly carcinogenic, causing single strand 
breaks (SSB) and doubles strand breaks (DSB) in the DNA of a cell [23]. 
Repair is achieved through non-homologous end-joining (NHEJ) or 
homologous recombination (HR) which is often successful when repairing 
DSBs [24]. SSB and base damage are typically repaired using Base Excision 
Repair (BER). However, for DSB, a higher frequency in incorrect repair 
prevails and thus the cell fate can be either death or initiation of 
carcinogenesis [24] and in some cases the mutation can persist without any 
obvious effect.
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Figure 3; Ionising radiation on an atom.
Orbiting electrons are given sufficient 
energy to leave their shell. Image from 
http://www.eeae.gr/
Figure 4: Ionising radiation on base pairs 
within DNA.
The radiation ionises the atoms that constitutes 
the nitrogenous bases of DNA. Image from 
http://www.radtrainonline.com/free/viewslide.as 
2?
CourselD=39&ModulelD=167&SlidelD=3Q11
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Radiation of sufficiently high energy can lead to ionisation; in relation to 
DNA damage, the radiation ionises the atoms that constitutes the nitrogenous 
bases of DNA (see Figure 3 and Figure 4). Ionising radiation also results in 
radiolysis, the interaction of ionising radiation with water in the body. This 
interaction engenders a series of chemical reactions resulting in endogenous 
free radicals, called reactive oxygen species (ROS), which are highly 
dangerous due to their reactivity.
H2O ^  H2O0+ +  e"
Equation 1
//2O0+ ^  H +  +  °0 H
Equation 2
Water is ionised by removing an electron to create the hydroxyl radical 
(-0H) (see Equation 1 and Equation 2.). The hydroxyl radical is a vigorously 
reacting free radical and therefore participates in a sequence of reactions 
resulting in hydrogen peroxide and hydroxyl radical. Primarily the OH radical 
reacts with DNA resulting in base damage and strand breaks following the 
passage of a radiation track. The life time (approximately 4 x 10'  ^s) and 
diffusion distance (approximately 6 nm) of OH radicals in the cell is very 
short [25], therefore both direct and indirect damage are all produced with a 
few nm (base pairs) of the passage of the radiation track. Hence the OH 
radicals oxidise the DNA of a cell by removing electrons from the comprising 
atoms of the DNA such as the nitrogenous bases. Oxidised bases can result in 
transversion mutations where purine bases, such as adenine and guanine are 
replaced with a pyrimidine base such as thymine or cytosine. Ionizing radiation 
produces cluster DNA damage and therefore not only produces SSB and DSB 
but complex SSB and complex DSB (additional strand breaks and/or base
48
damage). These clustered lesions are unique to ionizing radiation and unlikely 
to be generated endogenously or by other exogenous agents [26].
Carcinogens can be environmental, such as the first known carcinogen, 
coal tar [27]. In 1775, Percivall Pott discovered coal tar causes scrotal cancer 
(squamous cell carcinoma) [27]. Pott observed superficial sores on the 
scrotum and related the ailments to cancer. Remission often occurred in a 
matter of months after castration.
Tumour Development
As mentioned at the beginning of this chapter, tumour development is a 
multistep process; the first step, tumour initiation, begins with an accumulation 
of mutations over time, which has the abnormal capacity to proliferate 
uncontrollably by mitosis thus forming a neoplasm or tumour. Oncogenes and 
proto-oncogenes such as the ras oncogene aid tumour development. The 
c-ras and v-ras oncogenes have been found to initiate carcinogenesis in 
squamous papilloma [28]. Furthermore, other oncogenes such as B-cell 
lymphoma 2 (Bcl-2) contribute to the development of cancer through the 
inhibition of apoptosis (see Section 2.5.2).
Tumour suppressor genes maintain homeostasis by the regulation of 
cell numbers for normal tissue through the monitoring of cell proliferation, 
differentiation and apoptosis [29]. In particular, the p53 tumour suppressor 
gene has been widely researched due to the mutated form frequently found in 
human cancer incidence [29]. Loss of function of the p53 gene plays a part in 
the initiation of carcinogenesis [28]. Yuspa et al. [28] used the v-ras oncogene 
to transduce keratlnocytes of new born mice with and without the p53 gene.
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Papilloma was developed in all mice that were homozygous positive for p53 
(i.e. p53 positive on both alleles), whereas mice that were heterozygous for 
p53 developed papilloma, of which nearly half later progressed to 
carcinomas. Finally, those that were homozygous negative for p53 developed 
squamous cell carcinoma [28]. Therefore, this evidence indicates an active 
role of the p53 gene in the development of cancer.
The second phase of the multistep process, tumour promotion, involves 
tumour promoter substances that increase both the cancer inducing effects of 
carcinogens and increase the cell proliferation of existing tumours. Although 
tumour promoters are involved in the amplification of carcinogenesis, they are 
unable to directly cause cancer. Examples of these substances are hormones, 
such as oestrogen which, when in excess amounts, can promote the 
development of endometrial cancer. Finally, in this multistep process, as 
additional mutations of tumour cells occur, the development of the tumour 
continues to the next stage, tumour progression.
During the preliminary stages of tumour growth the ratio of surface area 
to volume is sufficient so that the diffusion of nutrients and waste to and from 
the surrounding tissues [30] does not limit the growth rate. As a result, tumour 
growth is exponential. While the tumour grows, the ratio decreases rapidly, 
hence direct diffusion is no longer an adequate source of nutrient or gaseous 
exchange. Consequently, angiogenesis is necessary to facilitate further 
growth of the tumour.
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Figure 5: Spatial three layer schematic structure of a tumour.
The inner layer consists of CSC cells, which are hypoxic and quiescent, and necrotic areas 
too. The intermediate region, which is composed of precursor cells and the proliferating 
peripheral layer containing the more differentiated cells of the tumour population
Angiogenesis, the growth of new blood vessels, occurs due to 
secretions of growth factor such as vascular endothelial growth factor 
(VEGF) [31]. Angiogenesis occurs in normal tissue as well as with tumours, 
however, tumour cells have increased expressions of VEGF, due to the ras 
oncogene or loss of the Von Hippel-Lindau (VHL) tumour suppressor gene. 
Upregulation of VEGF therefore overcomes signals from normal cells [13]. 
Folkman discovered that angiogenesis occurred before the transformation of 
cells to neoplastic cells [30], and observed the breakdown of the venule basal 
lamina, whilst endothelial villi project through [30]. Another process that 
engender angiogenesis is the regulation of the angiogenic inhibitor 
thrombospondin-1 by the p53 gene, therefore, loss of p53 action allows 
endothelial cells of blood vessels to proliferate [13].
Blood vessels are required to allow for gaseous exchange as well as to 
supply nutrients to the tumour and facilitate the growth of the tumour. Folkman 
observed that growth was limited, in avascular tumours, to 2-3 mm in
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diameter [30]. Blood vessels only reach the outer layers of the tumour, due to 
nutrient consumed by the cells nearer to the surface of the tumour. Therefore, 
the tumour develops a three layer concentric structure shown in Figure 5 [32]. 
Persano et al. [32] define the three layers as the following; the oxygenated 
peripheral layer containing the more differentiated cells of the tumour 
population that have a low proliferative rate, the intermediate region, which is 
composed of heterogeneous population of cells with high growth rates, and 
finally the inner region of the tumour which is made up of necrotic areas as well 
as CSC cells, which are hypoxic and quiescent. Throughout the three layers of 
the tumour structure, cells have been found to be phenotypically different, thus 
having an effect on the clinical treatment of the tumour. The 
0-6-methylated-DNA-protein-cysteine methyltransferase (MGMT) status of the 
cells changes throughout the concentric structure [32] which in turn has an 
effect on the efficacy of treatment with TMZ, a chemotherapy drug, used 
concurrently with radiotherapy as well as with adjuvant radiotherapy when 
treating GBM (see Section 2.6.2). Furthermore, due to the oxygen 
enhancement ratio (OER), cells in hypoxic areas required three times more 
dose than cells that reside in the more vascular areas, therefore possibly 
contributing ti the resistence of the CSC cells to treatment.
Concluding Comments
In summary, the development of cancer is a multistep process that 
engenders the accumulation of mutations brought about by carcinogenic 
processes. Tumour promotion is aided by tumour promoters, and progression 
via processes such as angiogenesis. Further research has investigated the
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involvement of CSC cells on tumour initiation and growth. There are several 
biological functions that are necessary for the survival, proliferation and spread 
of the disease and have been carefully classified as the hallmarks of cancer.
2.3. Cancer Stem cells (CSC) and Brain Tumour Stem Cells (BTSC)
Many studies draw attention to the fact that CSC cells share comparable 
features to normal stem cells, such as the signalling pathways and 
differentiation and self-renewal processes. This next section will give a 
summary of the fundamental concepts of stem cells to understand, as a whole, 
the complexity of cancer stem cells including some basic definitions.
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Figure 6: Basic four level stem cell hierarchy for somatic stem cells.
Stem cells become more specialised as they differentiate down the hierarchical cascade.
Embryonic and somatic (adult) stem cells, have the capability to 
differentiate down a hierarchical differentiation cascade into more specialised 
cells at each level (Figure 6). Stem cell differentiation is necessary to replenish 
cells, within the tissue, that are lost due to injury, damage and senescence. 
The potency of a stem cell, describes the potential of the stem cell to 
differentiate into different types of more specialised cell. Furthermore, the 
potency varies with the type of stem cell (see Table 1) [33].
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Potency Cell Definition
Totipotency Zygotes Ability to differentiate into all types of 
differentiated cells for all organs. 
Therefore the cells can develop an 
entire organism.
Pluripotency Embryonic stem cells 
(ESC)
Ability to differentiate into the germ 
layers and therefore the potential to 
develop any tissue in an organism. 
Flowever pluripotent stem cells are 
unable to form an entire organism.
Multipotency Flaematopoietic stem 
cells
Neural stem cells
Multipotent cells have the ability to 
develop into many differentiated cell 
lineages, however these type of stem 
cell are restricted to a specific function 
or organ.
Table 1: Definitions of the three main potencies of stem cells; totipotent, pluripotent and 
multipotent.
Two distinct properties of stem cells are the ability to self-renew their 
potency and to differentiate into more functionally specialised cell types [34]. 
Self-renewal ensures that the stem cell population within the tissue, or 
population of cells, is constantly replenished, such that the stem cell divide into 
new stem cells via asymmetric self-renewal (see Figure 7) and symmetric 
self-renewal (see Figure 8) [34]. During the process of asymmetric 
self-renewal, a stem cell produces one daughter stem cell and one more 
differentiated daughter cell. This concept can also be referred to as 
asymmetric differentiation and was first observed by Flacker in 1892 [35]. 
Finally, another method of proliferation is symmetric differentiation, such that 
the stem cell produces two differentiated daughter cells (see Figure 9).
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Normal stem cells were first defined in 1868 by Ernst Haeckel who used 
the term stammzelle to describe the evolution of multicellular organisms from 
single cellular organisms [35]. In 1877, Haeckel drew analogies between the 
evolution of unicellular organisms with the zygote [35]. Rudolph Virchow 
proposed the “embryonal rest theory” that suggested a direct link between 
embryonal cells and cancer due to similarities in their histology [36,37]. In 
1875, Julius Cohnheim further postulated that tumours developed from the 
somatic stem cells within the organ or from stem cells that circulate in the 
blood [37]. Many comparisons can be made between normal stem cells and 
CSC cells; therefore, understanding the intricate characteristics of stem cells 
could facilitate understanding of the initiation and progression of tumours.
Definitions of stem cells became more established in the 1960s; 
particularly multipotent cells such as haematopoietic stem cells due to the work 
of Till and McCulloch in 1961 [35,38], who successfully showed that single 
cells derived from bone marrow, could proliferate and produce a hierarchy of 
multiple differentiated types of blood cells. Furthermore, the embryonal rest 
theory progressed further in the 1980s due to the development of flow 
cytometry, which allowed for the isolation of the different non-cancerous cell
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lineages within bone marrow. Isolation of cell lineages from heterogeneous 
populations of cells were achieved using fluorochromes attached to 
immunoglobulins (Ig), also known as antibodies, that are specific for cell 
surface proteins present on certain cell types. In 1981, Martin successfully 
exploited this technique by isolating the inner cell mass of a mouse embryo 
which form extra uterine teratocarcinomas [39], thus supporting the embryonal 
rest theorem. Cells extracted from the teratoma were defined as embryonal 
carcinoma cells. Conditioned serum free growth media stimulated cells to 
survive in vitro and develop colonies that resembled normal embryo cell 
features, which could be induced to differentiate into various cell lineages [39]. 
17 years later, Thomson derived the first five human ESC (hESC) cell lines, all 
of which had similar surface marker proteins and engendered extra uterine 
teratocarcinomas.
Like normal somatic stem cells, CSC cells are capable of limitless 
self-renewal. Self-renewal allows for the maintenance and repopulation of the 
tumour during regular growth, and when cells need to be replaced due to 
damage or death from cancer treatments [40], or for regrowth to replenish lost 
cells due to surgical resection [41]. Signalling pathways are activated when 
proportions of the subpopulations are lost or over-expressed [40,42]. It is 
postulated that the CSC cells are more resistant to current treatment 
modalities [40]. In particular CSC cells, which are widely accepted to be 
quiescent, are thought to be resistant to antimitotic chemotherapy drugs, since 
these therapeutic regimes target rapidly proliferating cells [40]. Therefore, it is 
possible that, if CSC cells are thought to be the driving mechanism for the
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growth of the tumour, remission may occur if these resistant cells survive 
treatment and are left behind to repopulate the tumour.
Furthermore, Ignatova et al. [43] directly compared isolated nestin^ cells, 
typically expressed by normal neural stem cells (NSC), with nestin’^  cells in 
gliomas. Nestin is an intermediate filament protein used as a marker to isolate 
neural stem cells. Using immunostaining and reverse transcriptase- 
polymerase chain reaction (RT-PCR) analysis, results showed notable 
comparisons with clonogenic frequencies and a self-renewal capability due to 
sister clones also expressing nestin'" cells [43]. Furthermore, the glioma 
derived samples show differentiation in sister clones, thus showing the 
capacity to differentiate to more terminally differentiated lineages such as 
astrocytes [43].
Ignatova’s work is somewhat supported by studies from Nguyen et 
al [36]. Nguyen describes two biological models for the differentiation cascade 
of a CSC cell; a hierarchical structure and a stochastic structure [36]. Like 
Ignatova, Nguyen suggests that the first mutated cells in tumour development 
are comparable to the somatic stem cells of the tissue they are engendered 
from. The hierarchical model clearly defines a subpopulation of cells within the 
tumour population, and establishes that CSC cells can only be maintained 
through self-renewal and not through reversible differentiation [36]. 
Additionally, the model suggests that growth, survival and differentiation are 
dependent on external factors such as the availability of growth factors [36].
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Conversely, the stochastic model proposes that every cell within the 
population has CSC cell properties, however this stem cell status varies with 
endogenous factors and therefore growth and differentiation are independent 
of their environment [36]. Another characteristic of the model is that although 
all cells can be a CSC cell at any given time, only a proportion of cells are in 
the CSC cell state. This theory therefore represents two experimental aspects; 
firstly that only a minor proportion of the population, although varying, are CSC 
cells. Secondly, the model also adheres to the observed stochastic expression 
of stem cell markers [36], which is successfully demonstrated by results from 
Quintana et al [44].
Quintana et al. [44], have shown that phenotypic changes in the 
progression of stage III melanoma cells are reversible. 28% of single 
unselected cells from patients with stage III melanoma were injected into NSG 
mice and engendered tumours [44]. Furthermore, 32% of single unselected 
cells from stage III melanoma xenografts were injected into NSG mice and 
also produced tumours [44]. Quintana also shows that when collating both 
xenografts and patient data, there is no correlation (r^  = 0 06) with the growth 
rate of tumours and the frequency of tumorigenic cells [44]. However, using 
NFK_plot reader to read and separate xenograft data and patient data, there 
appears to be a negative correlation (r^  = 0 97) for single cells derived directly 
from patients. Additionally, for all markers, both negative and positive fractions 
produce tumours that corresponded to the original tumours. These results 
therefore suggest that it is possible that not all tumours contain CSC cells, or 
can give reasons to believe that tumour cells do not differentiate down a
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hierarchical cascade due to irreversible genetic and epigenetic changes, but 
instead have reversible phenotypic changes.
Studies have shown that CSC cells are present in many solid tumours 
such as non-small-cell lung cancer, breast cancer, GBM and many more [45]. 
Present studies on cell surface markers suggest that GBM is composed of a 
heterogeneous subpopulation of BTSC cells and progenitor cells [46,47], 
which are considered to grow and progress similarly to a normal somatic stem 
cell (see Figure 6). Like NSC, BTSC cells have the ability to travel around the 
brain through blood vessels and white matter tracts and express many of the 
same protein markers such as the CD133, CD15 or nestin [38]. Progenitor 
cells often express markers such as the proteoglycan NG2 [48]. However 
definitive markers that explicitly identify tumour stem cells and progenitor 
cells are not yet known, as these cells do not express the same marker 
continuously throughout the cell cycle [46,49,50]. Therefore, the use of 
antibodies as a conclusive marker may be questionable. Nevertheless, results 
for Singh et al. [47] demonstrate that cells expressing CD133 have been found 
to be capable of tumour initiation in mice [40].
Singh et al. [47], characterised subpopulations of cells from several 
diseases, including medulloblastoma, by use of a neurosphere assay using 
human neural stem cells as a control [47]. The required frequency of BTSC 
cells needed to generate neurospheres ranged from 0 3-25 1% depending on 
the disease, for GBM the necessary frequency was 11-4% [47]. Results 
showed nestin’" and GDI 33"" medulloblastoma cells, gave rise to secondary 
neurospheres with the same morphology and phenotypes as a brain tumour
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in situ’, thus indicating that the tumour population develops from these 
cells [47]. However, CD133’ cells did not engender neurospheres, which 
therefore implies that these medulloblastoma samples follow the CSC cell 
hypothesis. When differentiated, 81% of the population expressed p-tubulin 3 
(P-tub-3), a marker for neural cells. Furthermore, possible precursor cells were 
identified in two medulloblastoma patients where cell expressed both p-tub-3 
and GFAP, an astrocyte marker.
Progenitor cells constitute up to 30 0% of the tumour population in rats, 
both in vivo and in vitro [51]. However, human cells expressing NG2 has been 
found to have a mean average of 83 0% of the population, in vitro [48]. BTSC 
cells and progenitor cells have the capability to proliferate via self-renewal 
and asymmetric differentiation [46,48,51], and the cell cycle times differ from 
very long cell cycle times for BTSC cells and very short cycle durations for the 
rapidly proliferating progenitor cells [48].
Noble et al. [52] describe the differentiation cascade to begin with the 
division of the BTSC cells to intermediate progenitor cell types such as the 
glial restricted precursor (GRPC) cell line which further divides to the 
oligodendrocytetype-2 astrocyte (0-2A) cell line [52,53]. The 0-2A  will then 
differentiate to a terminally differentiated oligodendrocyte (TDO) [52]. Noble et 
al. [52] also reviewed the lineage of astrocytic cell types, and assumed the 
transition to be very similar to the transition of an oligodendrocyte.
Characterisation and isolation of the different cell lines within a tumour 
population are important to understand the histology of the cell. As mentioned
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in Section 2.2, the histology of cells can vary greatly in a heterogeneous 
tumour population. Immunocytochemistry facilitates the investigation of the 
level of heterogeneity of the tumour population through the expression of 
various cell surface proteins, some of which are characteristic and serve as 
markers of the different tumour types.
Much controversy has been raised concerning the validity of the 
antibody markers for a given cell line, because many cell lines express 
several different markers that have been classified for a specific cell type. 
Many studies have researched the complexity of the growth of heterogeneous 
tumour populations and the classification of a particular cell line by a given 
antibody marker is not wholly definitive. However, recent research by Ye et al. 
has led to the discovery of a possible correlation between the mitochondrial 
membrane potential (A'fm) and cell type [45]. Normal progenitor cells such 
as myoblasts and neuroblasts show evidence that the A'+’m increases as they 
differentiate, however the directional change is not uniform for every cell type 
as some cell types have shown to decrease in A’+'m with differention [45]. 
However, regardless of directional change, A'+'m does change with 
differentiation for normal cells. Using A549 cells (adenocarcinomic human 
alveolar basal epithelial cells) Ye separated the population according to high 
and low A'i'm [45]. It was found that the subpopulation of cells with high A'i'm 
also expressed CD133 and the low A'i'm population had very few cells 
expressing CD133 [45]. The underlying reasons for the change in A'i'm are 
due to ROS within the cells, as they are associated with signalling for 
differentiation [45].
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Concluding Comments
For many decades, research has investigated the growth, proliferation 
and differentiation of normal embryonic and somatic stem cells. With the 
development of FACS more pioneering research, due to the isolation of the 
stem cells, was possible. In more recent years, the discovery of CSC cells has 
transpired and with the knowledge and techniques already available from 
studies on normal stem cells, discovery and progression on this field of cell 
biology has flourished. Furthermore, there is a general consensus that CSC 
cells are a subpopulation of cells that require to be removed from the tumour 
population to prolong remission, as they are responsible for the generation of 
all cells within the tumour.
2.4. Cell Cycle
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Figure 10; The four main stages of the cell cycle.
The cell begins In the G1 phase and migrates round the cycle to the M phase where the cells 
divide. Image from http://learnlnqlab.co.uk/headstart/cvcle3.htm
The cell cycle is an ordered set of processes that all eukaryotic cells 
undergo in order for growth and replication to occur. Typically the cycle 
consists of 4 phases; G1, S, G2 and M (Figure 10). The progression of the cell
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through each of the phases is controlled by cell cycle checkpoints, which are 
regulated by cyclin-Cdk (cyclin dependent kinase) complexes [54,55]. Cdk is 
activated when bound to cyclin and phosphorylated by ATP [23].
G1 Phase S Phase G2 Phase M Phase
Cyclin D-cdk4 Cyclin A-cdk2 Cyclin A-cdkl Cyclin B-cdkl
Cyclin D-cdk6 Cyclin A-cdk2
Cyclin E-cdk
Table 2: Regulatory cyclin-cdk œmplexes for each cell phase.
The sensitivity of cells, to damage by radiation, varies through the cell
cycle. Generally cells are more radiosensitive during the G2 and M phases, 
and more radio-resistant through the G1 and S phase [56].
The first gap phase is the first phase of interphase and usually the 
longest phase of the cell cycle. The cells grow in mass due to the production of 
organelles and enzymes needed for DNA synthesis during the S phase. At the 
end of the G1 phase, the cell will verify sufficiency of the external and internal 
environment for DNA replication. Extensive research has investigated the G1 
to S phase a regulatory point known as START for yeast cells, Saccharomyces 
cerevisiae. START regulates the availability of nutrients to support the 
progression of the cell throughout the cell cycle [57]. Furthermore, cell size is 
also monitored by START to maintain a constant cell size within the 
population; generally the daughter cells of S. cerevisiae are much smaller than 
the mother cell and thus the daughters cells need to reach a minimum size 
before transition to the S phase.
in 1974, Pardee discovered the progression from the G1 phase to the S 
phase for eukaryotic cells is controlled and regulated by the restriction point.
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The restriction point is analogous to START [58], however the cells are 
regulated by the concentration of growth factors as opposed to nutrient 
availability. Zetterberg et al. [59] separates the Gi phase into two sub-phases; 
the post mitotic sub-phase (from M to R), Gi_pm, and the sub-phase leading to 
the S phase (from R to S) Gi-ps. During the Gi.pm sub-phase, growth factors 
bind to receptors on the cell surface membrane. This binding initiates calcium 
ion uptake and the phosphorylation of proteins such as the Rb protein to 
become hyperphosphorylated by the cyclin D-cdk 4/6 complexes and the 
cyclin E-cdk 2 [59] (see Figure 11). Phosphorylated Rb is inactive and 
therefore no longer inhibits transcription through the binding with transcription 
factors (E2F family protein) which consequently does not prevent growth [59]. 
The inactive form of Rb controls the activity of many cellular proteins such as 
E2F, which are responsible for the transcription of targeted genes on the DNA 
that are necessary for progression throughout the cell cycle [59]. Similarly to 
START, if the cell passes this checkpoint the cell is committed to progress to 
the S phase and through the rest of the cell cycle [59,60].
The following factors will result in the cell not passing the Gi checkpoint; 
radiation induced damage [23] and thus the reason for cells being more 
radio-resistant in this phase, availability of growth factor, inhibition of protein 
synthesis or if the cell is receiving inhibitory signals from other cells [59]. 
Instead, the cell will be arrested in a quiescent phase Go [59]. Cells return back 
to the cell cycle at exactly their exit point when returning to the cell cycle from 
Go [59]. Transition from Gi to S can also be constrained by the availability of 
proteins that are essential to complete DNA synthesis. The availability of
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proteins is directly proportional to the cell size and therefore, in effect, the size 
of the cell is also monitored [59].
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Figure 11 : Phosphorylation of Rb protein.
Active form of Rb binds to E2F and inhibits transcription. Image from [23].
As well as the restriction point in G1, there are also cell cycle checkpoints
elsewhere throughout the cell cycle. These check points are vital to ensure the
DNA is valid and undamaged. This is achieved via a number of mechanisms
that bring about cell cycle delay for DNA repair and maintain this delay until
repair is complete [60]. Subsequently, the cell cycle is reinitiating, by the
checkpoints, once repair is complete [60]. Furthermore, cell cycle checkpoints,
in each phase of the cell cycle, allow for the coordination of the phases to
ensure that they occur in the correct order, via feedback mechanisms [57].
The 8 phase of the cell cycle is the point at which the DNA of the cell is 
synthesised. The checkpoints at the end of the 8 phase respond to any 
complications with DNA replication [23] as well as the restriction of DNA 
replication to once per cycle. Any damage to the DNA is responded to by the 
following protein kinases; ataxia-telangiectasia-mutated (ATM) for D8B, and 
ATM and Rad3-related protein (ATR) for defective DNA replication forks or
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processed DSB. These protein kinases initiate DNA damage response through 
the phosphorylation of proteins that activate checkpoints responsible for 
monitoring DNA damage [61]. These processes are important to ensure repair 
before the M phase of the cycle, and, for this reason, the cell is very 
radio-resistant during the S phase.
The G2 phase of the cell cycle is the final phase of interphase. The cell 
develops and prepares the organelles for division during mitosis. The G2/M 
checkpoint is vital for normal cell division as it is the quality assurance before 
the cell divides [23]. Two identical sets of chromosomes with no damage or 
breaks in the DNA strands must be present at this point [23]. If the DNA 
replication is not complete, then a signal will be generated to arrest the cell in 
the G2 phase. In addition to DNA replication, the G2 checkpoint also monitors 
any damage to the DNA. If DNA damage is detected the cell is arrested in G2 
for repair before mitosis can begin. If the DNA damage cannot be repaired, the 
cell may endure several fates; either apoptosis, necrosis or mutation [23]. Cell 
death following radiation often occurs at mitosis as a result chromosome 
aberrations either at the first or subsequent divisions. These aberrations can 
result in permanent cell cycle arrest and therefore can induce senescence by 
which cells lose their reproductive ability.
Weinert et al. observed that the RAD9 gene in S. cerevisiae is 
responsible for cell cycle arrest due to DNA damage that allowed damaged 
cells from irradiation to enter the M phase of the cell cycle [62]. Although the 
RAD9 gene is responsible for checking the integrity of the DNA, it has no role 
in the repair of the DNA at this point. As a result of Weinert’s work, parallels
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were made between the research on the radiosensitivity of 
ataxia-telangiectasia (AT) patients treated with caffeine and results from 
budding yeast cells with a defective RAD9 gene [61]. As a result from these 
findings, it was found that the drug methyl benzimidazole-2-yl-carbamate 
(MBC) had inhibitory effects on microtubule formation during anaphase and 
sufficiently delays the cell for repair before proceeding to the M phase [61,62].
The M phase has two main parts: mitosis and cytokinesis. During mitosis 
the cell continues through a series of events for nuclear division (see 
Glossary). In 1970, Zirkle discovered that during metaphase, the spindle 
assembly checkpoint (SAC) prevents progression on to anaphase. The main 
observations made were that if the chromosomes are not correctly aligned and 
the kinetochores are separated from the spindle fibres [63], SAC becomes 
activated. In its normal state SAC is inactive and activated SAC inhibits cell 
division cycle 20 (CDC20). CDC20 function activates the anaphase promoting 
complex (ARC) responsible for metaphase to anaphase transition [63]. 
Experiments in vitro show the action of the checkpoint proteins (known as the 
mitotic checkpoint complex (MCC)) also inhibit the action ARC [63].
Concluding Comments
The cell cycle is a precisely refined process that ensures the integrity of the 
cell via checkpoints. The cell cycle checkpoints are vital for the repair and 
survival of the cell, therefore the sensitivity of the cell to radiation or drug 
exposure can vary throughout the cell cycle.
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2.5. Cell Death
This section reviews in detail the possible death modalities of eukaryotic 
cells, to discuss the reasoning for the chosen end point assay needed for the 
experimental aspect of this report. Cell death is defined to be a point at which 
the cell has reached a molecular or structural change that irreversibly effects 
the function and integrity of the cell, for example, cell fragmentation, 
mitochondrial membrane permeabilisation (MMP) and the breakdown of the 
plasma membrane to name a few [12]. All processes before this event are 
reversible and the cell is therefore considered to be dying [12]. The NCCD 
have classified four modalities of cell death; apoptosis, necrosis, autophagy 
and cornification, however this review will only give a more detailed account on 
apoptosis and autophagy. Cornification is a form of programmed cell death of 
the epidermis and therefore, for the purpose of this review has little relevance.
2.5.1. Necrosis
Necrosis can be characterised by oncosis [12]. Recent research shows 
that necrosis is not a form of uncontrolled and accidental cell death, but is 
regulated by cell receptors [12,14]. Cells undergoing necrosis release 
proinflammatory signals to surrounding areas, subsequently signalling to 
immune inflammatory cells [12]. In tumour cells, immune inflammatory cells 
encourage tumour proliferation by secreting growth factors [12]. Therefore, a 
number of tumours allow for some necrosis to occur to enhance 
proliferation [12].
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2.5.2. Apoptosis
Apoptosis is an intricate process that has been studied extensively over 
the past few decades. It was first discovered by Vogt in 1842, however Kerr et 
al. coined the term apoptosis in 1972 [64]. Apoptosis is often incorrectly 
referred to as the process of programmed cell death or caspase activation. 
However, the NCCD now define apoptosis to be cell death that exhibits the 
following morphological features [12]:
• Cells become rounded due to the breakdown of the cytoskeleton.
• Retraction of pseudopods.
• Condensation of the chromatin, a process known as pyknosis, which 
causes the cell to reduce in volume.
• Fragmentation of the nucleus and hence the chromatin is then dispersed 
throughout the cytoplasm, this is known as karyorrhexis.
• Blobbing
• The organelles within the cytoplasm become slightly modified
• The cell breaks into apoptotic bodies (vesicles) and in vivo the cells are 
engulfed by phagocytes.
Apoptosis is an extremely important process needed for cell 
conservation [13], as well as a defence mechanism against oncogenesis [65]. 
The induction of apoptosis can include a number of factors such as the 
deprivation of growth factor, the effect of free radicals, viral infections, ionising 
radiation, cytokines and any other factor that could lead to cell stress [66]. 
There are two main apoptotic pathways, of which are initiated either 
intrinsically or extrinsically [67].
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The mitochondrial pathway
MMP is a fundamental trait of intrinsic induction and is therefore known 
as the mitochondrial pathway [68]. MMP releases many mitochondrial proteins 
into the cytoplasm such as cytochrome c, which binds with APAF1 to form an 
apoptosome, which in turn activates caspase 9 (see Figure 12) [65,67]. 
Caspase 9 initiates a cascade of caspase activation which ultimately 
instigates apoptosis [65,67]. Other mitochondrial proteins, such as SMAC, bind 
to and inhibit proteins that inhibit apoptosis known as inhibitors of 
apoptosis (lAP) [67].
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The deafh-recepfor pathway and ceram/de
On the contrary, extrinsic instigation, known as the death-receptor 
pathway is induced by the binding of cytokines known as death ligands such 
as Fas or the tumour necrosis factor alpha (TNF-a) to cell surface 
receptors [65,67]. Cytokine and death receptor binding initiates a number of 
mediating processes that eventually activate the caspase cascade with or 
without the mitochondrial pathway [67].
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Different death receptors activate distinct signalling pathways, however, 
in general, when TNF cytokines bind to their specific death receptors, they 
trimerises the death domain (DD) to cytoplasmic regions on the receptor [69]. 
This in turn causes TNFR-associated death domain (TNFRDD) to bind with the 
trimer, which subsequently causes Fas-associated death domain (FADD) to 
bind also [69]. Finally the enzyme caspase 8 binds to the FADD forming the 
death-inducing signalling complex (DISC) which activates the caspase 
pathway [69,70].
Early studies of death-receptor induced pathways suggested that 
ceramide acted as a downstream secondary messenger from TNF-a [71]. 
Ceramide was thought to arbitrate the apoptotic pathway as it controls many 
of the intracellular enzymes that can bring about apoptosis [71,72], Flowever, 
more recent studies have found that the presence of ceramide can activate 
apoptosis independently from TNF-a [66,73]. Karasavvas and Zakeri found 
that when treating the human lymphoma cell line U937 separately with TNF-a 
and ceramide, DNA fragmentation resulted more rapidly (90 min) from TNF-a
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treated cells than cells treated with ceramide alone (12 h) [73]. Furthermore, 
intracellular levels of ceramide were measured to ensure that the time 
difference in the induction of apoptosis was not due to the ceramide levels 
produced by TNF-a or the uptake time of exogenous ceramide [73]. Results 
showed that cells treated with only TNF-a produced very small concentrations 
of intracellular ceramide after 1 hour of exposure and that the effects were 
irreversible [73]. Flowever, the ingested levels of exogenous ceramide were 
much greater, despite induction of apoptosis being a slower and having a 
reversible effect [73].
Studies have found that the anti-apoptotic protein, Bcl-2, does not inhibit 
the effect of generated ceramide from TNF-a, which affects the primary levels 
of the cascade [66]. However, Bcl-2 does block the uptake of external 
ceramide in cells, which activates the later stages of the caspase cascade 
directly [66]. These results therefore question the role of ceramide as an 
exclusive secondary messenger from TNF-a.
The action o f the caspase cascade
Caspase proteolysis of key cellular proteins can result in either a gain in 
biological function, or more frequently, a loss of function by selective cleavage 
of the polypeptide chains [74]. Cleavage of the inhibitory domain of the 
nuclease known as caspase-activated DNase (CAD) is a well-known example 
of gain in function [74]. Active CAD results in DNA fragmentation, a common 
morphological feature of apoptosis. Furthermore, nuclear shrinking and 
budding results from the breakdown of iamin [74].
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Apoptosis and cancer
As mentioned in Section 2.2, apoptosis has a substantial part in the 
induction and or prevention of cancer. Oncogenes can inhibit apoptosis which 
can therefore lead to tumour initiation and progression. Furthermore, the ability 
of tumour cells to elude apoptosis allows for rapid and limitless 
proliferation [13]. Yanish-Rouach et a!., suggests that wild type p53 mediates 
apoptosis in murine myeloid leukemic cells [75]. Expression of the p53 gene 
was restored in the leukemic cells and results showed that cells died via 
apoptosis with characteristic morphologies such as DNA fragmentation and 
condensed chromatin.
Ceramide brings about apoptosis on cancer cells, and it is thought that 
there is a relationship between the p53 and the Bcl-2 proteins [65-67]. The 
relationship between p53 and ceramide is not entirely clear however studies 
have shown that generated ceramide from TNF-a is a downstream response 
from p53 whereas exogenous ceramide is upstream to p53 [67]. Tumour cells 
have adapted to avoid apoptosis by an increased level of antiapoptotic 
proteins or, conversely, by decreasing the quantities of proapoptotic 
proteins [14].
In summary, apoptosis is a complicated form of programmed cell death. 
There are two main pathways involved; the mitochondrial pathway and the 
death-receptor pathway. Recent research has investigated a possible 
ceramide pathway; however ceramide is distinctly involved in the 
death-receptor pathway. There is a precise relationship between apoptosis 
and cancer. Apoptosis has an active role in the defence against
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carcinogenesis, and hence against tumour initiation, promotion and 
progression. However, if cancer prevails, tumour cells have many mechanisms 
to evade apoptosis.
2.5.3. Autophagy
There are three main modes of autophagy; firstly the most common 
pathway macrophagy, as well as microautophagy and the chaperone-mediated 
autophagy pathway [76]. Autophagy has roles in both cell survival and 
promotion of cell death [77], and is characterised by the following 
morphological features defined by the NCCD [12]:
• Lack of chromatin condensation.
• Vacuolisation of the cytoplasm.
• Accumulation of autophagosomes.
• When in vivo, little or no uptake by phagocytes.
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Figure 14: The autophagy pathways.
Pathways for macroautophagy, microautophagy and chaperone-mediated autophagy. Image 
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neurodegenerative_diseases/research/research2/index.html
74
Macroautophagy is a catabolic pathway in which the cell sequestrates 
and delivers cytoplasmic organelles, mainly protein substrates, to lysosomes 
for degradation, by the production of autophagosomes [76,78]. An 
autophagosome is a double membrane bound, acidic vesicular 
organelle (AVO) which then deforms its membrane to fuse with lysosomes to 
make autolysosomes [12,76]. The formation of autolysosomes allows for the 
degrading of the cytoplasmic material within the autophagosome by the 
hydrolytic enzymes from the lysosome. Microautophagy is similar to the 
macroautophagy pathway however the lysosome itself deforms its membrane 
to engulf the cytoplasmic substances [79].
During chaperone-mediated autophagy, cytosolic proteins bind with 
receptors on the lysosome membrane [79]. These receptors act as a mediator 
to transfer the protein substrates into the lysosome. Chaperone proteins 
recognise signals from specific amino acid sequences within the protein 
substrates, which cause them to bind, making a chaperone-substrate 
complex [79]. A second chaperone protein, within the lysosome, brings about 
the transfer of the substrate into the lysosome [79].
Regulated by autophagy related-genes (ATG) such as LC3, ATG5 and 
ATG7 [80], autophagy is a form cell death as well as a response to starvation, 
development and protection from disease [76]. Starvation inhibits the activity of 
the mammalian target of rapamycin (mTOR) [81] a regulatory protein of cell 
growth. Inhibition of mTOR results in cell arrest in the G1 phase of the cell 
cycle and initialises autophagy [81] as a survival response to recover nutrients 
needed for protein synthesis and ATP synthesis [77,78]. Studies have shown
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that cells can survive, via autophagy, for several weeks when deprived of 
growth factors, using cytoplasmic proteins for nutrients [77]. Furthermore, for 
homeostatic purposes, the role of autophagy is to remove unwanted or 
damaged proteins and organelles [80,81].
Yao et al. have shown that GBM cell lines die via autophagic pathways 
as opposed to apoptosis after irradiation [82]. Results indicated how the 
radio-resistant GBM cell line, T98G, and the radiosensitive GBM cell line, 
A172, both showed induced death via autophagy as opposed to apoptosis 
after doses of 5 Gy [82]. Furthermore, chemotherapy drugs and y-radiation 
have been found to activate autophagy pathways and therefore can either 
contribute to cell death or, conversely, add to the resistance of tumours cells in 
response to these treatments [80]. Lomonaco et al. explored the role of 
autophagy in response to y-radiation (5 Gy) in tumours derived from the glioma 
stem cell lines HF2355 and HF2359 [80]. Results showed that for both cell 
lines, GDI 33  ^ cells showed increased levels of the autophagy-related proteins 
ATG5, ATG12, LC3 and LC3-II when irradiated with 5 Gy y-rays; however cell 
viability only slightly decreased [80]. Therefore, this response suggests that 
autophagy acts as a defence mechanism to y-radiation, thus contributing to 
their radio-resistance in comparison to the G D I33' cells.
When treated with the autophagy inhibitor bafilomycin A1, the HF2359 
cells isolated for G D I33"^  showed a significant decrease in cell viability 
(p < 0-001) [80]. Furthermore, treatment with 3-methyladenine (3-MA) also 
showed a decrease in cell viability (p < 0-05) of the HF2359 cell line [80]. In 
addition, silencing of the autophagy-related proteins ATG5 and beclini
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significantly increased sensitivity to y-radiation in HF2359 CD133^ cells [80]. 
On the contrary, CD 133' cells showed a decrease in expressions of ATG5, 
ATG12, LC3 and LC3-II when irradiated with 5 Gy y-rays, and are therefore 
more sensitive to y-radiation [80]. However, treatment with bafilomycin A1 and 
3-MA did not significantly reduce cell viability (p < 0 05) [80].
In 2004, Yu et al. investigated the role of autophagy in cell death and the 
regulatory gene involved [83]. Using the mouse fibroblast cell line L929 and 
the human lymphoma cell line U937, results showed that inhibition of caspase 
activated apoptosis via zVAD, cell death still occurred and was characterised 
with AVOs [83]. To confirm death via autophagy, both zVAD treated cells were 
reduced in ATG7 and beclini expression, which consequently inhibited cell 
death [83]. Therefore inhibition of the caspase activated cell death can result 
in autophagic cell death. Furthermore, the two autophagy genes beclini and 
ATG7 are important genes required for death via autophagy pathways. 
Furthermore, autophagic cell death was inhibited when signalling pathways 
from the receptor-interacting protein (RIP) and Jun amino-terminal kinase 
(JNK) were downregulated.
In addition, Shimizu et al. showed that simian virus 40 (SV40) 
transformed embryonic fibroblasts cells deficient in the proapoptotic proteins 
Bax and Bak also undergo cell death via autophagy [84]. Results indicated that 
cells underwent autophagic cell death when treated with the drugs etoposide 
and staurosporine, both of which have been found to induce death via 
apoptosis [84]. Furthermore, death was halted when cells were treated with the
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autophagy inhibitor 3-MA or when essential autophagic genes such as APG5 
and beclini were silenced [84].
Concluding Comments
To summarise, there are two main types of programmed cell death that 
this review explores; apoptosis and autophagy, both of which have distinct 
characteristics to distinguish between the two. Autophagy can be either 
survival promoting or death promoting, depending on the conditions of the cell 
and the surrounding environment. Apoptosis has two main pathways that lead 
to the activation of the caspase cascade and therefore ultimately ending in cell 
death.
Both apoptosis and autophagy can promote cell death, therefore aid the 
prevention of tumour initiation or progression, or conversely, evade cell death 
therefore promote tumour progression after exposure to drug or radiation 
treatment. In particular, GDI 33’" cells have been shown to be radio-resistant 
due to autophagy pathways. The contributions of both apoptosis and 
autophagy to cell survival in cancer cells indicate possible treatment strategies 
to counteract this effect.
Furthermore, when considering experimental end point assays to quantify 
the effect of drug exposure or radiation on the cell, using a death pathway 
assay such as the assays for apoptosis or necrosis would only give an 
indication of the effect associated with the corresponding death pathway. 
Other assays such as MTT assays are a quick and effective way to quantify 
effect after short periods of time, however when dealing with treatments such
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as irradiation where effect may not present until a full cell cycle, then this 
method would also only give part of the result, especially when dealing with 
slow growing cells. Therefore, it is preferential to use a clonogenic assay which 
measure survival and proliferation of the cells after periods of up to 3 weeks.
2.6. Current Treatments
2.6.1. Introduction
Many techniques are used in the diagnosis and treatment of cancer and 
new advances are constantly being sought. Screening of cancer can result in 
the early detection of the disease. If detected in the early stages, some 
cancers can be radically treated. GBM is the most aggressive form of glioma, 
classified by the World Health Organisation (WHO) as a grade III or IV 
tumour [1] The grade of the tumour is a metric that represents the biological 
aspects of the tumour cells; such that, at grade IV the tumour has a high 
proliferation rate, necrosis-prone cancer cells and is highly malignant. GBM is 
the most common form of brain tumour worldwide, grade IV accounts for 
23 0% of all primary brain tumours [85]. GBM is more common in individuals 
aged between 45 and 65 years, with a higher incidence occurring in men 
(maleifemale = 1 5:1) [85].
2.6.2. Radiotherapy
There are two forms of radiation; electromagnetic radiation and particle 
radiation involving alpha and beta particles, neutrons and ions. Both forms of 
radiation are carcinogenic and damage the DMA of cells [23]. Alpha particles 
have high linear energy transfer (LET) and thus the average energy 
transferred per unit distance traversed is greater than for the electrons
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produced by x-rays which have low LET [86]. Low and high LET often 
generate SSB and DSB in the DMA, which results in mutations such as 
chromosomal translocation and base deletions, increasing LET is associated 
not only with an increase in the frequency of complex DSB but also an 
increase in the complexity of the DMA damage produced. The amount of 
energy absorbed per unit mass emitted by a radiation source is measured in 
Gy.
The outlook for patients with GBM has remained dismal, despite 
advances in surgery, radiotherapy and chemotherapy. Even now, 
multi-modality treatment for GBM is largely non-curative. As mentioned in the 
previous section (Section 2.6.2), for patients in whom cure is to be attempted, 
after surgical resection (i.e. the removal of the main bulk of the tumour), the 
current international approach for the radiotherapy is to deliver a total dose of 
60 Gy divided into 30 fractions each of 2 Gy, with treatment given with one 
fraction per day, on a 5 days per week basis, over 6 weeks. Typically, this is 
combined with concurrent TMZ chemotherapy. After completion of the 
concurrent chemo-radiotherapy, patients usually receive 6 months of adjuvant 
chemotherapy using TMZ [2]. With this approach the median survival has been 
extended to 14 6 months, with 2 year survival of 26 5% [87]. Prior to the 
results from the EORTC-NCIC randomised trial, when radiotherapy was used 
alone following surgery, the survival rate was unsatisfactory, with a median 
survival of only 12 1 months and a two year survival of only 10.4% [87].
To counteract the rapid proliferation of tumour cells, the treatment 
schedule CHART delivers a collective dose of 54 Gy, which is divided into 36
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fractions of 1 *5 Gy. Three fractions a day are given, with 6 hour intervals for 12 
days[9]. The CHART trial for patients with locally advanced lung cancer 
demonstrated an increase in 2 year survival from 20 0% to 29 0%, a relative 
increase of 45 0% [9]. Treatment over the weekend is not always possible in 
which case the patient receives CHART Weekend Loss (CHARTWEL) [88]. 
This treatment allows normal tissue to repair from sub-lethal damage between 
dose fractions, and thus repopulate. The lower total dose and dose per 
fractions, compared with conventional radical fractionation, reduces latent 
effects and overall treatment time [89-91]. CHART treatments were conceived 
as a radiobiologically optimised regime ab initio. Trials undertaking CHART as 
a treatment schedule include head and neck cancer [90,91], non-small cell 
lung cancer (NSCLC) [9,92], rectal adenocarcinoma [89] and high grade 
astrocytoma [10].
Patients with head and neck carcinoma, who showed an immediate risk 
for recurrence and a WHO grading of 0 or 1, were considered for CHART. 
Each patient underwent surgery for the resection of the tumour. Various 
morbidities took place during and after treatment such as the death of one 
patient due to tumour progression 4 weeks after treatment, dysphagia present 
in 65 2% of patients and mucositis in 87 0% of patients during treatment [90]. 
All patients had erythema resulting in desquamation [90]. Despite these 
adverse effects, CHART greatly improved recurrence free survival by 15 0% 
compared with conventional treatment [91].
Further CHART trials were undertaken on NSCLC. CHART resulted in an 
increase of 8 0% and 9 0% in 1 and 2 year survival for NSCLC respectively
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compared with the conventional treatment [9]. The success of CHART with 
NSCLC, resulted in its use in the treatment of high grade astrocytoma and 
GBM. The course of therapy distributed the dose over 19 consecutive days, in 
three daily fractions of T05 Gy in 6 hour intervals [10]. The first and last 
fractions of the day were modulated to the tumour volume, whilst the middle 
fraction irradiated the whole brain [10]. This treatment pattern gave a total 
dose of 59 8 Gy to the primary tumour volume (PTV) and 39 9 Gy to the entire 
brain [10]. 36 patients were recruited for the trial and results gave a median 
survival of 58 weeks [10]. In addition to the complications of CHART in head 
and neck carcinoma, seven patients developed brain oedema, hence 
treatment was disrupted [10]. Although the median survival rate was improved 
with the treatment of CHART and previous studies, comparative to NSCLC, the 
result was not greatly improved and not sufficient enough to compensate for 
the unwanted side effects [10].
CHART on high grade astrocytoma has not substantially improved the 
survival of patients; however the decrease in treatment time is beneficial [10]. 
Therefore, one can conclude that not all cells are sufficiently irradiated during 
treatment and that the cells that survive are important in the re-growth of the 
tumour.
Previous clinical trials have compared variations of accelerated 
hyperfractionated radiotherapy (AHRT) with conventional radiotherapy. Buatti 
et al. [93] compared conventional fractionation with AHRT, a regime of two 
fractions of 1.5 Gy a day for 20 days. The treatment improved 2 year survival 
to 16 0% and gave a median survival of 13.8 months. However, this result.
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was not significantly different from results achieved through conventional 
radiotherapy [93].
In 2000 further studies in AHRT were conducted for GBM and anaplastic 
astrocytoma patients [94]. The schedule administered a total dose of 60 Gy to 
patients in two daily fractions of 2 Gy for 5 days a week for 3 weeks [94]. The 
treatment resulted in some toxicities such as; conjunctivitis, grade 1 skin 
reactions and somnolence. Median survival of GBM patients was only 10 
months and therefore did not improve from the standard radiotherapy 
treatment. Furthermore, 1 and 3 year survival rates at were 35 0% and 6 0% 
respectively [94].
The existing fractionation schedules are designed to counteract the rapid 
proliferation rate of the tumour; hence many of the regimes involved delivery of 
more than one dose a day. CHART offered three equal fractions of 1.5 Gy a 
day at equal intervals of time. Variations of AHRT gave administered doses of 
1.5 Gy twice a day for 20 days and two deliveries of 2 Gy a day for 3 weeks. 
All variations did not significantly improved the median survival of patients, 
however the reduce treatment time, with little increase in adverse effects, was 
often favourable with patients. It cannot be ignored that some of the benefits 
from CHART or AHRT may be due to the exploitation of low dose 
hyper-radiosensitivity. (Also see Section 3.5.2). Previous research has shown 
that more than 26 human cell lines show low dose hyper-radiosensitivity 
(HRS) [95]. It has also been suggested that radiotherapy would perhaps 
benefit from a dose of 0.5 Gy given at 7-8 h intervals [95].
83
Experimental survival curves, with doses ranging from 0 0 to 1 0 Gy, 
show an abrupt fall in the survival fraction [96], which draws attention to the 
HRS of the cell line. The HRS is optimum with doses of 0 7 to 0 8 Gy [96]. The 
abrupt decrease in survival fraction is followed by a sudden increase of 
survival as the dose rises above TO Gy. It is apparent that some cells have 
been found to be radiosensitive at three fractions of 0.8 Gy with 4 h 
intervals [96]. Observations have revealed particular sensitivity during the G2 
phase of the cycle [97].
2.6.3. Chemotherapy Drugs
Treating cells with cytotoxic drugs can result in a range of cell fates, 
including necrosis, apoptosis and autophagy (see Section 2.5).
GBM patients who are treated radically, the current international 
approach for the radiotherapy is to deliver a total dose of 60 Gy divided into 30 
fractions each of 2 Gy, with treatment given with one fraction per day, on 5 
days per week, over 6 weeks. Typically, this is combined with concurrent TMZ 
chemotherapy. After completion of the concurrent chemo-radiotherapy, 
patients usually receive 6 months of adjuvant chemotherapy using TMZ [2]. 
With this approach the median survival has been extended to 14 6 months, 
with 2 year survival of 26 5% [87]. (See Section 2.6.2)
Stevens et al. [98] developed the alkylating drug, TMZ. TMZ is lipophilic 
enabling 30 to 40% of the drug to cross the BBB and is therefore 
predominantly used for the treatment of GBM [99]. Hydrolysis of its active 
metabolite, (3-methyl-(triazen-1-yl)imidazole-4-carboxamide) MTIC, does not
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require metabolic activation [98]. Hence, transformation can occur after 
crossing the BBB, which has a great advantage over its predecessor 
dacarbazine (DTIC) [99]. The breakdown of MTIC to the highly reactive ion, 
methyldiazonium, causes two types of methylated guanine, O® and methyl 
guanine [99]. Removal of the methylated guanine by repair enzyme leads to 
the generation of single and double strand breaks in the DNA, which in turns 
leads to the activation of apoptosis [99]. Patients that express the gene MGMT 
or 0-6-alkylguanine-DNA alkyltransferase (AGT) are therefore capable of 
repairing the methylated guanine. By methylating the MGMT promoter gene 
and therefore silencing the action of the enzyme increases patient survival in 
the EORTC and NCIC trials from 15 3 months to 21 7 months [100].
Camptothecin (CRT) is an anticancer drug that has similar effects to 
radiation and is therefore discussed in this report. CRT, a cytotoxic quinoline 
alkaloid, inhibits the action of topoisomerase. This enzyme exists in two forms, 
topoisomerase I and II (Topo I and II), and brings about the disentanglement of 
supercoiled DNA. This process is achieved through the induction of temporary 
single or double stranded breaks depending on the respective isozyme [101]. 
The DNA is then later re-joined again by the enzymes. CRT binds to the 
covalent bond between the DNA and the enzyme, creating a ternary complex 
which is stable and thus preventing the re-joining of the two strands of 
DNA [102]. This inhibition results in apoptotic cell death because the enzyme 
is essential for DNA replication due to the alteration of the tertiary structure of 
DNA [103]. CRT specifically targets cells in the S-phase of the cell cycle and 
inhibits both DNA and RNA synthesis in mammalian cells, which is irreversible 
at high doses [104].
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Early studies used HeLa cells, an immortal cell line derived from cervical 
cancer, to analyse the effect of CRT on DNA synthesis by regarding the 
molecular weight of the DNA. The results showed that CRT inhibits cleaving of 
DNA (the joining of sugar phosphate backbone through a covalent bond) and 
separates the DNA into fragments during both the S and G1 phase of the cell 
cycle. Furthermore, results showed that when the drug was removed, repair 
was equally efficient from both phases. Cleaving and repair of the DNA were 
proved possible when CRT was removed; however cells that were exposed to 
CRT during the S phase cannot progress to the G2 phase as DNA and RNA 
synthesis were irreversibly inhibited [105]. Therefore, one can assume that the 
cells could either suffer necrosis or apoptosis. CRT could block the cells in the 
S phase, causing them to be stuck and thus eventually die of necrosis. 
Alternatively the cells could undergo fatal breaks in the S phase that go 
undetected, which may cause death occurring during metaphase (term 
recommended by NCCD [12]).
Demecolcine is also an anticancer drug that engenders similar effects to 
radiation and is therefore discussed in this report. Demecolcine is derived from 
a natural toxin colchicine. Previous studies have shown that demecolcine 
depolymerises the microtubules in cells [106,107]. Microtubules are 
responsible for forming the spindle fibres during mitosis. With demecolcine 
present, the fibres do not form and the cells are prevented from completing cell 
division, thus resulting in apoptosis [108]. Therefore, one can deduce that cells 
with notably high proliferation rate are more probable to be affected by the 
drug. One relevant feature of cancer cells is their rapid proliferation rate; 
therefore the drug will mainly target the propagating neoplasms.
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A study by Jha ef a/. [109] concluded that demecolcine affects the 
progression of mostly only tumour cells, and not normal cells, because of the 
mutation of the tumour suppressor gene in cancer cells. The tumour 
suppressor gene is responsible for synthesising proteins needed to regulate 
the stability of microtubule spindles in the presence of demecolcine during the 
G2 phase. It is thought that a mutation in this gene causes the cells to alter the 
stability of the microtubule and hence disrupt the function of cell 
cycle-regulator proteins. Studies previously undertaken show cells to develop 
hyperploidy when exposed to demecolcine [110]. However, this result is 
dependent on the cell line and the concentration of the drug. V79 cells (a 
Chinese hamster lung cell line) have shown hyperploidy during the M phase 
of the cell cycle with the presence of demecolcine; however HeLa-S3 cells do 
not [110].
A continuation of this study showed that concentration of demecolcine 
played an important role in the inhibition of the cell cycle [111]. When V79 cells 
were exposed to 0 01 pgmL'  ^of demecolcine, the DNA histograms showed an 
insubstantial difference to the cells that had no exposure to the drug (i.e. the 
control). The concentration of demecolcine and the type of cell line having an 
effect on the cell propagation, the length of exposure to the drug also has an 
important role. For example, concentrations of 0 3 pgmL'^of drug for 12 hours 
showed no affect. However, after 48 hours, the histogram showed a peak in 
the G1 phase of the cell cycle, which later resulted in the degradation of DNA. 
Doses of 0 1 pgmL'  ^ resulted in apoptosis because the cells became tetraploid 
(4n) at the G1 phase after mitosis. It was suggested that this result could be
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caused by a pre-cell division signal initiated by demecolcine that brings about 
DNA replication. A prolonged M phase would then allow for hyperploidy.
Concluding comments
GBM is composed of a heterogeneous population of cells, derived from a 
BTSC cell. The differentiation of the BTSC cell line generates a heterogeneous 
population of cells. Although glioma are contained within the central nervous 
system (CNS) due to the blood brain barrier (BBB), glioma cells are very 
invasive and have the ability to travel around the brain through blood vessels 
and white matter tracts, thus making complete resection difficult [41]. 
Remaining cells after resection could therefore repopulate a tumour and hence 
cause remission. If BTSC cells play an essential role in the growth of tumours, 
treatment approaches could be more beneficial if adapted to target these cells. 
Treatment could include a novel radiotherapy schedule which is 
radiobiologically optimised.
Furthermore, it is postulated that the heterogeneity of the tumour 
population could account for the poor response to current treatment modalities 
due to possible differences in sensitivities to of each of the different cell 
lineages. Therefore the analysis of the varying sensitivity and HRS of cells to 
radiation with respect to the differentiation cascade may be beneficial. In other 
words, does sensitivity or HRS increase or decrease as tumour cells become 
more differentiated? if the main bulk of the tumour is killed, yet residual 
subpopulations of BTSC cells remain, this could result in recurrence. Therefore 
it is important to investigate and understand the cell biology of the tumour
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mass and its constituents. Hence, a large aspect of this project will investigate 
the morphology, growth and sensitivity of BTSC cells.
To achieve control of a rapidly growing glioblastoma, it is necessary to 
provide a treatment to overcome potentially rapid proliferation of tumour cells. 
In considering treatment, the goal is to eradicate the tumour without exceeding 
the radiotherapy tolerance of the surrounding normal brain. Hence it may be 
useful to design a fractionation regime that incorporates the use of HRS as 
well as hyperfractionation of radiotherapy when treating glioblastoma. As it is 
clear that not all cells respond abnormally to low doses, it is important to 
include larger doses in the fractionation pattern to cater for cells that are 
radiosensitive at doses of around 2 Gy.
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3. Literature Review: Mathematical Aspects
3.1. Introduction
This review will give a description of the current models used to simulate 
cell transition around the cell cycle, as well as modelling the effects of drug 
and radiation on cells. The Hill model will be introduced and its uses in 
pharmacokinetic/pharmacodynamics modelling evaluated. Furthermore, two 
survival models will be discussed; the LQ model and the IRR model. The 
intentions are to fully understand the mechanisms of these models so that the 
parameters can be incorporated into the population balance model used in this 
project, and the data can be statistically analysed.
The main aim of modelling any process is that the functions used, closely 
represent the outcome of the system being modelled, from the initial 
conditions. Models can be used to optimise systems or offer a form of control 
over a range of processes. Furthermore, due to the attractors of the system, 
mathematical modelling allows us to predict the future events of several 
processes and biological networks. Mathematical modelling is a fundamental 
tool in radiobiology and is needed to analyse and compare data from which the 
optimum outcome can be achieved.
3.2. Pharmacokinetic and Pharmacodynamic (PK/PD) Modelling 
PK/PD modelling serves as a vital tool in clinical trials as it can be used to
determine and optimise different dose deliveries and treatment possibilities. 
Furthermore, PK/PD modelling can also help to reduce the number of clinical 
trials needed, as it can identify whether drugs are unlikely to reach their 
therapeutic goal, before proceeding to the first phases of clinical trials [112].
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Additionally, PK/PD models, have the potential to accelerate the procedure of 
clinical trials by reducing the number of phases required in the process, and 
therefore reducing the time taken for beneficial drugs to be delivered to 
patients [113].
As a definition, pharmacokinetics provides an understanding on how a 
drug is absorbed, distributed, metabolised and excreted, to then describe how 
the drug passes through the body. These four sub-divisions make up the 
ADME model [114], which allows for the design of pharmaceutical drugs from 
first principle, therefore reducing the possibility of the failure of the drug to 
progress to the market.
In 1910, Hill introduced a deterministic model, to understand the effect of 
haemoglobin aggregation on its dissociation curves when in solution of 
different salts [115]. The aggregation of haemoglobin (Hb) molecules gave rise 
to inconsistencies in experimental results [115]. Therefore, Hill considered the 
possibility of different sized aggregates within the solution, and therefore, using 
the law of mass action, defined a general formula from two equilibrium reaction 
equations (Equation 3) for the dissociation curve with aggregated haemoglobin 
molecules [115], such that y is the percentage of Hb saturated with oxygen, x
is the partial pressure of O2 (mmHg), K is the equilibrium constant, and n is 
now known as the Hill coefficient [115].
Equation 3
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The effect of many chemotherapy agents on cells can be modelled by 
use of the Hill Model (Equation 4), particularly when the relationship between 
the dose and effect is non-linear.
E  =  Er,
a
Equation 4
Where C represents the concentration of drug (pM) and parameter ICso 
denotes the concentration of drug that is needed to inhibit growth of the tumour 
to 50% of the original size. The parameter Emax was originally included and 
represents the control, i.e. the growth rate effect on the cells with no drug 
present. Hence when the distribution of cells is normalised Emax =  1, the 
gradient of the concentration-effect curve corresponds to the parameter y, 
which will always be negative if the drug has an inhibitory effect.
Concluding Comments
PK/PD modelling has an important purpose in the pharmaceutical 
industry, such that it can aid the progression of drugs from the laboratory to the 
clinical trial and finally its availability in the market. Therefore, this can reduce 
the costs of drug development, as recognition of any failures is often identified 
early in the process. One of the first models used for the purpose of PK/PD 
modelling was the Hill model and is still widely used, despite the initial process 
of the model was to explore the uptake of oxygen on aggregated haemoglobin.
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3.3. Modelling Cell Cycle Transitions and Cancer Stem Cells
For several decades the modelling of cell cycle transitions have been 
investigated extensively, and is useful in determining the growth and 
proliferation of cells with particular interest in tumour cells to understand the 
growth kinetics [116] and the effect of treatment [117]. Validations of models 
are vital, therefore many design approaches for systems are considered with 
experimental reasoning [118,119]. Basse et a/. [118] explored a cell cycle 
model with respect to the DNA content of the cell over time, as it can be easily 
verified with flow cytometry data from the human melanoma cell line 
NZM6[118]. Furthermore, inhomogeneities or errors from experimental data 
can be accounted for in the model, particularly when the phases have been 
compartmentalised [118]. Both direct validation of the model and the 
incorporation of errors from experimental set up, contribute considerable 
strengths for the model, however boundary conditions must be carefully 
chosen, particularly when dealing with experimental data such as DNA 
content, which must always be positive [118].
Commonly compartment models are used to describe transport 
processes in biological systems, and are particularly used in PK/PD 
modelling [120]. Material Compartmental modelling can also allow for cell cycle 
phase control with respect to the number of cells within each phase of the cell 
cycle over time (see Section 2.4). Transition of cells from each phase of the 
cell cycle, and therefore each compartment of the model, can be governed by 
transition parameters [118] or transition functions [119]. Basse et al. uses 
transition probabilities that are fixed for each phase of the cell cycle, and with 
Steel’s equations [121] can be used to calculate phase durations (in hours)
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from FACS data [118]. However, the transition parameters were calculated on 
the assumption that the death parameters for each phase are zero, which is 
unrealistic.
Compartmentalising the phases of the cell cycle allows for more control 
over the model particularly when simulating the effect of drugs on cells, such 
as paclitaxel. Paclitaxel is a mitotic inhibitor [118], and the effect of the drug 
can be easily simulated by setting the transition rate at the M phase to zero at 
time of drug delivery, such that the cells do not divide at the M phase [118].
Other methods of incorporating the effects of cell death via DNA 
degradation and senescence as well as reversible cell cycle arrest can be 
achieved with a removal phase [118]. Basse et al. models the decrease in 
DNA content and totals the number of cells lost in all four phases through the 
use of a removal phase [118]. Furthermore, compartment modelling of cell 
cycle phases can encompass senescence by including a Go phase and thus 
modifying the G1 transition to include transition to Go as well as S [118]. Cell 
Cycle arrest is incorporated into the model by decreasing the transition rate for 
each of the cell phases [118]. However this will be difficult to validate with 
experimental data due to complications in isolating cause of cell death (see 
Section 2.5).
Other approaches to cell cycle modelling are the use of population 
balance models with respect to age and time [119]. Similarly to Basse et 
al. [118], Faraday [119] uses age elements for the phases of the cell cycle also 
with a death phase, however with the additional phase G T for quiescent cells
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to account for initial conditions. Furthermore, the G1 phase is subdivided into 
two phase; G1a and G 1b, and cells can die and therefore do not necessarily 
commit to the S phase. Therefore, the model contradicts the biological results 
of Zetterberg (see Section 2.4), such that cells in the Gi.ps phase are 
committed to transition to the S phase. The model was associated with a 
material balance for continuous stirred tank reactor (CSTR) model, cells flow 
from one phase of the cell cycle to another, however, it is assumed that there 
is no flow of cells into the system. Phase transition is under the control of 
transition functions rather than fixed transition parameters used in the Basse 
model. Additionally, transition from the G ib  phase to the S phase is governed 
by the cumulative intracellular glutamine which was considered the growth 
limiting nutrient in Faraday’s work [119], whereas transition from the death 
phase D is governed by cumulative ammonia concentration [119].
Further exploration of modelling cell populations have developed, due to 
the exploration of biological models of stem cells and CSC cells that give rise 
to heterogeneous populations of cells. Compartmental modelling allows for 
each subpopulation to be distinct and therefore proliferation, division and cell 
death can be controlled in terms of the modelling rules that govern them. 
Models have been used to investigate the effect of mutations that alter cell 
death and proliferation, in normal heterogeneous populations derived from 
stem cells [122]. With the assumption that growth and death in a system of 
normal cells reaches a steady state [122], mutations that alter cell death or 
proliferation and engender an unstable system, where a stationary state is not 
reach and exponential growth occurs, are considered to be a tumour initiating 
process (see Section 2.2).
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Results show that although these mutations are a contributing factor to 
tumour initiation, it is not completely sufficient in promoting 
tumourigenesis [122]. If death is reduced at the progenitor level (sometimes 
referred to as semi-differentiated cells), certain conditions can still generate a 
system at steady state [122]. This is mainly because the population is not 
solely driven by self-renewal as some of the population comes from the 
differentiation of the stem cell population [122]. Furthermore, decreased death 
at the terminally differentiated level does not result in exponential growth, 
although the population is increased [122], growth at this level only increases 
linearly as TDC do not proliferate or self-renew [122]. Tomlinson’s model [122] 
has many advantages, such that the mutation that alters either cell death or 
proliferation can be isolated and therefore directly related to whether it initiates 
exponential growth and therefore a tumour. Furthermore, the model can also 
isolate the mutation to a specific level of the stem cell hierarchy. However, time 
is not accounted for in the model and therefore the growth of each 
subpopulation is considered to be the same, which is improbable.
Deasy et a/. [116] developed a non-compartment model based on 
non-cancerous muscle derived stem cells (MDSC). Moreover, the model is a 
non-exponential based model to allow for the assumption that not all cells 
divide, such as TDC [116]. The purpose of the model is to investigate some of 
the underlying mechanisms of cell proliferation, and therefore the model can 
potentially determine the parameters for the division capabilities of the cells, as 
well as the proportion of cells in each phase of the cycle and hence establish 
any synchronisation of cells. Experimentally, subpopulations of MDSC cells 
can be distinguished by the division time (DT) and the number of
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non-quiescent cells [116]. Therefore the model is based on two parameters, 
DT and mitotic fraction (a) with Equation 5 [116], where No is the initial number 
of cells, N is the total number of cells over time t.
N = No
1 -
0 5 + (2 -  4a)
Equation 5
The growth of MDSC cells, and therefore DT and a, is affected by the 
cytokines available [116]. Deasy et al. experimentally investigated the use of 
six different cytokines and used the model to determine the effect on DT and a.
The model is a successful tool used to determine not only the growth rate 
of cells, but also the division time, namely the time a cell takes to divide into 
more differentiated cells. However, the model considers the population as a 
whole and therefore the division time may be obscured by other 
subpopulations of cells particularly after the first division time. Furthermore the 
model does not consider the loss of cells in the system through senescence 
and death or flow, diffusion or motility.
3.4. Optimisation Algorithms
Optimisation is a mathematical discipline associated with finding the best 
solution to a given set of circumstances or drawbacks without the need to find 
all solutions. The regarded circumstances are expressed as function(s) that 
can be solved finding the global maxima or minima. A simple method would be 
to differentiate the function and to then find the maximum or minimum 
depending on the nature of the system. However, difficulty arises when a 
function or model, such as the Hill Model, is a non-differentiable function.
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Further complications to the problem include a possible set of constraints and 
the existence of local maxima or minima. Consequently a range of optimisation 
methods, known as direct search methods, have been developed over the 
years to contend with these challenges.
Direct search algorithms were first introduce in the 1950s. However, they 
were substantially slow and an inefficient way of finding a best possible 
solution [123]. A further complication with direct search methods is the 
assurance of finding a global maximum or minimum. It is not possible to be 
certain that the solution the method has identified is a global or only a local 
solution. The ambiguity of the solution was an issue with the Nelder Mead 
algorithm, which was then modified and improved [124]. The improvements 
were simple steps, such that additional constraints ensured that the angle 
0G[O, tt], and at each iteration the algorithm is improving on a solution [124].
I
The random search method is an adaption of trial and error. Provided the 
search region is large enough to cover the global minimum, the random search 
method has an advantage over the Nelder Mead optimiser because it is more 
likely to find the global optimum. The method is instigated with an initial search 
region and the initial values which are compared with a very large initial value 
for the minimum (E). If the new value is less than the current minimum, then 
the associated parameters are assigned to the new best possible parameters. 
An attempt is made to improve the new parameters by adding a random 
amount to each parameter (i.e. finding another point within the designated 
search region) and comparing the related optimum to the previous result. This 
process is iterated until the algorithm continually did not find a better optimum
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value. The search region is contracted and the process is repeated until the 
maximum number of iterations (set by the user) is reached. Various methods 
have tried to take into consideration the drawback; however there is quite often 
a compromise with computational effort and speed. One example is the 
controlled random search method, whereby the trial points are predetermined 
to avoid repetition and the search region is strategically placed [125].
3.5. Cell Survival Curves
A cell survival curve illustrates the relation between the fractions of cells 
that survive after being targeted with radiation or chemotherapy drugs. The 
survival fractions are illustrated over a range of doses of drug or doses 
radiation received. Cell survival curves are plotted as a logarithm of the 
surviving fraction, and usually an increase in exposure results in a reduction in 
cell survival. However, this relation is not always linear and varies with the 
dose or time of exposure (i.e. dose rate).
3.5.1. Linear Quadratic
The most frequently used model for a relation between photon irradiation 
dose and cell survival is the LQ model. The LQ model uses the following 
equation to estimate the survival fraction (SF) at different doses (d):
ln(5F) =  - ia d  +
Equation 6
Initially, the log of the cell kill is linearly related by the constant a  and 
predominates at low doses. At larger doses the log of the cell kill is mainly 
quadratic and is described by the constant p.
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Furthermore, the LQ model has the potential to describe the effects of 
both lethal and sub-lethal radiation and can be represented by the two 
radiosensitivity coefficients a  and p. The LQ model serves as an improvement 
over previous modeis, such as the cumulative radiation effect (CRE), nominal 
standard dose (NSD), and, time, dose and fractionation (ID F ) methods. These 
modeis were derived from previous clinical data instead of the radiobiologicai 
effects on the ceil [126].
The LQ model incorporates the occurrence of double strand breaks, the 
repair and mis-repair of double strand breaks and lethal legions [126]. 
However, the main criticism of the LQ model is the absence of other events 
that occur on the cell due to radiation exposure such as the bystander effect. 
In addition, the LQ model assumes that all cell kill is a response to 
chromosomal aberrations, however there are many other causes of cell death 
such as necrosis and apoptosis. Likewise, the model does not incorporate the 
other factors of the therapeutic ratio: redistribution, repopulation and 
reoxygenation as it is an in vitro model.
Experimental results show that the relation between cell kill and higher 
doses is exponential, and therefore never results in a straight iine 
asymptote [127]. Additionaily, the lower dose region of the curve (less than 
1 0 Gy) is an extrapolation from the data at higher doses [96]. Thus, 
depending on the cell line, the LQ model is accurate only for doses of a 
specific upper and lower bound. This model has many deficiencies hence the 
following chapters describe alternate and improved models.
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3.5.2. Low Dose Hyper-radiosensitivity and the Induced Repair Response 
Model
As mentioned in Section 2.6.2 many cells are sensitive at iow doses. 
Previous research has shown that more than 26 human cell lines show 
HRS [95]. Such cell lines include T98G, a glioma cell line, which expresses 
evidence of HRS throughout the cell cycle [95]. It is apparent from 
experimental studies that severai glioma cell lines, which were thought to be 
radio-resistant at 2 0 Gy, do not follow the predictions from the LQ model. This 
inconsistency with the LQ model is because the sensitivity of the cells to 
radiation is underestimated by a at low dose.
Experimental survival curves, with doses ranging from 0 0 to 1 0 Gy, 
show an abrupt fali in the survival fraction [96], which draws attention to the 
HRS of the cell line. The HRS is optimum with doses of 0 7 to 0 8 Gy [96]. The 
abrupt decrease in survival fraction is followed by a sudden increase of 
survival as the dose rises above TO Gy. The rapid rise in the survival fraction 
is consistent with the theory of increased radio-resistance with increased dose. 
This effect can be modelled by use of the IRR equation which, compared with 
the LQ model, gives a more accurate representation of the survival fraction in 
relation to dose. The IRR model (Equation 7) modifies the LQ model to cope 
with the effects doses less than 1 0 Gy.
InSF =  -  d —
Equation 7
The sensitivity parameter a is separated into two further parameters ttr 
and «S. The standard coefficient a  becomes ttr at conventional doses of 2 Gy
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or more, whereas as is the sensitivity parameter for very low doses (typically 
less than 1 Gy). The factor dc describes the change in the curve from a low 
dose response to a high dose response.
Several studies have suggested that the reasons for the HRS-IRR effect 
could be related to the adaptive response mechanism, so that the initial low 
doses prepare the cell age distribution for further irradiation [128]. Other 
theories suggest the two-population theory, such that the more sensitive cell 
lines are eliminated by the smaller doses and the more resistant cell lines are 
kiiled by a larger dose [95,128]. Some glioma cell lines have been proved to be 
radiosensitive when irradiated with three fractions of 0 7 Gy or 0 8 Gy at 4 hour 
intervals [96]. It has been suggested that the efficacy of radiotherapy might 
benefit from doses of 0 4 Gy given at 7 to 8 hour intervals [95]. The response 
was assumed to be dependent on time, such that up to 4 hours is needed to 
reach the full extent of induced radio-resistance followed by a return of HRS 
6 to 8 hours later [95,128]. Hence it might be possible to design a treatment 
that exploits HRS by hyperfractionation of radiotherapy, for treatment of 
glioblastoma.
Other studies have explored the HRS with the phase of the cell cycle. 
Results have shown that those cells that show HRS only do so during the G2 
phase of their cell cycle. This behaviour is a result of damaged cells 
progressing to the M phase and thus leading to mitotic catastrophe [97].
There are many models used to measure the effects of radiation on cells, 
the local effect model (LEM). The LEM model measures the biological damage
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of the cell, and particularly measures the nucleus, with respect to energy 
deposition, which allows the measurement of damage to be independent of the 
radiation type [129].
Concluding Comments
Over the years several models have been develop to investigate the 
growth of cancer cells, mainly as a tool for further investigation on the effects 
of treatment or growth kinetics. As knowledge on CSC cells increase, many 
researchers became more interested on the growth of heterogeneous 
populations as it offered a more reaiistic representation of biological nature of 
a tumour. Compartmental modelling offers great control for further 
development of models, as well as the isolating the phase at which death can 
occur when needing to simulate the effects of drug or radiation. In addition, 
compartmental modelling can also give more control over the subpopulations 
of cells when modelling heterogeneous tumours, as well as giving a greater 
understanding on the effect on the mutations that alters the growth or death of 
a cell.
When validating models with experimental data, it is important to optimise 
the data to the parameters of the model when necessary. Many optimisation 
routines are available such as the Nelder-Mead method and the random 
search method, which are particularly successful for functions that are 
non-differentiable.
Furthermore, the effect of radiation and drug on cells has been broadly 
researched. There are many methods available to model not only the effect the
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drug has on the cell (PD modelling), but also the effect the body has on the 
drug such as the kinetics of drug uptake (PK modelling). Moreover, the LQ 
model has been used for many decades to model the effect of radiation on 
cells. However, more recently the IRR model has been used since the 
discovery of HRS, which divides the LQ model into two, to account for the 
effect at lower doses.
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4. Flow Cytometry
4.1. Introduction
This chapter will introduce the mechanisms involved within a flow 
cytometer. There are three main systems that make up a flow cytometer; 
fluidics, optics, and electronics. The fluidics system hydrodynamically focusses 
cells into a single stream to traverse through the laser. The optics system 
comprises of lasers to illuminate the cells a in the sample stream. Filters direct 
the resulting light signals to the appropriate detectors, which in turn are 
converted to electrical signals.
4.2. The Mechanisms
Flow cytometry is the measure of cells as they traverse through a laser. 
The cells must traverse through the laser as a stream of single particles, which 
is achieved by hydrodynamic focussing (see Figure 15). The sheath flow has a 
faster stream of fluid which encloses the central core in which the cells flow, 
provided the sheath has a laminar flow it will not disturb the flow of the 
cells [130]. As the cells pass through the laser, the size and complexity of the 
cell can be respectfully determined via the forward scatter (FSC) and side 
scatter (SSC) of the light as it interacts with the cell. Furthermore, if a cell is 
labelled with a fluorochrome, fluorescent channels detect specific waveiengths 
of light emitted, therefore measuring the quantitative data for the surface 
receptor, organelle or cellular molecules to which the fiuorochromes is bound.
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Figure 15; Schematic of a flow cytometer.
Cells flow as a single stream through the flow chamber. Emitted wavelengths of light are 
detected and.
Image from Life Technologies webinar:
http://probes.invitroqen.com/resources/education/tutorials/5Data Analvsis/plaver.html
The emitted light from the cells is passed to a dichroic mirror, which filters
and block specific wavelengths onto optical filters, such as long pass, short
pass or band pass filters. These filters allow precise wavelengths to the
photomultiplier tube (PMT). The emitted light will ionise the photocathode in
the PMT and produces a photoelectron as a result of the photoelectric effect.
These photoelectrons are attracted by the first diode and each successive
diode is more positively charged than its predecessor. As they travel to each
diode the electrons become more energetic due to the electric field and more
secondary electrons are emitted. This arrangement amplifies the current that
was originally emitted by the photocathode as shown in Figure 16, increasing
the voltage further amplifies the signal. Fluctuations of electron gain from diode
to diode contribute to the accuracy and the resolution of the detector. The
activation of the PMT detector is processed into a current and the related
voltage pulse is proportional to cell size, granularity or fluorescence depending
on the attribute measured.
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Figure 16: Photomultiplier Tube.
Image from http://elchem.kaist.ac.kr/vt/chem-ed/oDtlcs/detector/pmt.htm
Light absorbed by the fiuorochromes (excitation spectra ) excites the
electron from ground state to an excited state. Electrons return to the ground
state with the emission of a quantum of light, known as fluorescence or
emission spectra, which will have a lower energy and thus longer wavelength
than the absorbed light. The difference in wavelength between the emission
and excitation spectra is called the Stokes shift.
4.3. Becton Dickinson FACS Canto Flow Cytometer Analyser
The 6-colour BD FACS Canto is an analysis only machine, i.e. it is not 
capable of cell sorting. There are two excitation lasers; the blue argon ion laser 
with wavelength 488 nm and the red HeNe laser with wavelength 633 nm. 
There are six detection channels; fluorescein isothiocyanate (FITC), PE, 
allophycocyanin flurochrome (ARC F), peridinin-chlorophyll proteins-cyanine 
5-5 (PerCP-Cy5-5), phycoerythrin-cyanine 7 (PE-Cy7) and 
aliophycocyanin-cyanine 7 (APC-Cy7). The fluorescence that can be detected 
in each channel is shown in Table 3. The software used to analyse the results 
is BD FACS DiVa software v5.0.
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Laser 488nm 633nm
Detector FITC PE PerCP* PE-Cy7 ARC F APC-Cy7
Filter 530/30 585/42 670LP 780/60 660/20 780/60
Fluorochrome
choices
FITC
GFP
YFP
CFSE
CFDA
AlexaFluor 488 
calcein
PE
PI
PI
7AAD
PerCP
PerCP-Cy5.5
PE-Cy5**
PE-Cy7 ARC F
AlexaFluor 647
APC-CyT
APC-H7
Table 3: Fluorescence detected in each channel detector for Becton Dickinson FACS Canto 
Flow Cytometer Analyser
4.4. Becton Dickinson FACS Aria Flow Cytometer Cell Sorter
Fluorescence-activated cell sorting (FACS) provides a technique that 
separates and sorts heterogeneous population of cells. The fluorescence 
signal Is compared to the specified selection criteria on a data acquisition plot 
to separate out the Individual cells using gates (see Section 4.5). The flow 
chamber (see Figure 15) Is vibrated at a frequency of 20-60 kHz to break the 
sample Into droplets. The flow stream Is charged accordingly at the break off 
point and deflected on the corresponding voltage plate [131]. Using a negative 
or positive charge, cells can be sorted on two pre-deflned gates. A delay Is 
necessary between the time the cell passes through the laser and the break off 
point, to allow for Information to be received and processed by the electronics 
system. Collection of the sorted cells can be determined regarding yield or 
purity. Occasionally there may be an aggregation of cells In the deflected 
droplets. If cells are sorted with respect to high purity, the electronic circuitry 
detects these events and the sort decision Is aborted. However, sorting on 
high purity results In lower yield.
The FACS Aria Is a high speed, high pressure, 4-way sorter. It has three 
solid state lasers emitting at 407 nm (UV laser), 488 nm (blue laser) and
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633 nm (red laser). It is a digital system capable of high speed 4 ways and 
single cell sorting/analysis of up to 9 different fiuorochromes. The software 
used to analyse the data is BD FACS DiVa software v5.0
Laser Detector Filter Fluorochrome choices
405 nm
Violet 2 450/40 DAPI,
BD Horizon V450 
Pacific Blue 
Alexafluor405
Violet 1 530/30 BD Horizon V500 
AmCyan 
AlexaFluor 430
FITC 530/30 FITC
GFP
YFP
CFSE
CFDA
AlexaFluor 488 
calcein
PE 575/26 PE*
PI
488 nm 585/42 PE**
PI
PE-Texas Red 610/20 PE-Texas Red 
PI
PerCP-Cy5.5 675/20 PE-Cy5***
7AAD
695/40 PerCP
PerCP-Cy5.5
PE-Cy7 780/60 PE-Cy7
633 nm
ARC F 660/20 ARC F
AlexaFluor 647
APC-Cy7 780/60 APC-Cy7
APC-H7
Table 4: Fluorescence detected in each channel detector for Becton Dickinson FACS Aria 
Flow Cytometer Cell Sorter
4.5. Data Analysis
Analysed cells are presented on either a dot plot of FSC vs SSC (see 
Figure 17) or a histogram plot of fluorescence wavelength and count (see 
Figure 18). As the cell passes through the beam, the light scatter properties 
are measured by the FSC (size) and SSC (granularity) detectors which splits 
the light into “channels” relating to the detector gain applied in the experiment.
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Each event is assigned a channel value, when data is off the top of the scale; it 
goes into the last channel.
SFR10 Cells O nly
7 4 .3 1 % SFR10 Cells Only
g
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Figure 17: Dot plot of FSC and SSC.
FSC and SSC of cells each cell Is assigned a channel number that relates to the size or 
granularity of the cell.
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Figure 18: Histogram plot of fluorescence wavelength and count.
The histogram shows the number of events(count) falling into each “channel” that represents a 
wavelength.
Using a cells only control presented on a dot plot, cells of interest are 
selected with gate(s); debris and dead cells are therefore discarded. All 
subsequent plots are displayed with respect to the “cells only control” gate. 
The results for the isotype control and the stained cells(typically from a
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sample of 10,000 cells) are presented on histogram plots. A marker is used on 
the isotype control to measure the region that roughly gives less than 1% of 
signal. The measurement of this marker is therefore carried forward to the 
histogram plot of the stained cells, to determine the percentage of cells that 
are positive for the stain.
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5. Experimental Design and Techniques
5.1. Introduction
When modelling the growth of cells, and the effects of the inhibiting 
factors on their growth. It is important to understand the experimental 
processes that are involved. This understanding is to ensure that the model is 
a reasonable representation of cell growth, and to understand any 
discrepancies that might exist, between the experimental data and the model 
data. This chapter describes an overview of the whole experimental design as 
well as the details involved in the culturing of each cell line and the analytical 
techniques used in this study.
5.2. Overview of the Experimental Design
The design of these experiments is for the purpose of understanding the 
growth of a heterogeneous tumour population, using GBM as an example, as 
well as determining the radiosensitivity of the different cell lines within the 
population. The results from the experiments validate parts of the model 
described in Chapter 1, which can be used as a tool to predict tumour growth 
and optimise treatment schedules.
This study assumes the growth of BTSC cells to be analogous to the 
growth of NSC cells, such that BTSC cells can self-renew symmetrically and 
asymmetrically as well as undergo asymmetric and symmetric differentiation 
(see Section 2.3). The growth and differentiation of the tumour was analysed 
with the method described in Section 5.5. In summary, the stem cell enriched 
cell populations (that is the heterogeneous populations of cells grown in serum 
free conditions) were sorted for CD15 marker using the FACS Aria flow
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cytometer cell sorter (see Section 4.4, 5.4 and 5.5). The isolated CD15^ cells 
and CD 15' cells were then plated in either serum free media (SFM) or 
differentiating media (DM) (see Section 5.3) and analysed, over time, with the 
FACS Canto flow cytometer analyser for the number of cells that are CD15^or 
CD 15' cells within each population (see Section 5.4).
The radio-sensitivities for each of the different cell lines were investigated 
with the protocol described in Section 5.9. Cell populations were sorted with 
the FACS Aria (see Section 4.4 and 5.9) for the CD15 antibody marker (see 
Section 5.4) after which they were irradiated. Experimental survival curves 
were measures using the clonogenic assay (see Section 5.7). The LQ and IRR 
models, described in Section 3.5, were used to evaluate and compare the 
survival curves of each isolated cell line. Furthermore, the sorted CD15 
populations were also treated with temozolomide. The experimental survival 
curves generated, using a clonogenic assay, were evaluated using the Hill 
model (see Section 3.2).
5.3. Cell Culture
The human GBM cell lines used in this project were R10 and G25. All cell 
lines are patient derived cell lines provided by the Brain Repair Centre at the 
Addenbrooke’s hospital in Cambridge. All cell lines are enriched for stem cells 
and progenitor cells, and were grown and incubated at 37°C with a flow of 
5 0% of carbon dioxide (CO2 ) and disassociated with Accutase when 
passaged.
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The cells are maintairied in their BTSC cell and progenitor cell state when 
cultured under serum-free (SF) conditions. The SFM is composed of 
Neurobasal-A medium supplemented with 1% N2, 2% B27 (Invitrogen, Paisley, 
UK), 20 ng/ml human epidermal growth factor (hEGF) (Sigma-Aldrich, Dorset, 
UK), 20 ng/ml human fibroblast growth factor (hFGF) (R & D Systems, 
Abingdon, UK), 1% penicillin/streptomycin and 20 mM L-Glutamine. 
Extracellular matrix (ECM) gel (Sigma-Aldrich, Dorset, UK), diluted 1:10 in 
Neurobasal-A or fibronectin (Invitrogen, Paisley, UK) diluted of 1:5 with filtered 
PBS, was used as an adhesive substrate to coat the flasks for the stem cell 
enriched populations.
To differentiate the heterogeneous population of BTSC cells and 
progenitor cells, 10% foetal bovine serum (FBS) was added to the SFM and 
the hFGF and hEGF were removed. ECM and fibronectin were not necessary 
for the culture of differentiated cells.
When grown in SFM, the G25 and R10 cell lines will be referred to as 
SFG25 cells and SFR10 cells respectively, and, when grown in DM, the cells 
will be referred to as DMG25 cells and DMR10 cells for the remainder of this 
report.
5.4. Antibody Staining and Testing for Antibody Markers
For the purpose of testing the antibodies on each cell line and for growth 
and differentiation analysis, the Becton Dickinson FACS Canto flow cytometer 
analyser was used. Results were analysed using FCS Express Flow Cytometry 
software by De Novo. Cell lines that are positive for the stem cell associated
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marker CD15, were used in the project. The cell lines were also tested for the 
NG2 and CD133 markers. The antibodies used are shown in Table 5.
Antibody Isotype Host Flurochrome Source
NG2 lgG2a K Mouse Alexa Fluor 488 eBioscience
GDI 33 lgG2b Mouse APGF Miltenyi Biotec
GDI 5 IgM Mouse APGF Miltenyi Biotec
Table 5; Details of antibodies used for each experiment
For live staining of cells needed for flow cytometry analysis only, cells
were disassociated and then centrifuged before re-suspension in 500 pi of flow 
cytometry buffer; phosphate buffer solution (PBS) containing 1% FBS and 1% 
albumin bovine serum (BSA) (Sigma-Aldrich, Dorset, UK). The appropriate 
antibody was added and the cells were incubated in darkness for 60 minutes 
at 4°C. After staining, cells were washed twice before FACS analysis.
Antibodies can also bind non-specifically to cells by Fc receptors as well 
as non-specific attachment to the cell surface. Therefore, it is important to 
discriminate specific antibody binding from non-specific background with 
isotype control reagents. Furthermore, it is important to use unstained cells 
as a control to provide information about the background auto-fluorescence of 
each cell type. These control populations go through the same procedure 
described above for stained cells. Therefore, every sample analysed with flow 
cytometry will have seven sub-samples; unlabelled, NG2, CD133 or CD15 
labelled, CD133, CD15 or NG2 isotype labelled (see Figure 19). These 
experiments were performed in duplicates and on three separate days. If the 
cells are positive for more than one marker, the cells will be further labelled 
with double stains as follows; G D I5 with NG2 or CD133 with NG2.
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Cells Only CD15 CD15Isotype NG2
NG2
Isotype CD133
CD133
Isotype
Figure 19: Experimental setup for antibody staining.
Cells are tested the following antibody markers; GDI 5 and CD133, the markers associated 
with CSC cells and NSC cells and NG2, the marker associated with progenitor cells.
Before every use, the flow cytometer is calibrated with rainbow beads. To 
ensure the cells appear within the axis of the dot plot, the forward scattering 
and side scattering voltages on the FACS Canto were adjusted by the 
unlabelled cells (negative control). Cells were gated so that any debris or dead 
cells were disregarded, the voltages of the appropriate fluorescent channels 
were adjusted for single stained cell populations so that positively stained cells 
are within the plot.
5.5. Flow Cytometry and Fluorescent-Activated Cell Sorting (FACS)
FACS sorting was performed using a Becton Dickinson FACS Aria flow 
cytometer cell sorter described in Section 4.4. For live staining of cells needed 
for FACS, cells were disassociated and then centrifuged before re-suspension 
in 500 pi of sort buffer; PBS (CaVMg') containing, 25mM N-2-hydroxyethyl 
piperazine-N-2-ethane sulfonic acid (HEPES) buffer and 
5mM ethylenediaminetetraacetic acid (EDTA), filtered through a 0 22 pm filter. 
Cells must be in a single cell suspension and therefore strained through a 70 
pm cell strainer before staining. The appropriate antibody was added and the 
cells were incubated in darkness for 60 minutes at 4°C. After staining, cells
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were washed twice before FACS analysis. Control samples are used to set the 
machine up, these are; unstained cells, antibody stained cells and isotype 
control stained cells.
Cells were sorted with regard to purity, therefore aggregated cells were 
discarded. When sorted, the cells were collected in a sort buffer; RPMI 
containing 10% FBS, 25 mM HEPES buffer and 1% penicillin/streptomycin. 
After 30 minutes in the sorting buff, the cells were centrifuged, the sort buffer 
was aspirated and replaced with media ready to be plated for the necessary 
experiment. To check the purity of the collected samples, after sorting, the 
samples were analysed with the FACS machine to quantify what proportions of 
the cells were negative or positive for the marker.
5.6. Proliferation of Cell lines Within a Heterogeneous Tumour 
Population
The growth and differentiation of the SFR10 cells line was analysed with 
the following method. Using method described in Section 5.5, the SFR10 cells 
were separated into two subpopulations; isolated CD15^ cells and isolated 
CD15' cells. As mention previously in Section 5.4, it is essential that each 
antibody stain is compared to an isotype control and unstained cells.
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Figure 20; Schematic of experimental set using T25 fiasks.
The sorted populations were then plated in T75 flasks at a concentration
of 1 cells/ml in either SFM or DM (see Figure 20) and left for 
approximately 7 days before they were passaged. Half the population of 
confluent cells were used to passage and left to grow for further analysis, the 
remaining half was analysed with the FACS Canto flow cytometer analyser for 
the number of cells that are CGIS'" or CD 15' within each population. This was 
continued for up to 56 days.
5.7. Growth Analysis of Each Subpopulation of Cells
To describe the growth and proliferation of each subpopulation (isolated 
CGIS'" cells, isolated CG15' cells, GMR10 cells and SFR10 cells), growth 
curves were measured. Cells at concentrations of 1 x io^ cells/ml were 
seeded in ECM coated 24 well plates. Every 24 h, for up to 17 days, cells from 
three wells per plate were disassociated with 100 pi of accutase and counted 
using a haemocytometer to calculate the cell density per ml. Each set of 
experiments was performed on two separate days.
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5.8. Clonogenic Assay
The clonogenic assay is a gold standard procedure used to quantify the 
effectiveness of treatments, such as drugs or radiation, on cell survival. In this 
report, two clonogenic assays were used which will be referred to as the 96 
well plate method and the T25 flask method.
5.8.1. T25 Flask Method
Before the survival fraction can be calculated the plating efficiency must 
be determined with three flasks seeded with 100 cells in 5 ml of media and left 
to grow for 14-17 days to allow for colony formation. The plating efficiency can 
be calculated using Equation 8, which we assume that the calculated value is 
independent of the number of cells plated.
colonies observed (w ith no drug present)
Plating Efficiency ------------- number o f cMs piaied-----------
Equation 8
For the T25 flask method of the clonogenic assay, T25 flasks were 
coated with fibronectin at a dilution of 1:5 with filtered PBS. The cells were 
seeded at concentrations corresponding to the dose of drug or radiation, so 
that the resulting cultures produce a countable number of colonies when 
stained after incubation for 14-17 days. This rise in cell number is taken into 
consideration when calculating the surviving fraction (see Equation 9). All cells 
were fixed with 4% formaldehyde in PBS and stained with Giemsa stain 
(diluted 1:10 with PBS). Colonies were counted using a light microscope. Due 
to the quiescent nature of the CSC cells, colonies consisted of 30 cells or 
more. The survival fractions were then calculated, using Equation 9, with the
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plating efficiency taken into consideration. All experiments using this method 
were performed in triplicates and on three separate days.
Survival Fraction  =
colonies counted
cells seeded x Effic iency
Equation 9
Dose Plated
(Gy) Cells
0 300
0.25 300
0.5 300
1 750
2 1000
4 1500
6 2000
Table 6: Number of cells plated for the T25 method for each dose (Gy).
5.8.2. 96 Well Plate Method
Before the survival fraction can be calculated the plating efficiency must 
be determined. To calculate the plating efficiency, cells were plated at different 
plating densities (2, 5, 10, 50, 100, 200 and 300 cells per well) and incubated 
for up to 21 days to allow for colony formation. The plating efficiency can be 
calculated using Equation 10, in which we assume that the calculated value is 
independent of the number of cells plated. Wells with one or more colonies (of 
more than 30 cells) were counted as positive.
Plating E ffic iency  =
_ ,  f  number o f negative wells j  \
V__________________________ ' total number o f  wells)
number o f  cells plated per well
X 100
Equation 10
For the 96 well plate method of the clonogenic assay cells, 96 well plates 
were coated with ECM. The cells were seeded at concentrations 
corresponding to the dose of drug or radiation, so that the resulting cultures 
produce a countable number of colonies when stained after 21 days of
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incubation. This rise in cell number is taken into consideration when calculating 
the surviving fraction (see Equation 11). Wells with one or more colonies of 30"" 
cells were counted as positive. The survival fractions were then calculated, 
using Equation 11, with the plating efficiency taken into consideration. All 
experiments using this method were performed on three separate days in 
quadruplets, such that the 96 well plate was divided into quarters with each 
quarter sharing two edges.
_ ,  (number o f  negative wells / \
. ,  ^ V ' to tal number o f  wells)
Survival Fraction  =  ---------number o f  cells plated per well x  Plating E ffic iencyy
Equation 11
5.9. Radiosensitivity of Cell Lines Within a Heterogeneous Tumour 
Population
X-ray irradiation was carried out with the Gulmay kilovolt (kV) machine at 
the Royal Surrey County Hospital in Guildford. The T25 flask method for the 
clonogenic assay was used (see Section 5.8.1). Every experimental set up for 
the irradiation of the cells was exactly the same. The Gulmay machine was 
operated at a potential of 250 kV, providing a dose rate of 0 65 Gy/min with a 
20 X 20 applicator, the added filtration being composed of 1 5  mm aluminium, 
0 25 mm copper and 0 5 mm tin. All cell lines; SFR10, DMR10, isolated GDI 5"" 
RIO and isolated CD15" cells, were seeded onto fibronectin-coated T25 flasks 
and the seeded concentrations of cells increased with dose. Cells were 
exposed to doses ranging from 0-6 Gy, and then stained after incubation for 
14-17 days when colonies had formed.
B E D = D  \ 1 + ^
I f f
Equation 12
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The experimental data will be fitted to the LQ model (Equation 6) or the 
IRR model (Equation 7). The alpha-beta (a/p) ratio (Gy) and biologically 
effective dose (BED) (Gy) parameters (see Equation 12) will be used to 
compare the effect of radiation on each cell line. D is the total dose of the 
radiotherapy (60 Gy) and d is the dose per fraction (2 Gy). The a/p ratio can be 
defined as the dose at which the contribution from the a and p terms are equal. 
This parameter indicates cells that are late-responding or early responding. For 
early radiation effects, the a (or linear) component dominates at low doses, 
however the p (or quadratic) part of the equation accounts for late effects. The 
p coefficient represents the repair capacity of the cell, such that if p is large 
then the repair capacity is large and thus the time for repair is longer. 
Furthermore, the BED indicates the biological effect of any radiotherapy 
treatment that considers changes in dose delivered per fraction, dose rate and 
total dose [132].
5.10. The effect of Temozolomide
TMZ (Sigma-Aldrich, Dorset, UK) was reconstituted in dimethyl sulfoxide 
(DMSG) and PBS. The final concentration of DMSG did not exceed 0 02% to 
ensure the DMSG alone had no effect on cell viability. Both methods of the 
clonogenic assay were utilised (see Section 5.7). All cell lines; SFR10, 
DMR10, isolated G D I5’" RIO and isolated G D I5' cells, were seeded onto EGM 
coated 96 well plates and fibronectin-coated T25 flasks. Gells were exposed to 
TMZ at doses varying from 0-250 pM for 24 hours, after which the drug and 
growth medium mixture is removed. Gells were washed with PBS and the 
media replaced, then left to grow.
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Concluding Comments
This chapter has described the cell lines and methods used to complete 
the experiments needed to achieve the necessary results to answer the 
hypothesis of this project. The experiments are designed to elucidate our 
understanding in the growth of GBM, as well as the sensitivity to radiation and 
drug.
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6. Experimental Results and Analysis for Validation of 
the Model
6.1. Introduction
The first part of this chapter investigates the growth, proliferation and
differentiation of each sub-population of the tumour, to validate some parts of 
the growth aspect of the model described in Chapter 8. Furthermore, since 
there is very little existing data that investigates the sensitivity of these CSC 
cells to radiation and TMZ, therefore these sensitivities on the four 
subpopulations of the R10 cell line were investigated. Additionally, the results 
from the analysis of the radiosensitivity of these cells will be used to validate 
the computational methods used in the model to describe the effects of 
radiotherapy. All experiments were performed in either duplicate or triplicate, 
and the error bars represent the standard deviation (a) of the mean among the 
different experiments.
6.2. Growth Curves
Growth curves for the four cell lines SFR10, isolated GDIS'", DMR10 and
isolated CD 15" are shown in Figure 21 a, b, c and d respectively. Statistical 
significance was determined with the t-test using 95% confidence intervals 
from a normality assumption for linear regression. Using the trend lines of each 
growth curve, the doubling was calculated with the gradient of the line 
(Equation 13).
1
doubling time =
gradient
Equation 13
The doubling time for the isolated GDIS'" cell line is 1 45 days, and is 
significantly different to the doubling times of the SFR10, DMR10 and isolated
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CD15' cell lines. Furthermore, the doubling time for the isolated CD15' cell line 
is 1 20 days, which is significantly faster than all the other subpopulations of 
the R10 cell line. The DMR10 cell line has a significantly longer doubling time 
(2 38 days) than both isolated CD15^R10 and isolated CD15' cell lines. 
However, although the time to double for the DMR10 cell line is longer than the 
SFR10 cell line (which has a doubling time of 2 13 days), there is not a 
significant difference.
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Figure 21: Growth curves
Growth curves for a) SFR10 cells. The doubling time Is 2-134 days with confidence Interval 
1 -990 < P9 5  <2-301. b) Isolated GDIS'" cells. The doubling time Is 1-448 days with confidence 
Interval 1 -389 < jjgg <1 -512. c) DMR10 cells. The doubling time Is 2-383 days with confidence 
Interval 2-267 < [jgs <2-510. d) Isolated GDI 5 cells. The doubling time Is 1 -203 days with 
confidence Interval 1-156 < pgg <1-253. Error bars represent the standard deviation of the 
mean of two Independent experiments with triplicate data.
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6.3. Proportions of Cell lines Within a Heterogeneous Tumour 
Population
6.3.1. CD15 Profiles
The proportion of CD15^ cells and CD15' cells for the SFR10 cell line is 
shown in Figure 22, each experiment was repeated on three separate days. 
The average percentage of healthy and live SFR10 cells selected is 79 0% 
(o = ± 4 10%), the remaining 21 0% are either dead cells or cellular debris. 
From the healthy population of SFR10 cells, the average proportion of GDIS’*" 
cells is 85 2% (a = ± 5 72%). Furthermore, Figure 23 shows the proportions of 
GDIS’*’ and GDIS' cells for the DMR10 cell line, which was also repeated on 
three separate days. From the 78 0% (a = ± 6 74%) of selected healthy 
DMR10 cells, the average proportion of GDIS’*" cells significantly falls 
(p < 0 005) to 26 0% (a = ± 2 36%) when differentiated, using Welch’s two 
sample t-test [133].
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2.2 x10*‘
1,6 xIO*'
C
Figure 22: CD15 profiles for SFR10 cell line
CD15 profiles for SFR10 cell line, average percentage of CD15  ^cells in the SFR10 cell line is 
85 5% (a = 5 72%). The selected healthy SFR10 cells from the unlabelled sample is shown in 
red, the isotype control sample are shown in blue and the CDIS"” cells are shown in light 
blue, a) Percentage of GDIS'" cells is 88 9% when isotype control is deducted, b) Percentage 
of GDIS'" cells is 88 2% when isotype control is deducted, c) Percentage of GDIS'" cells is 
78 6% when isotype control is deducted, o denotes the standard deviation of the mean of 
three independent experiments.
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Figure 23: CD15 profiles fcrDMRIO cell line.
CD15 profiles for DMR10 cell line, the average percentage of CD15^ cells is 26 0%
(o = 2 36%). The selected healthy SFR10 cells from the unlabelled sample is shown in red, the 
isotype control sample are shown in blue and the GDIS'" cells are shown in light blue, a) 
Percentage of CD 15  ^cells 25 9% when isotype control is deducted, b) Percentage of CD15* 
cells is 28 4% when isotype control is deducted, c) Percentage of GDIS'" cells is 23 7% when 
isotype control is deducted, a denotes the standard deviation of the mean of three 
independent experiments.
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6.3.2. CD133 Profiles
For the investigation of CD133 expression on the SFR10 and DMR10 cell 
lines, all experiments were repeated on three separate days. The proportions 
of CD133'" and CD 133' cells in the SFR10 cell line are shown in Figure 24 a, b 
and c, and the mean average number of live and healthy SFR10 cells selected 
is 78 3% (a = ± 3 50%). From the healthy population of SFR10 cells, only an 
average of 1 -25% (o = ± 0-6%) were positive for the GDI 33 marker. To isolate 
these cells using FACS, this would require an unrealistic initial number of cells 
to produce the number of isolated GDI 33^ cells needed for the irradiation, drug 
and proliferation experiments. Figure 25 a, b and c shows the proportions of 
GDI 33^ and G D I33' cells for the DMR10 cell line. For all profiles, unspecific 
binding was responsible for any signal received, which is also true for the 
SFG25 cell line.
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Figure 24: CD133 profiles for SFR10 cell line.
The x-axIs for each histogram represents the wavelength. CD133 profiles for SFR10 cell line, 
the average percentage of CD133^ cells is 1 25% (a = ± 0 6%). The selected healthy SFR10 
cells from the unlabelled sample is shown in red, the isotype control sample are shown in 
green and the GDIS'" cells are shown in light black, a) Percentage of CD133'" cells is 1 32%, 
passage 8. b) Percentage of CD133"' cells is 1 81 %, passage 11. c) Percentage of GDI 33'" 
cells is 0 62%, passage 11. o denotes the standard deviation of the mean of three 
independent experiments.
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Figure 25: CD133 profiles for DMR10 cell line.
The x-axis for each histogram represents the wavelength. CD133 profiles for DMR10 cell line, 
for all profiles unspecific binding was responsible for any signal received.
CD 133 Isotype Control Histogram CD 133 Positive Cells Histogram
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CD 133 Isotype Control
Figure 26: CD133 profiles for SFG25 cell line
The x-axis for each histogram represents the wavelength. CD133 profiles for SFG25 cell line, 
for all profiles unspecific binding was responsible for any signal received.
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6.3.3. NG2 Profiles
Figure 27 shows the proportions of NG2'" and NG2' cells for the SFR10 
cell line, these experiments were repeated on two separate days. The mean 
average percentage of selected live SFR10 cells is 811%  of the population, 
(a = ± T 32% ). From the selected population of SFR10 cells, the mean 
proportion of NG2^ cells is only 2 83% (a = ± 2 36%). As discussed with the 
isolated CD133^ cells, for the purposes of isolating these cells with FACS, this 
would require unrealistic cell numbers for the intended experiments. 
Additionally, the standard deviation of the results is very high and therefore the 
stability of NG2 expression is uncertain. Furthermore, Figure 28 shows the 
proportions of NG2'" and NG2' cells for the DMR10 cell line. From the selected 
DMR10 cells, only 0 56% of the population were positive for the NG2 marker.
Moreover, the proportions of NG2^ and NG2' cells for the SFG25 cell line 
is shown in Figure 29, these experiments were repeated over two separate 
days. The average number of live and healthy cells selected was only 33-91% 
(a = ± 5-76%), from which the percentage of NG2^ cells is 54-63% 
(a = ±18-02%). Unfortunately, the passage number of the SFG25 cell line 
became too high and experimentation using this cell line became unstable. In 
addition, NG2 expression for both the SFG25 and SFR10 cell line fluctuates; 
this would create further complications if investigation of this marker continued, 
because the yield from sorting would not be conclusive enough to guarantee 
sufficient number of cells for each experiment. Therefore the use of the G25 
cell line and the NG2 marker ceased.
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Figure 27: NG2 profiles for SFR10 cell line
The x-axis for each histogram represents the wavelength. NG2 profiles for SFR10 cell line, the 
average percentage of NG2* cells is 2 83% with a = ± 2 36%. a) Percentage of GDIS'" cells is 
4 50%. b) Percentage of GDIS'’ cells is 1-16%. a denotes the standard deviation of the mean 
of two independent experiments.
DMR10 NG2 Isolype Control Histogram DMR10 Cells Isolated with NG2
NG2 Isolype Control
98.68% 1.32%
0 -10 10 10 10 10
Figure 28: NG2 profiles for DMR10 cell line
The x-axis for each histogram represents the wavelength. NG2 profiles for DMR10 cell line, 
the percentage of NG2* cells is 0 56%.
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Figure 29: NG2 profiles for SFG25 cell line
The x-axis for each histogram represents the wavelength. NG2 profiles for SFG25 cell line, 
average percentage of NG2* cells is 54-63% with a = ± 18-02%. a) Percentage of GDIS'" cells 
is 41 -89%. b) Percentage of GDIS'" cells is 67-37%. o denotes the standard deviation of the 
mean of two independent experiments.
Cell
Line
Marker Average % positive
SFRIO GDIS 85.52 ±5.72
DMRIO GDIS 25.97 ±2.36
SFRIO GD133 1.25 ±0.60
DMRIO GD133 0
SFRIO NG2 2.83 ±2.36
DMRIO NG2 0.56
SFG25 NG2 54.63 ± 18.02
Table 7: Summary of percentage of cells for each cell line that expresses each marker.
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6.4. Proliferation of Cell lines Within a Heterogeneous Tumour 
Population
97%
(/) 92% '
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1 1
82%
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Passage Number
Figure 30: Expression of CD15 marker for isolated CD15* cells in SFM
Proliferation profile for isolated GDIS'" cells grown in SFM and stained with GDIS antibody 
marker over seven passages, the duration between each passage is approximately 1 week. 
These profiles are based on live cells only. Error bars indicate the standard deviations of at 
least two experiments. The expression of the GDIS marker significantly falls (p < 0 03) on the 
4*^  passage (or 4 weeks)
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Figure 31: Expression of CD15 marker for isolated CD15' cells in SFM,
Proliferation profile for isolated GDI5' cells stained with GDIS antibody marker over seven 
passages, the duration between each passage is approximately 1 week. These profiles are 
based on live cells only. Error bars indicate the standard deviations of at least two 
experiments.
136
100%
80% -
u
40% -
20%
0%
21 32
Days
39 52
Figure 32; Expression of CD15 marker for isolated CD15* cells in DM.
Proliferation profile for isolated GDIS'" cells plated with differentiating media over time after 
sorting. These profiles are based on live cells only. Error bars indicate the standard deviations 
of at least two experiments. There is a significant loss of GDIS expression at each subsequent 
passage (p < 0.01S for the 2'^  ^passage, p < 0 026 for the 3''^  passage, p < 0 010 for the 
passage and p < 0 073 for the S'*' passage).
After sorting, the isolated cells for the CD15 marker were analysed for 
their proliferation methods. All proliferation experiments were performed in 
duplicates and statistical significance was determined using Welch’s two 
sample t-test. The results of all the proliferation profiles were based on live 
cells only.
Figure 30 shows the expression of the CD15 marker over time for the 
isolated GDIS'" cells, to analyse the self-renewal capabilities as well as 
differentiation to a progenitor cell. Once the SFR10 cells were sorted for the 
two subpopulations, the expression of the CD15 marker significantly falls 
(p < 0 03) on the 4**^  passage (or 4“^ week) from 98 4% (a = ± 0 34%) to 
96 9% (a = ± 0 31%). In comparison to the number of cells expressing GDIS
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in passage 1, there is a significant loss of CD15 expression for passages 4, 6 
and 7 (p < 0 011, 0-0007, 0-02 respectively).
Additionally, isolated GDIS'cells were grown in SFM and analysed for 
their expression of the GDIS marker over time. If the isolated GDIS' cell line is 
considered to be a progenitor cell, this proliferation analysis investigates the 
possible de-differentiation capability of progenitor cells. Figure 31 shows the 
number of isolated GDIS'cells that express GDIS after the first passage. 
Although expression of the GDIS marker fluctuates over the seven passages 
(or 7 weeks) for all passages, there are no significant changes in expression.
After sorting, isolated GDIS'" cells were grown in DM for up to S2 days 
(Figure 32). The growth of the cells was much slower; therefore the time 
between each passage was greater than a week. All subsequent passages 
resulted in a significant loss of GDIS expression, such that with each passage 
the expression of GDIS drops significantly compared to the previous passage.
6.5. Radiosensitivity of RIO Cell lines Within a Heterogeneous Tumour 
Population
For each experiment, a clonogenic assay, using the T2S flask method, 
was used to generate survival fractions (using Equation 9) for each of the cell 
lines when exposed to radiation (Gy). The experimental data were fitted to 
both the LQ and IRR models and optimised for the best possible solutions. All 
experiments were performed in triplicates and on three separate days, and 
statistical significance was determined using Welch’s two sample t-test.
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Figure 33. Survival fraction of experimental results for all subpopulations of the R10 cell 
line.
Survival fraction of experimental results for all subpopulations of the R10 cell line, plotted 
against the exposure to X-ray irradiation with doses of 0, 0 25, 0 5, 1, 2, 4 and 6 Gy. The LQ 
and IRR models were used for fitting, a) Survival fraction for SFR10 cells, the mean plating 
efficiency is 46-89% (a = ± 9-64%). IRR Ze  ^= 0 006 LQ Ze^ = 0 0276. b) Survival fraction for 
DMRIO cells, the mean plating efficiency is 116-89% (a = ± 8-15%). IRR le^ = 1-043.
LQ le^ = 0-012. c) Survival fraction for isolated CD15^ cells, the mean plating efficiency is 
25-37% (a = ± 3-34%). IRR le^ = 0-031. LQ le^ = 0-054. d) Survival fraction for isolated 
GDI5' cells, the mean plating efficiency is 16-17% (a = ± 3-22%). IRR Ze^ = 0-026.
LQ Ze  ^= 0-026. e) Survival fraction for all cell linesfitted with the LQ model. The error bars 
denote the standard deviation a of the mean of three independent experiments with triplicate 
data.
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Figure 34; a/p ratios for all subpopulations of the R10 cell line.
The error bars denote the standard deviation a of the mean of three independent experiments 
with triplicate data.
SFR10 DMRIO CD15+ GDIS'
Or 0 82 ± 0 27 0-46 ± 0-15 0 11 ±0 09 0.43 ± 1.33
0: Qs -100 ± 0 003 -0-26 ± 0 23 0-77 ±0-12 0-00 ± 1.360^
Do 0.64 ±0.12 0-63 ± 0-01 2 35 ±0  73 0.97 ± 2.45
P 0-00 ±0*20 0-00 ± 0-03 0 04 ±0-02 0.004 ± 0.19
a 0-47 ±0.038 0 391 ±0  07 0-54 ± 0-08 0.43 ± 0.09
a_i P 0 19 ± 0.078 0 118 ± 0 11 0-00 ± 0-00 0.06 ±0.10
BED2 108-97 ±20-01 96-33 ±20-98 60-00 ± 1.42 X -5 78.07 ± 12-70
Table 8 : Mean values and standard deviations of parameters for LQ and IRR models, as well 
as the a/|3 ratios and the BED2  (biologically effective dose at 2 Gy) for all subpopulations of the 
RIO cell line.
The survival curves for all four subpopulations of the R10 cell line are 
presented in Figure 33 a, b, c and d. The graphs show that the SFR10 cell line 
and isolated CD 15  ^ cell line follow the IRR model, as shown by the sum of the 
squared errors (le^) which were sufficiently reduced to 6 0 x 1CT^  and 
3 2 X 10'  ^ respectively, both of which were lower than the le^ for the LQ 
model. The lower value for the le^ when fitted with the IRR model suggests
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these cell lines may express HRS. In contrast, both the DMR10 and isolated 
CD15’ cell lines optimally fit the LQ model with corresponding values for Ze  ^of 
1 2  X 10'  ^and 2-6 x 10^\
As mentioned in Section 5.9, the alpha-beta (a/(3) ratio (Gy) and 
BED (Gy) parameters will be used to compare the effect of radiation on each 
cell line. Table 8 shows the BED2 (biologically effective dose at 2 Gy) for all 
cell lines and Figure 34 shows the resulting a/p ratios. The a/p ratio for the 
DMRIO cell line is 3 30 Gy, which is significantly different from the isolated 
GDI 5' cell line (p <0 011), which has an a/p ratio of 6 64 Gy. Furthermore, the 
SFRIO cell line has an a/p ratio of 2 45 Gy which is significantly lower 
compared to the DMRIO cell line (p<  0 10) and the isolated GD15‘ cell line 
(p < 0-008). The repair capacity for the isolated GDI 5' cell line is much higher 
than the early responding cell lines DMRIO and SFR10. Hence the BED2 for 
the DMRIO and SFRIO cell lines is lower, which suggests that these cell lines 
are more sensitive than the isolated GD15' cell line. Gonsidering the p 
coefficient for the isolated GDI 5  ^cell line tends to zero, the a/p ratio for all cell 
lines are therefore significantly different to the a/p ratio for the 
isolated GDIS'" cell line. Subsequently, when p tends to zero, as expected the 
BED2 tends to 60 Gy and therefore the isolated GDIS'" cell line is a very 
sensitive cell line.
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6.6. Sensitivity of RIO Ceil lines to TMZ Within a Heterogeneous 
Tumour Population
For each experiment a clonogenic assay, using both the T25 flask 
method and the 96 well plate method, was used to generate survival fractions 
(using Equation 9 and Equation 11) when exposed for 24 hours to varying 
doses of TMZ (pM). All experiments were performed in triplicates or 
quadruplets, depending on the method for the clonogenic assay, and on three 
separate days. The experimental data were optimally fitted to the Hill model 
and all statistical significance was determined using Welch’s two sample t-test.
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Figure 35: Survival fraction of experimental results for SFRIO cells, using the 96 well 
plate method.
Survival fraction of experimental results for SFR10 cells, using the 96 well plate method, 
plotted against the exposure to TMZ for 24 hours with concentrations of 0, 0.1, 1, 5, 10, 25 and 
50 pM. The mean plating efficiency is 1 ■36% (a = ± 0-089%), and the Hill model was used for 
fitting with le^ = 0-031. The error bars represents the standard deviation a of the mean of 
three independent experiments with quadruplet data.
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Figure 36: Survival fraction of experimental results of DMR10 cells, using the T25 flask 
method.
Survival fraction of experimental results for DMR10 cells, using the T25 flask method, plotted 
against the exposure to TMZ for 24 hours with concentrations of 0, 0.1, 1, 5, 10, 25, 50, 100, 
150 and 250 pM. The mean plating efficiency Is 149-38% (a = 38-56%), and the Hill model 
was used for fitting with le^ = 0-039. The error bars represents the standard deviation a of the 
mean of three Independent experiments with triplicate data.
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Figure 37: Survival fraction of experimental results for the isolated CD15* cell line.
a) Survival fraction using the 96 well plate method, plotted against the exposure to TMZ for 24 
hours with concentrations of 0, 0-1, 1, 5, 10, 25 and 50 pM. The mean plating efficiency 1-21% 
(a = 0-61 %), and the Hill model was used for fitting with le^ = 0-058. The error bars represents 
the standard deviation a of the mean of three Independent experiments with quadruplet data.
b) Survival fraction using the T25 flask method, plotted against the exposure to TMZ for 24 
hours with concentrations of 0, 0-1, 1, 5, 10, 25 and 50 pM. The mean plating efficiency Is 
27-11% (a = 11-95), and the Hill model was used for fitting with le^ = 0-002. The error bars 
represents the standard deviation a of the mean of three Independent experiments with 
triplicate data.
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Figure 38: Survival fraction of experimental results for the isolated CD15' cell line.
a) Survival fraction of experimental results using the 96 well plate method, plotted against the 
exposure to TMZ for 24 hours with concentrations of 0, 0 1, 1,5, 10, 25 and 50 pM. The mean 
plating efficiency is 0-647% (a = 0-19%), and the Hill model was used for fitting with 
le^ = 0-125. The error bars represents the standard deviation a of the mean of three 
independent experiments with quadruplet data, b) Survival fraction of experimental results 
using the T25 flask method, plotted against the exposure to TMZ for 24 hours with 
concentrations of 0, 10, 25, 50, 100, 150 and 250 pM. The mean plating efficiency is 10-61%
(a = 2-12%), and the Hill model was used for fitting with le^ = 0-028. The error bars represents 
the standard deviation a of the mean of three independent experiments with triplicate data.
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Figure 39: IC5 0  values for SFR10, DMRIO, CD15  ^ R10 and CD15' cells.
IC5 0  values for SFR10, DMR10, isolated GDI 5"^  and isolated GDI 5‘ cell lines. Both the T25 
flask and 96 well plate methods were used for the isolated GDI 5"' cell line and the isolated 
GDI5 cell line. The 96 well plate method was used for the SFRIO cell line and the T25 flask 
method was used for the DMRIO cell line were used. The error bars represents the standard 
deviation a of the mean of three independent experiments with either triplicate or quadruplet 
data.
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96 Well 
Plate Method
T25 Flask 
Method
Cell Line Mean I C 5 0 Mean I C 5 0
SFRIO 9.01 ± 0.08
DMRIO 10.45 ±0.05
GDI 5+ RIO 6.31 ±0.11 6.39 ±0.12
G D I5- RIO 5.36 ± 0.20 5.19 ±0.14
Table 9: The mean average IC5 0  values for each cell line using both methods.
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Figure 35 and Table 9 shows the survival fraction (calculated with 
Equation 11) for the SFRIO cell line after doses of 0-50 pM of TMZ. Results 
were obtained using the 96 well plate method for the clonogenic assay and, as 
expected, the relation between dose and survival fraction is non-linear and 
negative because of the inhibitory effect of the drug. The mean plating 
efficiency for the SFRIO cell line is T36%  (a = ± 0 09%) and the le^ was 
reduced to 3-07x10‘ .^ The IC50 value for TMZ on the SFRIO cell line is 9-01 
pM and is statistically different to all other cell lines for both methods. 
Figure 36 displays the effect of TMZ on the DMRIO cell line using the T25 flask 
method for the clonogenic assay, with doses varying from 0-250 pM. The 
survival fraction was calculated using Equation 9 and the plating efficiency is 
149-4% ( 0  = 38-6%). Figure 39 shows that the IC50 value for TMZ on the 
DMRIO cell line is 10-45 pM and is significantly different to the IC50 value for 
TMZ on the SFRIO cell line (p < 7-5 x 10’®). Therefore the DMRIO cell line is 
more resistant to TMZ than the SFRIO cell line. Furthermore, the IC50 values 
for both the SFRIO and DMRIO cell lines are significantly different to the IC50 
values for all the other cell lines for both methods (see Table 10).
The effect of TMZ on the isolated CD15^ cell line can be seen in 
Figure 37 a and b, obtained from the clonogenic assay using the 96 well plate 
and T25 flask methods respectively. Doses ranged from 0-50 pM when using 
the 96 well plate method, and from 0-250 pM for the T25 flask method. The 
plating efficiency for the cell line significantly changes (p < 0.06) with the 
method used, such that the plating efficiency for the 96 well plate method was 
1-21% (a = 0-61) and for the T25 flask method it was 27-1% (a = 11-95). The
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ICso value for TMZ on the isolated GDIS'" cell line, for the 96 well plate method 
was 6 31 pM, and similarly for the T25 flask method it was 6 39 pM (see 
Figure 39). The two IG50 values for the isolated GDIS'" cell line were 
statistically the same (p > 0 4). Therefore the isolated GDIS'" cell line is more 
sensitive to TMZ than both the SFR10 and DMR10 cell lines. Furthermore, 
both the IG50 values are significantly different to the IG50 values for all the other 
cell lines for both methods when they were used (see Table 10).
Figure 38 a and b shows the survival curves for the isolated GDIS' cell 
line when exposed to TMZ using the 96 well plate method and T25 flask 
method respectively. Similarly to the isolated GDIS'" cell line, the doses ranged 
of TMZ from 0-50 pM when using the 96 well plate method, and from 0-250 pM 
for the T25 flask method. The IG50 value for TMZ on the isolated GDIS' cell 
line was 5 36 pM for the 96 well plate method and 5-19 pM for the T25 flask 
method. Therefore, isolated GDIS'cell line is the most sensitive cell line to 
TMZ. Furthermore, these IG50 values were significantly comparable (p > 0 4) to 
each other and significantly different to the other subpopulations (see Table 
10). Similarly with the isolated GDIS'" cell line, the plating efficiencies for the 
isolated GDIS' cell line are also statistically different (p < 0 09) when using the 
two different methods.
Concluding Comments
The results presented in this chapter show that a proportion of the RIO 
cell line is positive for the GDIS marker, such that the cell line can be sorted 
with FAGS to isolate cells that are positive and negative for the marker.
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Therefore the R10 cell line can be divided into four cell lines; SFR10, DMR10, 
isolated GDIS'" and isolated GDIS' cells. Furthermore, each subpopulation of 
R10 cell has a significantly different doubling time.
This chapter also explored the expression of the GD15 marker over time 
for the isolated GDIS'" and isolated GDIS' cells. Significant loss of the GDIS  
marker from the isolated GD1S^ cell lines occurs on the 4^  ^ week, whereas 
expression of the GDIS marker by the isolated GDIS' cell line fluctuates over 
time. When the isolated GDIS'" cell line is grown in DM the loss of GDIS  
expression significantly decreases with each passage.
The final part of this chapter investigates the effects of radiation and TMZ 
on each subpopulation of cells. Both the a/|3 ratios and IG50 values for TMZ of 
each subpopulation are significantly different, interestingly, the order of 
sensitivity for radiation differs to the order of sensitivity to TMZ. These findings 
will be discussed further in the next chapter.
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7. Discussion of Experimental Results
7.1. Introduction
Due to the known heterogeneity of GBM many questions have been 
raised with regards to the growth of the tumour and the inherent sensitivities of 
the different cell lines to radiation and drug. This chapter discusses the results 
presented in Chapter 6, which attempts to elucidate some of these questions. 
Very little data is available on the therapeutic effects on CD15^ cells; therefore 
this study attempts to investigate the effects of radiation and TMZ on isolated 
CD15^ and isolated CD15' cells.
A number of studies have attempted to investigate the radiosensitivity of 
CSC cells positive for the CD133 marker, using specific death pathways as an 
endpoint. However, one assay for cell death is not sufficient to encapsulate all 
death pathways and therefore may conceal some of the effects from radiation 
or drug; therefore the results from the previous chapter used the clonogenic 
survival assay.
7.2. The Growth of GBM
In this project, the R10 cell line was either grown in different conditions or 
sorted using FACS to produce the following four cell lines; SFR10, DMR10, 
isolated CD1!^ and isolated CD15’. The doubling time significantly changes 
with each cell type with the exception of the SFR10 cell line, however the 
SFR10 cell line is a heterogeneous population enriched for BTSC cells and 
progenitor cells. Therefore it is to be expected that the doubling time for the 
SFR10 cell line is not significantly different from the doubling time of the other 
cell lines.
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The different doubling times support the probability that these cell lines 
are in fact phenotypically different from each other. The isolated CD 15" cell line 
has the fastest doubling time of just less than 29 hours. At this stage, we 
assume the population of the isolated CD15' cell line are heterogeneous, 
because they are not sorted for a specific cell marker, however for the absence 
of the CD15 receptor. Furthermore, if these cell lines are considered to be 
progenitor cell lines, then these results corroborate the theories brought 
forward by Persano et al. [32] and Panagiotakos et al. [40] such that 
progenitor cells have a high proliferation rate.
Moreover, the isolated CD15^ cell line has a longer doubling time in 
comparison to the isolated CD15* cell line. If the isolated CD1!^ cell line is 
considered to be a BTSC cell, the doubling rate therefore agrees with many 
studies that suggest that they are almost quiescent [32,40,42]. The doubling 
time of the DMR10 cell line is is significantly slower in comparison to the 
isolated CD15^ cell line, which also agrees with the work of Persano [32]. 
Although the DMR10 cell line is a heterogeneous cell line, the population is 
dominated by the more differentiated cells (Figure 23), namely the progenitor 
cells and TDC cells. Furthermore, the population is likely to be primarily TDC 
cells, because the doubling time is significantly different from the isolated 
CD 15' cell line. If the DMR10 cell line is predominantly composed of TDC cells, 
this suggests that signalling between the cell lines plays a part in the growth of 
the tumour, since the doubling time of the isolated CD15' cell line appears to 
be outweighed. This is further supported by Figure 31, which shows that when 
there are initially no isolated CD15^ cells in the population, over time the cells 
express CD15. This change in expression is possibly due to pathways being
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activated to maintain the BTSC cell subpopulation [40] and thus the cells 
de-differentiate.
The proportions of the isolated CD1!^ cell line found in the DMR10 
population, approximately agree with the range (0 3-25 1%) suggested by 
Singh et al. [47], however, differences between these results may be due to 
the fact the results are based on CD133 positive cells. Furthermore, the 
differentiation of the isolated CD15"" cell line when grown in DM is very slow, 
taking 4 weeks before the expression of the CD15 marker is lost. This is likely 
to be due to the quiescent nature of the cells, which in turn could affect the 
downstream processes initiated from cell to cell signalling. After the initial loss 
of expression of the CD15 marker, further loss increases exponentially, 
perhaps due to the rapid proliferation rate of the isolated CD 15" cell line.
Although there appears to be an expression of the CD133 marker in the 
SFR10 cell line after negation of the isotype control, nevertheless, it is 
probable that the signal is due to unspecific binding since all signal is lost in 
the DMR10 cell line. Panagiotakos et al. [40] suggest that it is highly 
implausible that the BTSC cell proportion would be completely lost due to cell 
signalling [40].
The NG2 marker is considered to be a progenitor marker [40], and 
expression of the NG2 marker for both the SFR10 cell line and the SFG25 cell 
line is not consistent. These inconsistencies therefore supports suggestions 
that the proportion of the progenitor cell lines vary when the proportion of the 
BTSC cells and TDC cells change [40]. Furthermore, Figure 31 shows
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inconsistencies of the CD15 marker expressed by the isolated CD15' cell line, 
which further suggests that these cell lines (or some of the cell lines) are 
progenitor cells.
Although these results do not conclusively clarify or quantify each of the 
mechanisms involved in the proliferation of the isolated CD 15* cell line, the 
results definitely suggest that growth of each cell type is aided via cell to cell 
signalling. Furthermore, Figure 31 also shows that in the absence of CD15* 
cells, the isolated CD15' cell line de-differentiates back to the CD15* cell line. 
This result not only reiterates that growth and proliferation is supported with 
cell signalling, it also indicates that there is an importance of the CD 15* cell 
line to drive the growth of the tumour therefore confirming our hypothesis. 
Furthermore, we hypothesised that BTSC cells and progenitor cells are 
capable of symmetric and asymmetric self-renewal, which is shown by Figure 
30. Figure 30 suggests the isolated CD15* cell line initially proliferates via 
self-renewal, however after 4 weeks of growth (4 passages) the cells also 
begin to proliferate via asymmetric self-renewal. Additionally, we hypothesised 
that the progenitor cells can also de-differentiate back to a BTSC cell. 
Figure 31 shows that although de-differentiation fluctuates over time, there is 
definitely evidence of de-differentiation to a BTSC cell.
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7.3. Radiosensitivity of RIO Cell lines Within a Heterogeneous Tumour 
Population
The four subpopulations of the R10 cell line were irradiated with X-rays at 
the Royal Surrey County Hospital. Very little data is available on the 
radio-sensitivity of isolated CD15* cells; therefore this study attempts to 
investigate the effects of radiation on CD15* and CD 15" cells. Furthermore, the 
results from the radiation experiments endeavour to answer our hypothesis 
that a heterogeneous tumour would give rise to subpopulations of different 
radio-sensitivities. However, the experimental data does not distinguish the 
sensitivity to radiation around the cell cycle. Further, investigation of phase 
sensitivity could contribute to our understanding of either the adaptive 
response mechanism or the two-population theory.
Using the BED, the radiosensitivity of each cell line is significantly 
different from each other, such that the order of sensitivity is as follows; the 
isolated CD15* was the most radio-resistant cell line, followed by the isolated 
CD15", DMR10 and finally the SFR10 cell line was the most radiosensitive.
From the results presented in Section 6.5 the isolated CD 15* cell line was 
significantly the more resistant subpopulation of the RIO cell line. Assuming 
this cell line is considered to be a BTSC cell line, this result coincides with the 
findings in the current literature. Lomonaco et al. [80] indicate that cells 
positive for the known stem cell marker CD133 are more resistant than the 
CD133" cell line due to their autophagic response, which acts as a defence 
mechanism to y-radiation, thus contributing to their radio-resistance. Due to the
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quiescent nature of the cell line, enough time was allowed for repair of any 
DMA damage.
The isolated CD15' cell line is the next most radio-resistant subpopulation 
of the R10 cell line. This may be due to the rapid doubling time of the cell line, 
such that from the cells that survive radiation they are able to quickly replenish 
the cells that are lost. Furthermore, results show (Figure 31) that the isolated 
CD15' cell line is capable of de-differentiating to a CD15* cell line to drive the 
growth of the cells and therefore contribute to the radio-resistance of the cell 
line.
As mentioned earlier, the isolated CD 15' cell line is likely to still be a 
heterogeneous population of cells, since they were not sorted for a marker but 
for the absence of CD15. Therefore, further separation of this cell line could 
reveal cells that have a range of sensitivities. However, from these results, 
radio-resistance decreases as the cells differentiate and become more 
specialised, thus indicating that more repair pathways are switched off.
These results confirm our hypothesis that a heterogeneous tumour 
population would give rise to subpopulations with different sensitivities to 
radiation. Furthermore the results indicate that delivery of a uniform dose of 
2 Gy per fraction may not be the optimal approach for treatment. It may be 
beneficial to exploit the different sensitivities using an asymmetric radiotherapy 
treatment (ART) such that the treatment delivers three fractions per day with 
regular and equal intervals between each fraction. The two initial equal low
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doses followed by a third dose of (2-2Diow) Gy, thus achieving a standard total 
dose of 2.0 Gy per 24 hour period (see Section 8.4).
Additionally the data presented show that the isolated CD15* cell line 
along with the isolated CD 15" cell line are more resistant that the SFR10 cell 
population which is made up of a mixed population of the these cell types. This 
implies that the survival curve for a mixed population is oversimplified by 
considering the survival curves of the two cell types independently and taking 
in to account their relative proportions due to the possible effects of cell to cell 
signalling on survival. Possible experiments that could determine any possible 
inter-cellular signalling could be to remix different proportions of the isolated 
CD15* cell line and CD15' cells and determining the clonogenic survival of 
these known mixed populations.
Furthermore, with further investigation of the cell signalling, other 
treatment strategies could be proposed using concomitant drugs that 
counteract the signalling. Particular focus on the isolated CD15' cell line should 
be considered to prevent de-differentiation to a CD 15* cell. Wnt signalling is 
responsible for the differentiation of stem cells [134]. However, the precise 
mechanisms of these signalling pathways are yet to be fully established, 
therefore the investigation of drug inhibition would be a future concept to 
explore.
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7.4. Sensitivity of RIO Cell lines to TMZ Within a Heterogeneous 
Tumour Population
The four subpopulations of the R10 cell line were exposed for 24 hours to 
TMZ and the associated IC50 values for each cell line were significantly 
different from each other. Furthermore, each of the IC50 values were very low 
which suggest that the MGMT status for every cell line is negative [99] (see 
Section 2.6.2) and therefore the double or single strand breaks due to the 
removal of the methylated guanine are not repaired.
The isolated CD 15' cell line was the most sensitive cell line to TMZ. In 
addition to the potential negative MGMT status of the cell line, the rapid 
doubling time may also contribute to the sensitivity due to mis-repair or lack of 
repair. The most resistant subpopulation of the RIO cell line to TMZ is the 
DMR10 cell line, however the IC50 was still very low (10-45 pM), which 
therefore suggests that the MGMT status is also negative. Contrary to the 
isolated CD 15' cell line, the longer doubling time may have aided with repair of 
the double or single strand breaks, or both, therefore causing the cell line to be 
slightly more resistant to TMZ. Aspects of this result disagree with the results 
of Persano et al. [32] who states that the more differentiated cells are 
M GMT and therefore the most sensitive cell line of the tumour, however the 
results of this project show that this cell line is the more resistant.
The isolated CD 15* cell line is significantly less sensitive to TMZ than the 
isolated CD15' cell line. Similarly to the DMR10 cell line, the slower doubling 
time may have contributed to the slight increase in resistance to TMZ. Again 
these results contradict the results of Persano et al. who states that the CSC
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cell is the most sensitive to TMZ with a positive MGMT status. Without any 
genotyping of the isolated CD15* cell line, the MGMT status is not conclusive, 
however with a very low IC50 value for TMZ it is very likely that the MGMT 
status is negative.
It is interesting that the SFR10 cell line is more resistant than both the 
isolated CD15' and the isolated CD15* cell lines. Considering the SFR10 cell 
line is a combination these two cell lines, it would be expected that if no cell 
signalling occurs, the IC50 value for the SFR10 cell line would be an average of 
these two cell lines. However, the IC50 value is significantly higher than both 
the IC50 values of the isolated cells, where p < 8  33 x 1 0 ‘® and 191 x 1 0 '^  for 
isolated CD15* cells using the 96 well plate method and T25 flask method 
respectively and p < T 37  x 10'  ^ and p < 4 82 x 10'  ^ for isolated CD15' cells 
using the 96 well plate method and T25 flask method respectively.
The two different methods for the clonogenic assay produce IC50 values 
for TMZ that are significantly the same for both the isolated cell lines. Although 
the plating efficiencies differed, this was considered when calculating the 
survival fractions (Equation 8  and Equation 10). Therefore, this results shows 
that either method can be used without altering the outcome of the 
experiments. The results from the TMZ experiment confirm our hypothesis, 
such that the subpopulations of a heterogeneous tumour would engender 
heterogeneous sensitivities to chemotherapy drugs. The differences in the 
plating efficiencies are not fully understood, however it is likely that it is due to 
the different adhesion substrates used for each method, such that fibronectin
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was used for the T25 flask method and ECM was used for the 96 well plate 
method.
Concluding Comments
This chapter discussed the experimental findings of this project, and 
where possible compared the results to the current literature. The first part of 
this chapter discusses the growth and proliferation of each cell line and 
supports our hypothesis that CSC cells and progenitor cells are capable of 
symmetric and asymmetric self-renewal and that progenitor cells can also 
de-differentiate back to CSC cells. All doubling times, with the exception of the 
SFR10 cell line, were significantly different and support the work of 
Persano [32] and Panagiotakos [40]. Furthermore, results from the proliferation 
of the marker indicate that the growth and proliferation of each cell line is 
assisted by cell signalling.
In addition, our findings proved our hypothesis such that, given a 
heterogeneous tumour population, each subpopulation has significantly 
different sensitivities to radiation and TMZ. These results could potentially alter 
the current approaches in the treatment of GBM, as they imply the possibility to 
individualise treatment to exploit this range of sensitivity. The results from the 
TMZ experiments do not follow the results of Persano [32] such that our results 
showed that the most resistant cell line to TMZ was the DMR10 cell line not the 
CSC cell line as suggested. Instead, our finding showed that the isolated cell 
lines (or CSC cells and progenitor cells) were more sensitive to TMZ. 
However, overall every cell line was sensitive to TMZ which suggests that the
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MGMT status was negative throughout the hierarchy, whereas Persano [32] 
suggested that the status changed with differentiation.
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8. Computational Methods
8.1. Introduction
Mathematical models, such as the model used in this report, can be 
descriptive, predictive or explanatory. Descriptive modelling involves designing 
a model for a given system, then fitting observed experimental data to the 
model in order to determine any unknown parameters. Mathematical models 
can be used for explanatory reasons for example to understand the underlying 
mechanisms for a given output. The purpose of this chapter is to describe the 
mechanisms of the model in detail, as well as relating the model to the 
simulated biological processes.
8.2. Population Balance Equation
A population balance equation is typically shown in Equation 14 and is 
usually a partial differential equation (PDE).
rate of change = inflow and outflow + birth -  death
Equation 14
Using Equation 14, the model is based on the PDE below (Equation 15).
^ -  n,(t,T.)) -  -  X
*
Equation 15
The variable (t, Xx) is the age density of the population (cell m'  ^h' )^ in each 
phase (x ) of the cell cycle with ages between t and x%. The independent 
variables t and xx respectively denotes time and the age of the cell in phase x.
The term ^ ( n x ( t ,T x )  -  rixiCt,Tx)) represents the inflow and outflow of the 
cell population within the system of volume V. The system in this circumstance
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is the tumour mass and the flow (F ( t ) )  into and from the tumour is normally 
assumed to be zero. The term n x i (t, X x )  denotes the age distribution of cells 
within a given phase (x ) that enters the control volume and the term Hrjx 
describes the movement of cells to the subsequent phases and will be referred 
to throughout the report as the transition rules.
Removing the inflow and outflow term, and rearranging the equation we have
G-
drixCt.Tx) dn^Ct.Tx)
■ + — ;-------= -  /  ndt ' dtx Z -ij= i- I
Equation 16
The function n x i( t ,  Xx) can be expressed with the chain rule so that the 
resulting PDE shown in Equation 17 which corresponds to the population 
balance equation shown in Equation 16.
Dt \  dt J V  Ô T  /
Equation 17
The rate of change in age with respect to time is constant and thus the 
PDE is reduced to an ordinary differential equation (ODE) {Equation 18) with 
the characteristic equations £  = £  = l-
Equation 18
Equation 16 is the primary equation to be solved by numerical method 
employed in the simulation program. As mentioned in Section 3.3, transition 
rules can be modelled as functions of limiting nutrient content or limiting space
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or by fixed probabilities. Fixed probabilities are used in this study to model the 
transition of cells around the cell cycle and down the BiDMuLD (see Figure 1).
8.3. Modelling the Growth of BTSC Cells
As shown by the experimental aspect of this report, the BTSC cell line 
proliferates in a distinct manner. The differentiation cascade begins with the 
division of the BTSC cell to a range of progenitor cells, which will then 
differentiate to a terminally differentiated cell (TDC) [135]. The population 
balance equation (Equation 15) is solved numerically with respect to the age of 
the cells and time [136], and can model many cell cycles concurrently [137]. 
Similarly to the work of Tomlinson et a/.[122] this solution was achieved 
through use of compartments, such that each cell cycle can have any number 
of phases with its own time period, which are composed of one or more 
compartments which are referred to as age elements. The age elements, 
arranged as linked lists; are a discretisation of the population equation 
(Equation 18), and allow the determination of the age density of the cells within 
the cell cycle [119,138]. Each element of the list represents At (e.g. an hour) of 
the lifespan of the cells.
Previously work of this model [6], introduced a basic four level, 
uni-directional differentiation cascade to simulate the growth of BTSC cells and 
their progeny, as well as incorporating the effects of radiation. As a 
modification to the work, this study assumes that when proliferating, the BTSC 
cell line will divide down a differentiation cascade with only three levels; BTSC 
cells, progenitor cells and the TDC cells. Furthermore, the cascade is now 
referred to as the BiDMuLD cascade (Figure 1). The tumour will proliferate as
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a result of the following six processes; symmetric and asymmetric 
differentiation, symmetric and asymmetric de-differentiation and asymmetric 
and symmetric self-renewal.
The model assumes the BTSC cell is positive for a stem cell marker and 
negative for a progenitor marker. This cell line is capable of four modes of 
proliferation; symmetric and asymmetric differentiation and asymmetric and 
symmetric self-renewal (see Figure 40). Conversely the furthermost 
differentiated progenitor cell is assumed to be positive for a progenitor marker 
and negative for a stem cell marker, whereas the transient progenitor cells 
are assumed to be either positive for both the progenitor and stem cell markers 
or negative for both. These three cell lines are capable of all six method of 
proliferation (see Figure 40). The model allows for up to two TDC cells; TDC1 
and TDC2. These cell lines are not capable of proliferating, they are expected 
to grow and die (see Figure 40)
To implement this proliferation down the BiDMuLD cascade in this model, 
each age element of the discretised population balance has an associated list 
of transition rules which determines where cells leaving the age element will be 
directed. The model calculates the number of cells in each age element after 
every time step by the use of the transition rules. When each new time step is 
calculated, the cells progress from one age element to another.
The transition rules can represent phenomena other than proliferation, 
e.g. cell death, and damage due to radiation. Table 11-Table 15 show the 
transition rule parameters with their descriptions and the values used to model 
the experimental data. Although generically the model is capable of modelling
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BTSC cells that are positive for two antibody markers, the R10 cell line was 
only tested for the CD15 marker due to time restriction of this project. 
Therefore some of the parameters are set to zero, however scenarios can be 
developed for a model based on proof of principle.
Asymmetric differentiation and the associated asymmetric self-renewal 
are computationally distinct, despite resulting in the same biological outcome. 
Asymmetric self-renewal simulates the progression of one new cell to the start 
of the current cell cycle. Contrary to asymmetric self-renewal, asymmetric 
differentiation is associated with the new daughter cell starting a new cell 
cycle. For similar reasons, the asymmetric de-differentiation and the 
associated asymmetric self-renewal are also computationally distinct. It is 
assumed that the values for all transition rule parameters that are concerned 
with asymmetric self-renewal are set equal to the values of the corresponding 
rule for asymmetric differentiation or de-differentiation.
The boundary conditions were carefully chosen, as described below, to 
produce a robust model. The simulation was started with just one BTSC cell in 
the G1 phase and no attempt was made to simulate the mutation event from a 
NSC. All tumours were grown for 2016 iterations, the equivalent to 3 months of 
real-time tumour growth. It was assumed that all the parameters associated 
with the transition rules were constant with time; no other tumour aging effects 
were considered (Figure 45). Furthermore, it was assumed the cells will always 
propagate along the differentiation cascade; hence all transition rules for 
symmetric differentiation were designated default rules.
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Normal Transition
—► Recycle Transition 
;> > Symmetric Self-renewal 
Asymmetric Self-renewal 
Asymmetric Differentiation
TDC2TDC1
Figure 40: Transition rules for the BDML cascade.
Schematic of transition rules showing the growth methods for normal transition around the cell 
cycle and recycle around each phase of the cell cycle, as well as the proliferation routes for 
symmetric self-renewal and asymmetric differentiation/self-renewal.
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-►  Normal Transition
Recycle Transition
Symmetric Differentiation
Symmetric De-differentlon
TDC1 TDC2
Figure 41; Transition rules for the BDML cascade.
Schematic of transition rules showing the growth methods for normal transition around the cell 
cycle and recycle around each phase of the cell cycle, as well as the proliferation routes for 
symmetric differentiation and symmetric de-differentiation.
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-►  Normal Transition 
Recycle Transition 
Asymmetric Self-renewal 
Asymmetric De-differentiation
TDC1 TDC2
Figure 42: Transition rules for the BDML cascade.
Schematic of transition rules showing the growth methods for normal transition around the cell 
cycle and recycle around each phase of the cell cycle, as well as the proliferation routes for 
asymmetric self-renewal and asymmetric de-differentiation.
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-►  Normal Transition
Recycle Transition
r
TDC1 TDC2
Figure 43: Transition rules for the BDML cascade.
Schematic of transition rules showing the growth methods for normal transition around the cell 
cycle and recycle around each phase of the cell cycle, as well as the routes from each cell line 
to death.
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8.3.1. Boundary Conditions for Equation 18:
The proliferation factor (P) for this model is set as two. Descriptions of each 
parameter can be found in Table 11-Table 15.
%T5CGi(t»0) = (%rSCGi(t<TB7-SCci) ^ ^^^^Glrecycle)
+  [^P X  U b t s Cm ^ ’ ^BTSCi^  X  ( b T S C st +  ^ '^ ^ ^ asrcN n eg  ^ ^ ‘^ ^ “srcjvpos)]
+  [P  X  U B p y ie g j^ {t,T 2 P fie g j^  X  (^BPnegaddpTSC  ^  ^ ^^ ^ d sd d B T S C ^ l 
+  [P  X  'Hb Pp o s m (P>^BPp o s m )  ^  (.^ ^ P ^ ^ ad d B T sc  ^ ^ P ^ ^ s d d g p s c )^
Equation 19
TT-BTSCs(- '^ )^ ~ i } ~  ^^ ^^ Glrecycle)''^ BTSCGi(j^ ’ '’^ BTSCci) + (j^ BTSCsi^ >'^ BTSCs) ^ '^^ ^^ Srecycle)
Equation 20
T^BTSCG2^ t>^ ) = ( l  -  BTSCs^ ^^ ^^ ^^ riBTsCs{^ ’ '^ BTSCs) + (^ Br5CG2 ( '^’^ B7SCg2 )  ^ '^^ ^^ Glrecycle)
Equation 21
T^BCmC^ 'O) = ( l  -  ^ ’^ ^^ Glrecycle) ”B7’SCg2 (^ ' ■^B7’5Cg2) + (^ BTSCm(^ >'^ BTSCm) ^ ^ ’^ ^^ Mrecycle)
Equation 22
C^NnegGl^ '^ ~ (j^ BPnegGiip’ B^PnegGi^  ^ ^^^^^Glrecycle)
+ [P X ’n.BTSCM^i>'^ BTSCM)  ^{P'^ ^^ cidBPneg + ^'^^^sdppne^
+  [P  X  flB P n e g M ^ '^ B P n e g M )  ^  { P ^ ^ ^ 9 s r  "F ^ P ^ ^ d a s rp p o  "F P P ^^dasrpTS C ^^
+ [P X nppoMi^ .'BpROM)  ^(P^ a^ddBPneg + ^^^sddgpneg)]
Equation 23
'^BPneggO^' 0 )  ~  ( l  “  P P ^ ^ d G lre c y c le )  ^C NnegG iO '>'’^ BPnegGi) "F (j^B Pnegs(j-> '^B Pnegs) ^  ^ ^ ^ ^ d S yecyc le^
Equation 24
^BPnegG2~ ~ PP^ 3^Srecycle)^ BPnegs(j'>'^ BPnegs)
+ {j^ BPnegGz^ ’ B^PnegG-i)  ^^^ ^^ dG2recycle)
Equation 25
’^ BPnegMi^ i^ ) — ( l  BPTie^ G2recyc(e) ^ BPnegGZ(^ ' ^ BPnegGz)
+  {j^ B P n e g M ^ t'^ B P n e g P )  X  9 M recycle)
Equation 26
B^PposGi(f'O) -  (^ BPposGi(^ '^ BPpoSGi)  ^^^ P°^Clrecycle)
+  [ P  X  riBTSCM(.^>'^BTSCM) ^  {P '^ ^^adcN pos  ^ ^ "^ Q d c jv p o s )]
+ [P X Wfipposjif (t» Tgpposj )^ X B^PpOS^ r *F PPpOSasr[jG2 PPpO^aargrgc)] 
■F [P X I^ PROmO-i'^ PROm)  ^(p^ a^ddBPpos ^^ s^drfflppoj)]
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Equation 27
0 )  =  ~  PPpOSQi^^^^i^)nBpposQPti'BBPpoSGi} "F (j^BPposs(p>^BPposs) ^  P^P^^Srecycle)
Equation 28
^ B P p o s G z ^ ^ ' ~  ~  PPP^^Srecyclè)^BPposs(j->^BPposs) "F (^ B P p o s g g (t, Tgppogg^) X  BPpOSG2recyclè)
Equation 29
^B P p o S M ^ ^ '^ ) ~  ~  PPP^^O2recyclè)^BPpoSG20'’ ^BPpoSG2) {j^BPpoSM^'^BPpoSj^ ^  PPP^^Mrecycle)
Equation 30
TT^PPOciCt, 0) = (îîpPOGi(t.TpROci) ^ ^^ ^Glrecyclè)
+  [ p  X  'HBPnegM(j'i^BPnegi4) ^  (P P ^^Q adppo  "F PP^^dsdpRo)^
+  [ p  X  UBPposi^fO'i'^BPposM) ^  (P P p O ^ a d p ;;^  +  PPP^^sdppo)^
+  [ p  X  'flpBQj^{t,TppojP^ X  (^PROsr +  PPOasrpDO ^ ^ ^ clsttda ^^^asrpppos  '*’
Equation 31
)lpPOj(t, 0) =  {^ -  PPOGl^^^^i^nppo^J^t.XpRo^^ +  {npRo^it.XpRo^ x  P^O^recycZe)
Equation 32
^PPOgzCt, 0) = ( l  -  PPOs^ ^^ i^J^ Upposit.TpROs) + (jIpR0g2(.^ ’ '^ PR0g2) ^  ^^ ^G2recycle)
Equation 33
” P P O m (^ '0 )  “  “  ^^^G2recycle)^PROG2(^''^PROG2) +  (^PROjnC^’ '^PROm )  ^  ^^^M recycle)
Equation 34
'^TDOgq — ^  ^PR0m (P>'^PR0m )  ^  (.PP^adTDO  ^ ^ ^ s d p D o ) ]  W t DOgoO-’ ‘^ TDOgo)  ^  TPO recycle]
Equation 35
'^TDAgo — [F* ^  ’^ PROm O i^ '^PROm )  ^  ( .P P ^ a d ro A  "F P P ^ s d ro A ^ l \V-TDAgo0 ' ’ ^TBOgo)  ^  P P ^ re c y c le ]
Equation 36
8.3.2. The Recycling Algorithm
Like stem-cells, BTSC cells are capable of very long cell cycles and to 
model these long cell cycles as well as cells that are proliferating quickly, a 
very large number of age elements (0(n)) might be needed. The computational 
effort to solve the model increases as O(n^). The model utilises a numerical 
algorithm that recycles cells around one age element to reduce the 
computational effort and memory needed to simulate a combination of very
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long cell cycle times with much shorter durations. This algorithm simulates 
cells recycling within an age element to increase the effective time step. The 
fraction that recycles ( r )  is related to the effective age length of the element. 
As a result, it was only necessary to have one age element for each phase of 
each cell line.
The recycling technique was achieved by the following theory. Let the 
mean residence time of a cell within an age element be cp (hour). At be the
change in time and F be the flow of cells through the age elements. Then we 
have the following equation:
M ean resident tim e =  
At
Change in  tim e  
Flow  o f cells
<p = T
Equation 37
Consider a conserved flow of cells, F, into an age element, with width A t and 
divide the flow of cells that leave the element into rF, as the rate of cells to be 
recycled as shown in Figure 44.
At>
r f
f
Figure 44: Diagrammatic explanation of recycling theory.
The external environment of the age element would perceive the flow of
cells that enters and leaves the element to be ( l - r )F ;  however the age
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element would perceive the flow to be F. Hence the overall residence time (poA 
would be as follows:
At (p
VoA —( l - r ) F  (1 -r )
Equation 38
This technique allows for a much longer phase because, as r increases to 
unity, (poA tends to infinity (i.e. the cells stop cycling). Hence, the rate at which
BTSC cells progress round the cell cycle is slowed down without increasing the 
number of age elements. As a result, the user can control the duration of the 
phases independently of the number of elements. The effect of recycling cells 
within an age element is to produce a cell compartment. The effect of this 
recycle to produce compartments is to alter the detailed dynamics of the cell 
cycle because it creates a partial de-synchronisation.
8.3.3. Methods for Modelling Growth
Katzung et a i [139] suggested that given a the total cell cycle time Tc, the 
durations for the cell cycle phase of proliferating tumour cells are as follows: 
G1 =  0.47c, 75 =  0.397c, G2 =  0.197c and M =  0.027c. If the integration 
step length is 1 hour, by use of Equation 38, the required recycling fraction in
the phase is fr  =  l - — Y All tumours were grown for 2016 iterations, the\ (POA^'
equivalent to 4 months of real-time tumour growth, before applying 
radiotherapy to the tumour. The parameters for the isolated CD 15  ^ cell line 
corresponds to the BTSC cell line, the isolated CD 15' cell line corresponds to 
the progenitor cell line and the DMR10 cell line relates to the TDC cell line. The 
growth parameters used for the of the tumour can be found in 
Table 11-Table 15.
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8.4. Fitting Experimental Data to the Model
Fitted parameter values were obtained by implementing the Nelder Mead 
method. The foremost reason for the use of the Nelder Mead method is that 
the algorithm can cope with models that are non-differential and multivariate 
where a gradient method would not suffice. The algorithm finds the best 
possible solution by creating a (n -F 1) e R polygon or simplex, where n 
represents the number of vertices of the polygon and the number of variables 
in the function needed to be optimised. The Nelder Mead method, for the Hill 
model, starts with five real arbitrary points or nodes (n +  1) 6 R. The algorithm 
orders the vertices in terms of solutions to the functions. The mid-point (or 
centroid) of the edge connects the best and 2"  ^ best vertices of the simplex. 
The worst point is then transformed around the centroid via four processes; 
reflection, contraction, shrinkage and expansion to find a better vertex. This 
process is then iterated a number of times to find an optimum solution [140].
The proportions of the isolated CD 15  ^ cell line when grown in DM over 
time were used to calculate the proportion of dead cells as well as cells that 
are negative for the CD15 marker. However, a marker was not used to 
separate the proportion of progenitor cell lines (isolated CD 15" cell line) and 
TDC cell lines. Therefore, the proliferation parameters were optimised by 
minimising the le^ between the results of the model and the experimental data 
for the BTSC cell line.
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8.5. Methods for Modelling Fractionation
The effect of radiotherapy on tumour cells was applied to the model to 
simulate the effects of various fractionation methods. The technique developed 
creates an additional transition rule in each age element of the cell cycle. The 
rule calculates the fraction of cells killed by radiotherapy, known as the kill 
fraction (KF = 1 -  SF). If no radiotherapy is applied then the kill fraction is zero. 
The user has the option of choosing different radiotherapy schedules. From 
these schedules, the kill fraction is calculated from the dose which is 
determined with the survival curve module. The survival curve module 
implements either the LQ [141], IRR [128] multi-target single event 
(MTSE) [142] or RCR [143] models as chosen by the user.
* Œii*RT^ù^kf
Equation 39
Where = kf
From the kill fraction, the survival fraction can be calculated to ascertain 
the number of cells in each age element after every iteration (i). To allow the 
tumour to grow, the program prompts the user for the time of the first 
radiotherapy fraction.
Population balance models are vulnerable to the creation or destruction 
of objects (in this case, cells) as a result of numerical errors that escalate over 
time. The extra rule however, does not necessarily conserve the number of 
cells. Hence the new sum of transition rules has to be scaled at the end of 
every iteration to ensure conservation.
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Given the existence of multiple lineages of cells, for example BTIC and 
progenitor cells, it is possible that both radiosensitivity and the expression of 
HRS might vary. To address this possibility, a novel ART pattern was 
simulated and compared with a conventional radiotherapy schedule. It has 
been assumed that the treatment delivers two initial equal low doses (Diow) that 
would probably in practice be much less than Dc. The first two doses, Diow, are 
followed by a third dose of (2-2Diow) Gy, thus achieving a standard total dose 
of 2.0 Gy per 24 hour period. The regular and equal intervals between each 
fraction can likewise be varied; however the maximum interval is 8 hours to 
allow for all three fractions to be delivered within 24 hours. Assuming a portion 
of the population of cells possesses HRS, the initial low doses (less than 
0 6 Gy) will kill those cells that are sensitive to very low doses. As a result, the 
tumour population becomes partly synchronised, so that the relatively more 
radio-resistant cells remain. In the interval between the second and third 
fractions, these cells proceed round the cell cycle into a more radiosensitive 
phase.
The final larger dose has 2 rationales. Firstly, for cell lines that do not 
exhibit much variation in sensitivity around the cell cycle, the final larger dose 
will achieve a cell kill comparable to that achieved by a single 2 Gy fraction; for 
those that do have variable sensitivity, the final fraction can be timed to exploit 
the partial synchronisation achieved by the first 2 fractions. Secondly, whether 
cell lines exhibit HRS or not, the final larger dose produces substantial cell kill, 
nearly comparable to 2 Gy.
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To allow the proportions of the different cell lines within the tumour to 
reach constant values, the tumour was grown for 2016 iterations, the 
equivalent to approximately 4 months. The radio-sensitivity parameters applied 
to the tumour are shown in bold font in Table 8. The parameters for the 
isolated CD15'^ cell line corresponds to the BTSC cell line, the isolated 
CD 15" cell line corresponds to the progenitor cell line and the DMR10 cell line 
relates to the TDC cell line. The tumour was irradiated starting on iteration 
2017 with the ART, varying the initial doses from O-O-TO Gy furthermore, the 
model allows for the inter-fraction intervals to vary from 1-8 hours. From the 
variations of dose and dose rate, an optimum ART schedule can be found in 
terms of cell survival and regrowth rate.
For comparison, a hypothetical tumour that shows no HRS, such that the 
BTSC cell line are given the radiotherapy parameters that follow an LQ 
response and was irradiated with the standard radiotherapy (STD RT) as well 
as the optimum ART schedule. The parameters used for the LQ or IRR models 
can be found in Table 8 in Section 6.5, however the hypothetical tumour was 
give LQ parameters only.
Concluding Comments
This chapter has described the methods used to model the growth of a 
heterogeneous tumour population including an algorithm to manage the large 
variations in cell cycle durations. The sensitivity to radiation can be applied to 
each phase of the cell cycle for each cell line, so that optimised treatment 
strategies can exploit the fluctuations of radio-sensitivity.
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9. Theoretical Results
9.1. Introduction
This chapter investigates the growth of a heterogeneous population using 
a population balance model described in the Chapter 8. Two radiotherapy 
schedules, the ART treatment and the STD RT treatment, are applied to the 
simulated tumour using the methods described in Section 8.4. Before 
irradiation, the tumour was grown for 12 weeks (2016 iterations). Results were 
collected for each hour and for each 0 1 Gy increment of the initial dose. The 
effectiveness of the treatment patterns will be compared by both cell survival 
and regrowth time.
9.2. Fitting Experimental Data to the Model
The experimental data collected in Section 6.4 was fitted to the model 
with the method described in Section 8.4. The Nelder Mead method was used 
to fit 14 proliferation parameters in the model. However, the growth parameters 
for each phase of the cell cycle for each cell line were calculated, and fixed, 
with the method described in Section 8.3 using the experimental data collected 
in Section 6.2. A marker was not used to separate the proportion of progenitor 
cell lines (isolated GDIS' cell line) and TDC cell lines. Therefore, the 
proliferation parameters were optimised by minimising the le^ between the 
results of the model and the experimental data for the BTSC cell line. The 
objective function was minimised to 169%10^\ which consequently reduced 
the le^ between the results of the model and the experimental data for dead 
cells to 7 68 x 10' .^ The optimised parameters are found in Table 11-Table 15. 
As only one marker for BTSC cells were used in the experimental aspect of
178
this project, the first two cell lines of the model were switched off by setting the 
parameters to zero. The initial condition gives one cell in the G1 phase of the 
BTSC'/Progenitor"’ cells.
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9.3. Growth of a Heterogeneous Tumour Population
The model predicts the growth and proliferation, over time, of each cell 
line within the tumour from one BTSC cell. The proportion of the BTSC cell line 
exponentially decreases and the growth of the progenitor cell line results in a 
rapid exponential growth rate. The differentiated population also increases 
exponentially, however at a slower rate than the progenitor cell line. Figure 45 
shows that after around 500 iterations (approximately 3 weeks); the proportion 
of each cell line tends towards constants. After 12 weeks (2016 iterations), the 
BTSC cells are the predominant cell line and make up 29 4% of the tumour 
population. The progenitor cell line, TDC cell line and dead cells make up 
27-4%, 16 0% and 27 2% of the tumour population respectively.
1.0   BTSC
- -  -  Progenitor
 TDC
 Dead0.8
0.6
0.4
0.2
0.0
10000 500 1500 2000
Time (hr)
Figure 45; Proportions of subpopulations of cells.
The proportions of each cell line of the tumour after 2016 hours (iterations). The growth of the 
BTSC cell line results in 29 4% of the tumour population. The progenitor cell line, TDC cell line 
and dead cells make up 27-4%, 16% and 27 2% of the tumour population respectively.
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9.4. Modelling Fractionation
Every variation of the ART schedule was simulated, altering the initial 
doses by an increment of 0 1 Gy, as well as changing the inter-fraction interval 
by an hour. Furthermore, a tumour that expresses no HRS (i.e. using only the 
LQ parameters in Table 8) was also treated with the optimum ART schedule 
and the STD RT treatment. Figure 46 displays the total number of cells that 
survived after each treatment.
Before irradiation the tumour is grown for 12 weeks (2016 iterations) 
reaching a total of ^ 0 6 * 1 0 ^  live cells, which is reduced by the STD RT 
treatment to 932-6 live cells with a regrowth time of just over 61 days (1475 
hours) (see Figure 47). With regards to the ART schedule, the optimum length 
of time for the inter-fraction interval is 1 hour for all doses between 0-1 and 
1 -0 Gy. Figure 47 shows that the benefit of optimising with respect to dose is 
more distinct than optimising with respect to inter-fraction interval.
Furthermore, with respect to cell survival only, the overall optimal ART 
schedule delivers initial doses of 0-7 Gy every hour for 3 hours and diminishes 
the tumour to just 70-67 cells with a regrowth time of just under 71 days (1702 
hours). In terms of regrowth only, Figure 47 shows that two optimal ART 
schedules that deliver initial doses of 0-7 Gy and equally result in optimal 
regrowth times of 1702 hours, however one of the optimal ART schedules has 
an inter-fraction interval of 1 hour and the other optimal ART schedule has an 
inter-fraction interval of 2 hours.
All variations of the ART regimen are an improvement when compared 
with the STD RT treatment, when considering both regrowth time and cell
186
survival. It was identified that the most inefficient scenario for the ART 
treatment gives initial doses of 0 1 Gy, with 8 hour intervals between each 
fraction for both regrowth time (1543 hours) and cell survival (419-10 cells).
When a presumed tumour that does not express HRS is treated with the 
optimal ART schedule, the regrowth time is 1481 hours and the total cell 
survival is reduced to 1025-02 cells. Additionally, when the hypothetical tumour 
is irradiated with the STD RT the regrowth time and cell survival is 1665 hours 
and 89-77 cells respectively.
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9.5. The effect of the Optimal ART Schedule on Cell Type
The effect the ART treatment has on each cell type when compared to an 
untreated tumour and a tumour treated with the STD RT is shown in Figure 48. 
When treated with the optimum ART regimen, the progenitor cell line is the 
predominant cell line making up 41 1% of the population, whereas the BTSC 
cells were the least prevalent constituting 27-5%. Conversely, the BTSC cell 
line is the most dominant cell line for an untreated tumour (40 4%) and when 
treated with the STD RT treatment (49*5%). Furthermore, the STD RT 
treatment reduces the TDC cell line to just 14 2% of the population, whereas 
the proportion of TDC cells in the tumour population increases to 31 4% when 
treated with the ART schedule.
When comparing the hypothetical tumour that expresses no HRS, the 
most prevalent cell line after treatment with the STD RT is the BTSC cell line 
(44 0%) followed by the progenitor cell line (38-9%). On the contrary, when the 
tumour is treated with the optimal ART schedule, the most predominant cell 
line is the progenitor cell line (39-4%), followed by the BTSC cell line (34-9%). 
In comparison to an untreated tumour, the ART schedule reduces the overall 
proportion of the BTSC cell line in a tumour that does not express HRS, 
however not to the same extent as a tumour that expresses HRS in the BTSC 
cell line. In addition, the optimal ART treatment resulted in a greater reduction 
in the progenitor and TDC cell lines than on a tumour that does express HRS.
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Concluding Comments
These results show that the model can predict the growth of each cell line 
within a heterogeneous tumour population and that the proportions of each cell 
line within the tumour tends towards constants. For the tumour based on the 
R10 cell line, all variations of the ART schedule on a tumour results in a 
greater reduction in the total cell survival of the tumour as well as a better 
regrowth time, compared to the STD RT treatment. The optimal ART regimen 
delivers initial doses of 0 7 Gy with an hour between each dose. Furthermore, 
when delivered to a hypothetical tumour that does not express HRS, the STD 
RT engenders a better regrowth time compared to the optimal ART schedule.
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10. Discussion of Theoretical Results
10.1. Introduction
As mentioned previously in Chapter 7, the heterogeneity of GBM has 
raised many questions with respect to the growth of the tumour and the 
influence this may have on improving the current radiotherapy treatment. This 
chapter discusses the results presented in Chapter 9, which attempts to 
answer some of these questions. A number of studies have modelled growth 
of cells around the cell cycle [118,119] with the effect of drug on the cells [118]. 
Other models have used compartmental modelling to model the proliferation 
modes of heterogeneous systems derived from stem cells [116,122].
Using data collected in Section 6.2-6.4, the model attempts to predict the 
growth of a heterogeneous tumour population derived from one BTSC cell. 
Furthermore, the radio-sensitivities of each cell line are applied, based on the 
survival curve parameters determined from the radiation experiments in 
Section 6.5. A sensitivity analysis for the model is beyond the scope of this 
project as the version of the model uses 24 parameters.
10.2. Growth of a Heterogeneous Tumour Population
A model has been constructed which represents the different phases of 
different cell lines growing in a heterogeneous population. A numerical 
algorithm was used to reduce the computational effort of the simulation of the 
long cell cycles of cell lineages within the BiDMuLD cascade. The 
differentiation processes of asymmetric self-renewal, differentiation and 
de-differentiation, as well as symmetric self-renewal, differentiation and 
de-differentiation, are incorporated into the model. On a generic level, the
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model is capable of modelling any heterogeneous system, however for the 
purposes this report, aspects of the model are validated with experimental data 
from the R10 cell line. Therefore, the growth of a heterogeneous population of 
cells, derived from a stem cell is modelled using a population balance model 
described in Chapter 8.
The results from Section 9.3 show that the proportions of each cell line 
reach constants as the tumour grows. The BTSC cell line plateaux to 29 4% 
and are the most predominant cell line in the tumour. This is an overestimation 
in comparison to the proportion of isolated CD 15  ^ cell line shown in 
Section 6.3.1. The experimental data in Chapter 6 shows that the proportion of 
isolated CD 15  ^ cell line grown in DM results in a mean average of 26 0% of 
the population. Furthermore, Singh et al. [47] suggest that the required 
frequency of BTSC cells needed to generate neurospheres ranged from 
0 3-25 1% [47]. The slight differences in the experimental data of this report 
and work reported by Singh et al. [47], may be due to the large number of 
parameters optimised to only six data points. The model simulates the growth 
of three cell lines as well as the proportion of dead cells; however this was 
achieved with experimental data only from the isolated CD 15  ^ cell line and 
dead cells. Although the le^ was minimised to 1 69x10'^, with more data 
points for the proliferation of the BTSC cell line an even better fit may be 
achievable. In addition, after optimising the parameters, the model assumes 
that transition of BTSC cells to the death phase to be zero, although this cell 
line is very slow growing it is unlikely that no cells will die over time. 
Furthermore, using markers to distinguish between the progenitor cell lines
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and the TDC cell lines, when grown in DM, would also provide more data 
points to give a better fit to the model.
The experimental results of the proliferation of the isolated CD15" cell line 
show that the cell line de-differentiates to a CD15^ cell over time. This 
suggests that the transition rules for symmetric and asymmetric 
de-differentiation cannot be based on fixed fractions. It would be better to 
model the transition using either a periodic function or a feedback mechanism 
as it is suggested that the growth of a system of cell is aided with cell to cell 
signalling [40].
10.3. Modelling Fractionation
A wide range of radiation sensitivity can be achieved in the model. Any 
form of phase-dependent radiation sensitivity can be calculated, and the 
flexibility exists to combine this with any form of symmetric or asymmetric and 
hyperfractionated radiotherapy treatment schedule. The model has the 
foundations to support both the two-population hypothesis [95,128] and the 
adaptive response mechanisms [95] since the transition rules are easily 
adaptable. The tumour was grown for 12 weeks (2016 iterations) before being 
treated with either the conventional radiotherapy routine (2 Gy per day for five 
days a week for six weeks) or all possible asymmetric radiotherapy schedules, 
to find the optimum schedule.
With regard to both cell survival and regrowth time, the model predicts 
that all variations of the ART pattern are more effective in treating a simulated 
tumour validated with data based on the RIO cell line than the conventional
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treatment. The optimum ART schedule delivers initial doses of 0 7 Gy with 
intervals of 1 hour between each fraction. This course of therapy coincides 
with work from Beauchesne et ah [96]. However, the fractionation differs from 
the suggestions of published work by Joiner et al., which concluded that three 
doses of 0.4 Gy with inter-fraction interval of 4 hours for 5 days would optimally 
exploit HRS of the heterogeneous T98G cell line, a GBM cell line [95]. 
However, these treatment regimens are not entirely analogous in terms of total 
dose per day and total treatment time, and therefore could be the cause for 
any discrepancies. When presented with a hypothetical tumour that expresses 
no HRS the optimal ART schedule did not improve on the STD RT treatment. 
When regarding a clinical approach to ART, each of the doses are still 
practicable with modern treatments such as intensity modulated radiotherapy 
(IMRT).
Considering there are two optimal ART schedules in terms of regrowth
time, suggests that there is not a simple relationship between residual cell
number and regrowth time. This is the result of the heterogeneity of cells within
the differentiation cascade within the tumour. The TDC cell lineage within this
cascade cannot proliferate; its presence contributes to the cell number but not
to regrowth. In addition, the cell lineages which can proliferate have variable
cell cycle times. More simple models of asymmetric fractionation could not
resolve these complex interactions [128]. In this work, there is the clear
suggestion that heterogeneity does not reduce the sensitivity to the doses in
the hyperfractionation schedule, but does reduce sensitivity to the inter-fraction
intervals. Both treatments reduced the total cell number of the tumour to very
low levels, hence the model reveals that there exists an underlying mechanism
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involved in cell recuperation after irradiation. This further supports that the 
growth of a system of cell is aided with cell to cell signalling [40], since the 
model does not incorporate the effects of cell signalling. The model may 
potentially be modified to allow for the change in survival of the mixed 
populations using a negative feedback function. Moreover, the model shows 
that if a tumour expresses HRS in any cell line, then the ART schedule is 
better a treatment pattern to deliver to the patient, however, if there is no HRS 
at all then the STD RT is the best treatment. The difference in outcome of the 
two scenarios could have some clinical consequences.
Similarly to Basse et al. [118], each phase of each cell line in the model 
can have an allocated sensitivity to drug, however the function is not used in 
this project. In addition, the model is also capable of governing the 
radio-sensitivity for each of the phases in the cell cycle, although there is no 
experimental data from the RIO cell line for each of the phases, therefore the 
same sensitivity for each cell line is applied to each of its phases. Further 
validation of the model with regard to the possible heterogeneous sensitivity 
around the cell cycle could contribute to our understanding of either the 
adaptive response mechanism or the two-population theory.
Since the BTSC cell line express HRS the effect of the optimal ART 
schedule resulted in a greater reduction of the BTSC cell line (321%  
decrease), as opposed to the percentage increase in the proportions of the 
progenitor cell line and the TDC cell line. Consequently, the application of the 
optimum ART pattern was effective in the reduction of the tumours, and 
prevention or delay of tumour recurrences. Conversely, the STD RT treatment
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resulted in an increase in the proportion of BTSC cell line, and hence resulted 
in a higher probability of future recurrences because, over time, this cell lines 
will proliferate.
Concluding Comments
This chapter discusses the results from the modelling aspects of this 
project. The growth of a heterogeneous tumour population was modelled; 
growth parameters were developed from experimental data collected in 
Chapter 6 . Using fixed probabilities the BTSC cell line and progenitor cell lines 
proliferate via processes of asymmetric self-renewal and differentiation, as well 
as symmetric self-renewal and differentiation, progenitor cells can also 
de-differentiate back to CSC cells.
Phase-dependent radio-sensitivity for each cell line can be introduced in 
the model. The radio-sensitivity for each cell line and phase can be combined 
with a range of radiotherapy treatment schedules. The tumour was grown for 
1 2  weeks before being treated with either the conventional radiotherapy 
routine or all possible asymmetric radiotherapy schedules, to find the optimum 
schedule. The model shows that the ART schedule is a better treatment 
pattern to deliver to the patient if the tumour expresses HRS. The optimum 
ART schedule delivers initial doses of 0 7 Gy with intervals of 1 hour between 
each fraction. However, the optimal ART schedule did not improve on the STD 
RT treatment when presented with a tumour that expresses no HRS. 
Heterogeneity does not reduce the sensitivity to the doses in the
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hyperfractionation schedule, but does reduce sensitivity to the inter-fraction 
intervals.
The application of the optimum ART pattern was effective in the reduction 
of the tumours, and prevention or delay of tumour recurrences due to a greater 
reduction of the BTSC cell line. Conversely, the STD RT treatment resulted in 
an increase in the proportion of BTSC cells, and hence resulted in a higher 
probability of future recurrences because over time this cell lines will 
proliferate. Both treatments reduced the tumour to very low cell numbers, 
hence the model reveals possibilities of underlying mechanism involved in cell 
recuperation after irradiation. This supports that the growth of a system of cell 
is aided with cell to cell signalling [40].
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11. Conclusions and Recommendations
11.1. Conclusions
GBM is the most fatal and aggressive form of brain cancer and is 
composed of a heterogeneous population of cells, derived from a BTSC cell. 
Many CSC cell markers or progenitor markers have been used to isolate these 
cells to explore their growth and therapeutic sensitivities. In this work it is 
hypothesised that BTSC cells may be the driving force in the growth of a 
tumour, and, it is possible that given a heterogeneous population of cells, there 
will be a variation in the sensitivity of the tumour population to radiotherapy 
and chemotherapy.
Using four subpopulations of the R10 cell line, doubling times and 
proliferation methods were investigated and compared. The doubling time 
significantly changes with each cell type with the exception of the SFR10 cell 
line, and therefore supports the probability that these cell lines are 
phenotypically different from each other. The isolated CD15‘ cell line has the 
fastest doubling time which agrees with the work by Persano et al. [32] and 
Panagiotakos at al. [40] such that progenitor cells have a high proliferation 
rate.
Moreover, the isolated CD15^ cell line has a significantly slower doubling 
time and therefore corresponds with many studies that suggest that BTSC 
cells are quiescent cell lines [32,40,42]. Furthermore, the results supported the 
hypothesis in this work, that progenitor cells have the proliferative capability 
to de-differentiate to a BTSC cell indicating two aspects a) BTSC cells are 
essential in driving the growth of the tumour and b) cell to cell signalling may
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be involved in the growth of each cell type [40]. The doubling time of the 
differentiated population, DMR10, was significantly the slowest cell line, which 
also agrees with the work of Persano [32]. Furthermore, the results indicated 
that given a heterogeneous tumour population, the dominant cell line is likely 
to be primarily TDC cells.
The clonogenic assay was used as an end point assay in this project to 
encompass all forms of cell death as well as the latent effects of radiation. The 
hypothesis of this project states that a heterogeneous tumour would give rise 
to subpopulations of different radiosenstivities. The results showed the 
radiosensitivity of each cell line is significantly different from each other; and 
the trend of sensitivity down the hierarchy followed some of the work in the 
current literature [80]. Furthermore, results showed that the isolated CD1!^ cell 
line was significantly the least sensitive subpopulation of the R10 cell line. This 
result may highlight that due to the long doubling time, enough time is allowed 
for DNA repair. The isolated CD15' cell line is the next radio-resistant 
subpopulation of the R10 cell line, due to a rapid doubling time to quickly 
replenish the cells that are lost. However, the DMR10 cell line is the most 
sensitive subpopulation of cells due to the fact that these cells are 
non-proliterative and therefore if any damage occurs it is likely to be fatal. 
These results suggest that it may be beneficial to exploit the different 
sensitivities using an ART schedule.
The four subpopulations of the R10 cell line were exposed for 24 hours to 
TMZ and the associated IC50 values for each cell line were significantly 
different from each other. Furthermore, each of the IC50 values were very low
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which suggest that the MGMT status for every cell line is negative and 
therefore sensitive to TMZ [99].
The isolated CD15‘ cell line was the most sensitive cell line to TMZ, 
whereas the DMR10 cell line was the most resistant subpopulation. Aspects of 
these results disagree with the results of Persano et al. [32] who states that the 
more differentiated cells are M GMT and therefore the most sensitive cell line 
of the tumour. Furthermore, the isolated CD15^ cell line is significantly less 
sensitive to TMZ than the isolated CD15‘ cell line. Again these results 
contradict the results of Persano et al. who states that the CSC cell is the most 
sensitive cell line to TMZ with a positive MGMT status.
Interestingly, the SFR10 cell line was more resistant than both the 
isolated cell lines. Considering the SFR10 cell line is a combination these two 
cell lines, it would be expected that if no cell signalling occurs, the IC50 value 
for the SFR10 cell line would be an average of these two cell lines. However, 
the IC50 value is significantly higher than both the IC50 values of the isolated 
cells, which again suggests a role for cell signalling.
Two different methods for the clonogenic assay produce I C 5 0  values for 
TMZ that are significantly the same for both the isolated cell lines, thus 
showing that either method can be used without altering the outcome of the 
experiments. The results from the TMZ experiment confirm our hypothesis, 
such that the subpopulations of a heterogeneous tumour would engender 
heterogeneous sensitivities to chemotherapy drugs.
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It is evident from present studies that a number of radio-resistant glioma 
cell lines do not follow predictions from the LQ model because of cell sensitivity 
to radiation being underestimated by a at low doses. The overall effect can be 
modelled by use of the IRR model which, compared with the LQ model, gives a 
more accurate representation of the survival fraction because it modifies the 
LQ model to cope with the effects of doses less than 1 Gy.
The experimental results suggest that it may be beneficial to exploit the 
different sensitivities using ART, which delivers two initial equal low doses 
followed by a third dose of (2-2Diow) Gy, thus achieving a standard total dose 
of 2.0 Gy per 24 hour period (see Section 8.4). Furthermore, with further 
investigation of the cell signalling, other treatment strategies could be 
proposed using concomitant drugs that counteract or modify the signalling. 
Particular focus on the isolated CD15' cell line should be considered to prevent 
de-differentiation to a CD15^ cell.
The model appears to be fit for purpose, such that it is a computationally 
robust and efficient framework that allows for marked heterogeneity in cell 
cycle time and phase dependence of radio-sensitivity. The numerical algorithm 
successfully reduced the computational effort needed to model the growth of 
several cell lines going around their own cell cycles. The model has been 
populated with values from recorded data of the R10 cell line and it generates 
plausible outputs.
For a tumour with a homogeneous cell population with no HRS, the
standard radiotherapy treatment remains slightly more effective than ART.
However, all variations of the ART treatment plan are more efficient than
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standard radiotherapy, when treating a heterogeneous tumour or a tumour 
expressing HRS. Substantial work remains to be done before this could be 
carried forward into the clinic, but it suggests the possibility of a radiotherapy 
approach with higher efficacy for patients with GBM.
11.2. Future Work and Recommendations
The interaction between cells through cell signalling during growth and 
recuperation after treatment warrants investigation. Clearly the growth rate of 
cells is not sufficient to model accurately the growth of a heterogeneous 
population. Wnt proteins form a family of signalling molecules that regulate the 
cell to cell interactions involved in embryonic development, in particular Wnt 
signalling is responsible for the differentiation of stem cells [134]. Therefore, 
mutations in Wnt genes, or poor regulation of their processes, leads to 
abnormalities in growth and development, thus instigating 
carcinogenesis [134]. Furthermore, the proliferation results of the isolated 
GDIS' cell line (Figure 31) showed growth of the cells after treatment relies on 
cell to cell signalling, such that it is likely that these are the processes that 
maintain the BTSC cell line.
Another topic that needs to be explored is the effect of hypoxia on the 
cells. It is apparent that the oxic and hypoxic conditions have a momentous 
effect on cell sensitivity [128] and growth rate [32]. Persano et al. [32] suggest 
hypoxia controls the proliferation of the CSC cells to a specific phenotype. 
CSC cells are typically located in the hypoxic regions of the tumour, while more 
differentiated cells are found in the more oxic peripheral layers.
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Variations of the ART schedule needs to be explored. Radical treatment 
for GBM is currently radiation plus concurrent and adjuvant TMZ. Analysis of 
the ART schedule with TMZ could result in greater cell kill and regrowth time. 
Furthermore, there is an obvious need to explore the effects of ions as 
opposed to X-rays on the model. Using the ion beam at the University of 
Surrey, an important area to explore is the possible relation between LET and 
HRS. The effects of photon radiation can be compared with ion beam therapy 
with both the conventional treatment of GBM and the new ART treatment. The 
optimum times and doses the ART treatment will need to be investigated, 
however it can be postulated that time might not have an effect on the cells 
because it was a redundant parameter for photon radiation. When optimum 
combinations of these factors have been identified and the treatment is 
optimised, it is then possible to validate the model again, this time with 
particles.
Further isolation of the R10 cell line is necessary to understand fully the 
growth of the tumour and the inherent sensitivities to drug and radiation. 
Antibody markers such as A2B5 that isolate the progenitor cell lines, or G FAR 
that isolate TDC cell line, would provide a better representation of the tumour 
model both biologically and mathematically. Furthermore, the radio-sensitivity 
of each phase of the cell cycle needs to be investigated experimentally, for 
further validation of the model. More experimental data would result in a better 
fit of the proliferation parameters to the model.
Finally, a full sensitivity analysis of the parameters is essential. The 
duration of the cell cycle phases for the BTSC cells, progenitor cells and TDC
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cells and are calculated by the doubling times of the isolated GDIS'" and 
CD15' cell lines as well as the DMR10 cell line respectively. Furthermore, the 
phase duration of each cell cycle is calculated using Steel’s equations [121]. 
The parameters for the proliferation modes (asymmetric/symmetric 
self-renewal, differentiation and de-differentiation) for each cell line is 
determined by fitting the model to the experimental data provided by the 
isolated GDIS'" cell line only, therefore it would be important to understand fully 
the accuracy of the parameters.
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